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Endocannabinoids, such as Anandamide (AEA), are lipid compounds which, together with the 
receptors they bind to, form the endocannabinoid system (ECS) which, in animals, modulates 
mood, cognition, appetite etc. The ECS can be activated by phytocannabinoids such as 
cannabidiol (CBD) and as such, interest in its therapeutic use has grown substantially over 
recent years. However, not all of CBD’s effects can be explained by its binding to cannabinoid 
receptors and many other targets have been proposed. A better understanding of these 
alternative targets would increase the therapeutic potential of this phytocannabinoid in the 
future. 
Single-celled protists, such as amoebae, do not possess cannabinoid receptors yet they 
respond negatively to endo- and phyto-cannabinoids, suggesting they possess alternative 
targets only. This study therefore examined the involvement of three alternative targets, i.e., 
the Peroxisome-Proliferator Activated Receptor (PPAR), Dopamine Receptor and Serotonin 
Receptor, in the action of AEA and CBD on amoebae. 
Of the 20-amoeba species tested, only 6 showed a reduction in population growth in the 
presence of CBD (IC50, 0.98-7.31µM), i.e., Hartmannella cantabrigiensis, Naegleria gruberi, 
Vahlkampfia avara, Vermamoeba vermiformis, Acanthamoeba castellanii and Flamella 
arnhemensis. All but the latter two species also showed reduced population growth in the 
presence of AEA (IC50, 0.96-9.89µM). The negative effect of AEA could not be alleviated by 
blocking receptors with antagonists against the three PPAR isoforms (PPARs α, β and γ), the 
dopamine receptor or the serotonin receptor, suggesting that none were involved in the 
mode of action of AEA. However, the negative effect of CBD was alleviated with the 
antagonist for the PPARα receptor in V. vermiformis and that for the serotonin receptor 
(specifically 5-HT1A) in N. gruberi. Interestingly, CBD significantly affected the feeding 
behaviour of these two amoebae (but AEA did not), by stopping amoebic feeding completely 
(and causing a lag in the ingestion of prey), which was then followed by a reduced ingestion 
rate; both of which were dose-dependent.  
Further work with V. vermiformis showed that this CBD-induced cessation in feeding was not 
due to the halting of phagosome processing and defecation however, there was an interaction 
between CBD and C-type lectins recognising mannose, N-Acetyl-D-glucosamine (GlcNAc) and 
2 
 
N-Acetyl-D-galactosamine (GalNAc). Receptor-mediated phagocytosis in V. vermiformis 
involved all three C-type lectins and although CBD did not appear to directly interfere (bind) 
with any of them, its presence (together with sugars to block these receptors) led to a 
synergistic reduction in ingestion rate with mannose and GalNac (but no effect on lag) and an 
extension of the lag with GlcNAc (but no effect on ingestion rate). The ‘CBD-receptor’ 
(putative PPARα) and GlcNAc receptor were therefore considered to be involved with 
phagosome formation and not prey capture and phagosome filling. It is therefore 
hypothesised that, because only the three PPAR isoforms exist in vertebrates, V. vermiformis 
possesses a promiscuous PPAR-like molecule that can bind CBD at the same site it binds the 
PPARα antagonist. The instantaneous nature of the feeding lag suggests the presence of a 
non-genomic PPAR response whereby in its ligated state PPAR cannot bind with a necessary 
protein (possibly Syk, LAT or PKC) to initiate a downstream signaling cascade, which would 
normally culminate in actin polymerisation and phagocytic cup formation.  
In conclusion, amoebae provide an ideal model organism to evaluate the significance of 
alternative targets in the functioning of the ECS. And, as is the case with animals, multiple 
alternative targets appear to be present in amoebae; PPARα (for CBD) in one species, 
Serotonin Receptor (for CBD) in another species, with the other alternative targets for CBD 
and indeed AEA currently unknown.  And, considering multicellularity originated from free-
living single-celled protists, amoebae have also provided an opportunity to investigate the 
historical functioning of the ECS which appears to be in the main, involved with the feeding 









Chapter 1: General Introduction  
1.1. Introduction 
This introduction begins with an overview of the endocannabinoid system in humans which 
encompasses its role, the receptors involved and their ligands. It then evaluates the 
phylogenetic and experimental evidence for an endocannabinoid system in single-celled 
protists, in particular, the ciliate Tetrahymena.  It then moves on to amoebae, the organism 
used in this study and, in particular, reviews current knowledge regarding its feeding 
mechanisms. 
1.2. The Endocannabinoid System (ECS) in humans 
1.2.1. General overview 
The endocannabinoid system (ECS), also known as the endogenous cannabinoid system, is 
presents in almost all types of vertebrates including mammals, birds, reptiles and fish (Silver 
2019). It is one of the most important biological systems within the body with the function of 
maintaining homeostasis (Bih et al., 2015). As such, it is involved in the control of many 
processes such as mood, pain, cognition, appetite, memory, inflammation and reproductive 
function, and if perturbed, can lead to physiological or pathophysiological disorders (Hansen 
et al. 2006; Ngo et al., 2019). The ECS comprises cannabinoid receptors (CBRs), their 
endogenous ligands, i.e., endocannabinoids, and the enzymes that synthesise and metabolise 
them (Battista et al., 2012). Endocannabinoids initiate their action by binding to CBRs 
(Howlett et al., 2010), however, these receptors can also bind phytocannabinoids such as Δ9-
tetrahydrocannabidiol (THC) and cannabidiol (CBD), present naturally in Cannabis sativa 
(Pertwee et al., 2010; Wu, 2019). 
1.2.2. Main ligands of the endocannabinoid system  
Ligands for the endocannabinoid system are classified into two main groups; the endogenous 
endocannabinoids (neurotransmitter compounds formed in the brain and in peripheral 
tissues) and the exogenous phytocannabinoids (occur naturally in C. sativa). In addition, there 
are many synthetic cannabinoids (Table 1.1) (Svíženská et al. 2008; Madras, 2015). These 
endogenous, exogenous and synthetic cannabinoids are further classified based on their acyl 
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chain and, in the main, fall into two groups: N-acylethanolamines (NAEs) and 
monoacylglycerols (AcGs) (Piscitelli, 2015). 
Table 1.1: Common members for the three main cannabinoid groups. Their chemical structure, the 
enzymes that metabolise them and the receptor(s) they bind to (Bettinger and Chu, 2019). 
 
1.2.2.1. Endocannabinoids  
Endogenous cannabinoids are not synthesised and stored in tissues, but are formed “on 
demand" and are then released to bind with CBRs in order to elicit a response (Hansen et al. 
2006). The biosynthesis and breakdown of two well studied cannabinoids are summarised in 






Figure 1.1 Biosynthesis and degradation of the endogenous cannabinoids Anandamide (AEA) and 2-
arachidonoylglycerol (2-AG), showing the main enzymes that lead to their synthesis and hydrolysis 
(Scotchie et al., 2015). 
 
N-arachidonoylethanolamine (NAE) was the first endocannabinoid to be isolated (in 1992) 
from the brain of a pig (Onaivi et al., 2005). It is more commonly known as anandamide (AEA) 
were “ananda” means bliss (in the Indo-European language Sanskrit) and “amide” originates 
from its chemical composition (Mechoulam & Fride, 1995). AEA is a long-chain fatty acid 
ethanolamine and a representative of the NAEs. It is synthesised from N-arachidonoyl 
phosphatidyl-ethanolamine (NAPE) via hydrolysis with phospholipase D (NAPE-PLD) (Liu et 
al.,2008) (Fig. 1.1). This process is regulated by the calcium ions and cAMP (Tsuboi et al., 
2015). AEA is hydrolysed by the Fatty acid amide hydrolase enzyme (FAAH) into arachidonic 
acid and ethanolamine (Neelamegan et al., 2012) (Fig. 1.1). Anandamide predominantly 
influences the central nervous system (CNS) and the peripheral system (PNS) (Pacher et al., 
2006). Its actions are mediated by activation of the CB1 receptor in the CNS and the CB2 
receptor in the PNS (see 1.2.3.1) (Zou & Kumar, 2018). In addition, AEA can bind to the 
transient receptor potential channel vanilloid 1 (TRPV1), Dopamine receptor, Peroxisome 
Proliferator-Activated Receptor (i.e., PPARα and PPARγ) and various orphan G protein-
coupled receptors (e.g., GPR55) (see 1.2.4) (Pertwee et al., 2010; Lee et al., 2016). 
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The second endocannabinoid to be isolated in 1995 was 2-arachidonoylglycerol (2-AG) which 
is a member of the AcGs (Zou and Kumar, 2018). 2-AG is synthesised from diacylglycerol (DAG) 
which is mediated by two diacylglycerol lipases (DAGL) - DAGLα and DAGLβ (Fezza et al., 2014) 
(Fig. 1.1). It is hydrolised by monoacylglycerol lipase (MAGL) into arachidonic acid and glycerol 
although FAAH can also hydroylse 2-AG (Di Marzo et al., 1998) (Fig. 1.1). Like AEA, 2-AG 
predominantly influences the CNS and PNS (Kleberg et al., 2014) via activation of the CB1 
receptor (Zou & Kumar, 2018). However, it can also activate PPARα and GPR55, like AEA, 
(Kozak et al., 2002; Ryberg et al., 2007) but it cannot activate TRPV1 or the Dopamine 
receptor, unlike AEA (Garbutt, 1983; Starowiczet al., 2007). 
 
There are many other NAEs and AcGs but the current study included two NAEs, alongside 
AEA, which warrant an introduction: Palmitoylethanolamide (PEA) and Oleoylethanolamide 
(OEA).  
Oleoylethanolamide (OEA) is synthesised from oleic acid and phosphatidylethanolamine and 
is hydrolyzed by FAAH into oleic acid and ethanolamine (Thabuis et al., 2008). This 
cannabinoid also exists in many types of food, such as cocoa powder, nuts and oatmeal (Di 
Marzo et al., 1998; Astarita et al., 2006). In humans, OEA is known to have an essential 
biological action by regulating food intake, body weight and controlling the balance the lipid 
metabolism (Thabuis et al., 2011). OEA has a high affinity for the PPARα receptor (see 1.2.4.1) 
(Fu et al., 2003).  
Palmitoylethanolamide (PEA) is synthesised from N-acylated phosphatidylethanolamine 
(NAPE)-phospholipase D (Leung et al., 2006). Its degradation is mediated by FAAH to yield 
palmitic acid and ethanolamine (Skaper et al., 2018). It has been found to have an inhibitory 
impact on inflammation and cell degeneracy (Aloe et al., 1993; Mazzari et al., 1996; Berdyshev 
et al., 1998) and has a neuroprotective role in rodents (Lambert et al., 2001; Calignano et al., 
1998; Jaggar et al., 1998). Like OEA, PEA predominantly activates PPARα (see 1.2.4.1) (Lo 






1.2.2.2. Phytocannabinoids  
The phytocannabinoids belong to a family of terpenophenolic composites which are derived 
from the plant C. sativa (Happyana et al., 2013). Their chemical structure comprises a 
terpenoid ring derived structurally from C10 terpenoid subunits of geranyl pyrophosphate 
(ElSohly, 2007; Kis, et al., 2019).  They are biosynthesised within adhesive structures called 
glandular trichomes (Fig. 1.2), with each trichome containing different cannabinoids 
(Fischedick et al., 2010; Happyana et al., 2013). Further, cannabinoids comprise a 
considerable part of the resin and constitute about 30% of the weight of the dried flowering 
tops (ElSohly, 2007).  
Figure 1.2: Biosynthesis of phytocannabinoids takes place in the glandular trichomes of Cannabis 
savita. The molecular structure of some of the more common phytocannabinoids is shown (Tambaro 
et al., 2012; Palazzoli et al. 2018; The weed blog, 2012; www.compassclinics.com). 
 
C. sativa contains more than 85 cannabinoids (El Alfy et al., 2010) but those most common 
are the psychoactive Delta-9-tetrahydrocannabinol (THC) and its non-psychoactive isomer 
Cannabidiol (CBD) (Fisar, 2009). THC and CBD are synthesised from cannabigerolic acid (CBGA) 
which itself is synthesized from olivetolic acid  and geranyl diphosphate (Fellermeier and Zenk, 
1998; Dewick, 2009) (Fig. 1.3). CBGA is then converted to THC via oxidocyclase 
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tetrahydrocannabidiolic acid synthase (THCAS) whereas CBD is formed by oxidocyclase 
cannabindiolic acid synthase (CBDAS) (Sirikantaramas et al., 2004; Taura et al., 2007) (Fig. 









Figure 1.3: Synthetic pathway of Delta-9-tetrahydrocannabinol (THC) Cannabidiol (CBD) (Kis et al., 
2019). 
 
The exact function of phytocannabinoids in plants is still unclear, however the most supported 
theory is that they play a protective role by responding to an external physical or biological 
effect such as UV light, drying conditions, insects and bacterial infection (Bernstein et al., 
2019). Plants do not possess cannabinoid receptors or any endocannabinoids, however the 
endocannabinoid-like composites can be produced by plants such as PEA and MEA (N-
myristoylethanolamine). Those compounds can bind and activate CB-like receptors (Onaivi, 
2005). As for PEA, it can be found in various plants, for example, soybean and peanut and 
binds to unknown CB2-like receptor (Chapman, 2000). MEA is reported to be present in 
tobacco and Medicago truncatula, and acts as anti-alkalization agent as a means of immunity 
that depends on the rapid inflow of calcium ions (Ca2+) and rapid outflow of potassium ions 
(K+) (Chapman, 2000). This reaction is similar to that of the human immune cell response 
whereby suppression of calcium - potassium channels is mediated by cannabinoid receptors 
(Mackie et al., 1995). Tripathy et al. (2003) also demonstrated that CBR-like proteins are 
present in the membrane of plant cells and mediate the signalling pathways of the NAEs 
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compounds. Moreover, sequences of NAPE-PLD synthesising enzymes have been found in 
tobacco (Chapman, 2000). 
Phytocannabinoids (in particular THC, CBD and CBG) have multiple therapeutic effects which 
are summarised in (Table 1.2).  
Table 1.2: Examples of the therapeutic effects of Delta-9-tetrahydrocannabinol (THC), Cannabidiol 





















Relaxation of muscles 
 
Rahn and Hohmann,2009 
Hampson et al., 1998 
William et al., 1976 
Currais et al., 2016 










Breast cancer Inhibition 
Anti-bacterial (MRSA) 
 
Hampson et al., 1998 
Russo et al., 2005 
Jones et al., 2010 
Ligresti et al., 2006 






Growth inhibition of carcinoma 
Breast cancer inhibition 
Inhibition of melanoma cell 
Formukong and Evans, 1988 
Diaz-Laviada, 2010 
Baek et al., 1998 
McAllister et al., 2007 




Fungi, like plants, do not possess the main endocannabinoid receptors but they do possess 
the enzymes that synthesise and metabolise them (McPartland et al., 2006). The sequences 
of NAE synthesising enzymes (NAPE-PLD and MAGL) and hydrolysing enzymes (FAAH and 
DAGL) have been identified in the yeast Saccharomyces cerevisiae (McPartland et al., 2006) 
and in the fruiting body of Tuber melanosporum (truffle) (Pacioni et al., 2015). In addition, 
Muccioli et al. (2009) found that S. cerevisiae produces inactive PEA in a quantity similar to 
that produced in mouse brain (650 and 100-500 pmol/g, respectively) and Pacioni et al. (2015) 
found that the truffle of T. melanosprum contained high quantities of AEA (7.0 ± 5.8 
pmol/mg). 
 
1.2.3. Main cannabinoid receptors (CBRs) 
According to genome databases, Protists do not possess the main cannabinoid  receptors (see 
1.3) so only a brief introduction on them follows. 
1.2.3.1. CB1 and CB2 receptors 
Many cannabinoids initiate their action by interacting with CBRs in many parts of the CNS and 
PNS (Howlett et al., 2010). Ligands include AEA, 2-AG, CBD, THC and synthetic cannabinoids 
(Pertwee et al., 2010). The two main CBRs, CB1 and CB2, differ according to their chemical 
structure, characteristics of their binding to the ligand and their transduction signal system 
(Pertwee, 1995; Howlett et al., 2002). The CB1 receptor is found mainly on neurons in the 
brain and progressive loss of CB1 is an early sign for Huntington’s disease (Blázquez et al., 
2010). CB2 is more abundant in peripheral tissues and macrophages (Grotenhermen, 2004); 
although CB1 has also been described in many peripheral tissues within reproductive, 
gastrointestinal and cardiovascular systems (Pertwee, 2001; Szabo et al., 2001; Wagner et al., 
2001).  
CB1 and CB2 belong to a group of receptors that cross the cell membrane seven times and 
combine with proteins that bind guanine-nucleotide (Svíženská et al., 2008). They have an N- 
terminal extracellular area which has glycosylation locations, a C- terminal intracellular area 
bound to the G protein complex (therefore are G-coupled protein receptors), and 7 
transmembrane domains connected by three extracellular and three intracellular loops 
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(Duvernay et al., 2005). In humans, CB1 and CB2 are 48% similar with regards to amino acid 
composition (Munro et al., 1993).  
 
1.2.3.2. The transient receptor potential vanilloid type 1 (TRPV1)  
The transient receptor potential vanilloid type 1 (TRPV1) belongs to the transient receptor 
potential (TRP) superfamily and its natural ligand is capsaicin, found in chili peppers (Caterina 
et al., 1997). This receptor is primarily expressed in sensory neurons where it co-localises with 
CB1 and CB2, and is involved in temperature sensing, pain and nociception (Caterina et al., 
2000). Ligand binding leads to an influx of calcium (Ca2+) and sodium (Na+) causing the 
depolarization of the cells which induces the physical/neural effects (Liedtke et al, 2010). AEA, 
CBD and OEA act as full agonists (Bisogno et al., 2001; Zou and Kumar, 2018) but 2-AG does 
not bind to it (Starowiczet al., 2007). TRPV1 differs from both CB1 and CB2 in that it has six 
transmembrane domains and consists of an extra intramembrane loop which conjoins both 
the fifth and sixth transmembrane domains and shapes the pore channel region (Caterina et 
al., 1997; Iannotti et al., 2016). 
1.2.3.3. G-protein coupled receptor 55 (GPR55) 
GPR55 is the third true cannabinoid receptor and can bind all three groups of cannabinoids 
(endocannabinoids, phytocannabinoids and synthetic cannabinoids) (Ryberg et al., 2007). 
GPR55 is widely expressed in the CNS and PNS, often co-localising with CB1 (Sawzdargo at al., 
1999). Although AEA targets both CB1 and CB2, it has an even higher affinity for GPR55 
(Ryberg et al., 2007). THC, 2-AG, PEA are also agonists for GPR55 while CBD is an antagonist 
(Ryberg et al., 2007). Despite being the target for many cannabinoids, GPR55 displays low 
sequence identity to both CB1 (13.5%) and CB2 (14.4%) (Pertwee et al., 2010).  
There is another G coupled receptor, GPR119, which is found in the gastrointestinal tract and 
pancreas, where it stimulates the insulin secretion pathway (Li et al., 2018). It is only activated 
by fatty acid amides, including AEA, OEA and PEA, with OEA being the most efficacious 






1.2.4. Other receptors 
Many non-CBR receptors have been proposed to bind to cannabinoids (Bih et al., 2015) (Table 
1.3). Of those, the Serotonin receptor, Dopamine receptor and PPARs were considered 
putative cannabinoid receptors in protists (see 1.3.3). 
Table 1.3: Receptors, other than CB1, CB2, GPR55 and TRVP1, that have been shown to bind 





PPARs CBD, AEA, OEA, PEA, THC, 2-AG 
Opioid CBD, AEA, THC 
glycine CBD, AEA, THC 
Serotonin CBD, AEA 
dopamine CBD, AEA 
Nicotinic Acetylcholine CBD, AEA, 2-AG, CP55940, WIN55, 212-2 
Adenosine CBD 
 
1.2.4.1. Peroxisome Proliferator-activated Receptors (PPARs) 
PPARs belong to the family of the nuclear receptor and exist in three isoforms (α, β/δ, and γ) 
(Ferguson et al. 2018). OEA, PEA, AEA, 2-AG predominantly bind to PPARα (although they can 
also bind to PPARγ, O'Sullivan, 2016), while CBD and THC only bind to PPARγ (Kasten and 
Boehm, 2016). Only the break-down products of endocannabinoids activate PPARβ/δ, so 
many synthetic agonists have been manufactured for this receptor, e.g., GW0742 (Sznaidman 
et al. 2003). Ligand binding activates the metabolism of lipids and glucose (Haile and Kosten 
2017; Ferguson et al. 2018) and this occurs via two routes: the well-studied genomic route 
(see below) and the poorly studied non-genomic route (see Chapter 5).  
In the classic genomic response, a PPAR is ligand-activated then transported to the nucleus 
where it forms a heterodimer with another nuclear hormone, the retinoid X-receptor (RXR). 
The dimer binds to peroxisome proliferator-response elements (PPREs) located on the 
regulatory regions of target genes and carries out transcription (Fig. 1.4) (Chinetti-Gbaguidi 
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and Staels, 2009; Grygiel-Górniak, 2014). PPAR targeted genes are primarily involved in the 
regulation of metabolism and energy homeostasis, cell differentiation, inflammation and 
proliferation (Tyagi et al., 2011). 
PPAR activation is thought to occur via three main mechanisms (Fig. 1.4): 1) Direct binding of 
cannabinoids to the PPAR, 2) indirect binding through the conversion of cannabinoid into 
PPAR-active metabolites (for e.g. PPARβ/δ) and 3) activation of a cannabinoid cell surface 
receptor which results in activation through a cell signalling cascade (O’Sullivan, 2007). This 
signalling cascade has not been well researched but it is known that, in macrophages for 
example, the binding of Mycobacterium tuberculosis and M. leprae to the mannose receptor 
activates PPARγ alongside the activation of the p38 mitogen activated protein kinase (MAPK) 
pathway (Rajaram et al., 2010; Mahajan et al., 2012; Guirado et al., 2018; Diaz Acosta et al., 
2018) (discussed further in 5.3.4.3.).  
 
Figure 1.4: Schematic of the three main ways in which Peroxisome-Proliferator Activated Proteins 
(PPARs) are activated prior to forming a heterodimer with the Retinoid X-Receptor (RXR), and then 
binding to Peroxisome Proliferator-Response Elements (PPREs). 1) Binding of the 
endocannabinoid/cannabinoid, 2) binding of endocannabinoid/cannabinoid metabolites, 3) activation 
of a cannabinoid cell surface receptor (CB R) which results in PPAR activation through a cell signalling 
cascade (O’Sullivan, 2007). 
 
A 4th mechanism has also been proposed whereby fatty acid binding proteins (FABPs) 
chaperone cannabinoids from the outer cell membrane to the nucleus where they bind to 
PPARs (O'Sullivan, 2016). Specifically, binding of the PPARα ligands oleic acid, fenofibrate and 
GW7647 to FABP1 and FABP2 (Hughes et al., 2015), and OEA to FABP5 (Kaczocha et al., 2012), 
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promotes nuclear localisation and the activation of PPARα. THC and CBD have also been 
shown to be chaperoned by FABPs 3, 5 and 7, with equivalent binding to 3 and 7 but with CBD 
binding more strongly to FABP5 (Elmes et al., 2015).  
 
AEA and 2-AG activation of PPARα has been shown to induce neuroprotective properties (Sun 
et al., 2007) while OEA and PEA affect various physiological and pathophysiological functions, 
notably feeding and anti-inflammatory pain (Sun & Bennett, 2007; Hind et al., 2015; 
O'Sullivan, 2016). Activation of PPARγ by CBD has shown anti-carcinogenic properties by 
inhibiting tumour viability and metastasis (Fernández-Ruiz et al., 2015; Payandemehr et al. 
2015) while THC causes the dilation of blood vessels (Sun et al., 2006). In addition to 
phytocannabinoids, synthetic cannabinoids such as Thiazolidinediones (glitazones), a family 
of drugs used for Type 2 diabetes treatment, are common PPAR agonists, particularly 
Rosiglitazone, which has a high affinity and specificity for this PPAR (Lehmann et al., 1995). 
Only the break down products of endocannabinoids, especially of the NAEs, have been shown 
to activate PPARβ/δ, for example, arachidonic acid (AA) from AEA (Yu et al., 2014) and 
oleamide from OEA (Dionisi et al., 2012). 
PPAR activation can therefore be achieved with endocannabinoids, phytocannabinoids and 
their derivatives, and synthetic cannabinoids.  
 
1.2.4.2. Dopamine receptors 
Dopamine is a member of a group of neurotransmitters known as catecholamines that is 
produced by dopaminergic neurons in the CNS and is also present in the PNS, particularly in 
the kidney where it is involved in nephritic vasodilation (Romanelli et al., 2009). The primary 
function of dopamine is to control actions in the brain concerned with movement, cognition, 
feeding, sleeping and mood (Marsden, 2006).  The dopamine receptors it binds to are divided 
into five subtypes (D1 to D5) and all are coupled to Gi and Gs mediated systems of 
transduction and are therefore GPCRs (Rashid et al., 2007). These subtypes are further 
classified into two sub-classes (D1-like and D2-like) (Beaulieu and Gainetdinov, 2011) 
depending on their affinities for agonists and antagonists, their mechanisms of effectors and 
their patterns of distribution (Mishra et al., 2018). The D1 receptor (in D1-like class) 
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dominates the dopamine receptors in the CNS while D2 dominates those in the PNS, with D3, 
D4 (D2-like) and D5 (D1-like) being present at much lower levels (Romanelli et al., 2009). 
Ligand binding to D1 and D2 result in opposite effects (Fig. 1.5) with, for example, activated 
D1 causing the upregulation of cAMP while activated D2 causes its down-regulation (Neve et 
al., 2004; Guevara Lora, et al, 2016).  
AEA, CBD and THC are known to bind to dopamine receptors with THC binding to D1 
(Miyamoto et al., 1996) while CBD and AEA bind to D2 (Beltramo et al., 2000; Seeman, 2016). 
A recent study has shown that THC and CBD can bind to a heterodimer of D1-D2 receptors 
within the brain, with THC only binding to D1 but addition of CBD (ratio 1:3) prevented THC 

















1.2.4.3 Serotonin receptors (5-HT) 
Serotonin (5-HT) is a monoamine neurotransmitter biosynthesized in the CNS and PNS (Mazák 
et al.,2009). It is synthesized by a two-stage enzymatic process: firstly, hydroxylation of 
tryptophan by the enzyme tryptophan hydroxylase and secondly, decarboxylation of the side 
chain by aromatic amino acid decarboxylase (Nakamura and Hasegawa, 2009). 
The term serotonin is derived from the Greek word serum “ser” in combination with the Latin 
word tonic “tonin” because it was first isolated from serum and had the ability to cause a rise 
in blood pressure (Mohammad‐Zadeh et al., 2008; Nichols and Nichols, 2008). Serotonin acts 
locally as a hormone in the different tissues within the digestive system, the cardiovascular 
system and the immune system (Pithadia, and Jain, 2009). It has been identified as being 
involved in psychological diseases, for instance, depression and anxiety, as well as in 
Alzheimer’s disorder (Masson et al., 2012). This large number of roles has led to the 
development of several therapeutic composites such as antidepressants, antipsychotics and 
different anti-vomiting medicines (Cirillo et al., 2011).   
The pharmaceutical properties of serotonin are complicated, as its activities are mediated 
through a large number of 5-HT receptors (Celada et al., 2004). There are at least seven 
distinct receptor families (5-HT₁ up to 5-HT₇) with each family placed in different areas of the 
body and each instigating a different response (Frazer and Hensler, 1999). Apart from 5-HT3 
(a ligand-ion channel), all 5-HT receptor subtypes are GPCRs (Mazák et al., 2009) and ligand 
binding initiates the signaling cascade depicted in Figure 1.6.   
AEA and CBD have been shown to bind to a serotonin receptor. The activation of 5-HT1A by 
CBD reduces the damage of neurotransmitters that occurs as a result of neuropathic pain 
disorder (De Gregorio et al., 2019) while the activation of 5-HT3 by AEA has caused stimulation 


















Figure 1.6 Signalling pathway of the 5-HT receptor (Masson et al., 2012). 
 
 
1.3. Existence of an endocannabinoid system in single-celled eukaryotes 
A phylogenetic study by McPartland et al. (2006) examined whether all eukaryotes possessed 
known receptors and enzymes which participated in the endocannabinoid system (ECS) (Fig. 
1.7). The unicellular organisms included the yeast Saccharomyces cerevisiae, the obligate 
Plasmodium falciparum and the ciliate Tetrahymena thermophilia. The first conclusion of the 
study was that these protists did not contain homologues to the four main cannabinoid 
receptors (CB1, CB2, GPR55 and TRPV1). The second was that they all contained sequences 
for the enzymes Fatty Acid Amide Hydrolase (FAAH) and Monoacylglycerol Lipase (MAGL) 
which hydrolyse NAEs and 2-AcGs, respectively. Differences were then evident with regards 
to the synthesizing enzymes, with sequences for DAGL (synthesis of AcGs) being present in T. 
thermophila and S. cerevisiae (but not P. falciparum) while sequences for NAPE-PLD (synthesis 
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of NAEs) were present in P. falciparum and S. cerevisiae (but not in T. thermophila) 
(McPartland et al., 2006). Experimental evidence to substantiate these observations was 











Figure 1.7: A summary of the main components of the AEA and 2-AG cannabinoid system showing 
their synthesis (left), the four main cannabinoid receptors and their metabolizing enzymes (right) 
(Zhou et al., 2019).  
 
1.3.1. Endocannabinoids in Tetrahymena 
Anagnostopoulos et al. (2010) identified a suite of N-acylethanolamines (NAEs) and 2-
acylglycerols (2-AcGs) in Tetrahymena thermophila (Table 1.4) together with free fatty acids 
(FFAs). The concentrations of 2-AcGs were higher than NAEs and only small amounts of AEA 
and 2-AG were detected. Of the NAEs detected, GLEA, SEA and EEA are present in only trace 
amounts in mammals (Kleberg at al., 2014; Gaitán et al., 2018) while LEA, along with PEA and 
OEA, are more common and are primarily in the GI tract where they exhibit similar anorexic 





Table 1.4: Presence of N-acylethanolamines (NAEs) and 2-acylglycerols (2-AcGs) in the ciliate 
Tetrahymena thermophila together with their cellular concentration (Anagnostopoulos et al., 2010).  
Endocannabinoid Class Concentration (pM/mg of 
protein at 27oC) 
Linolenoylethanolamine (LEA) NAE 2.3±0.8 
Oleoylethanolamine (OEA) NAE 0.6±0.3 
Palmitoylethanolamine (PEA) NAE 1.8 ± 0.3 
Stearoylethanolamine (SEA) NAE 0.3 ± 0.1 
Eicosenoylethanolamine (EEA) NAE 3.2±1.5 
γ-Linolenoylethanolamine (GLEA) NAE 2.3±0.8 
   
γ-Linolenoylglycerol (2-GLG) 2-AcG 5100±620 
2-Palmitoylglycerol (2-PG) 2-AcG 770±120 
2-Linolenoylglycerol (2-LG) 2-AcG 4000±560 
2-Oleoylglycerol (2-OG) 2-AcG 1600±240 
2-Eicenoylglycerol (2-EG) 2-AcG 1500±290 
 
1.3.2. Enzymes in Tetrahymena 
Karava et al. (2001) were first to detected an enzyme in Teterahymena pyriformis which had 
the same function as FAAH (hydrolysing AEA to arachidonic acid and ethanolamine).  Karava 
et al. (2005) then went on to revealed the presence of 2 isoforms of FAAH in this species: a 
66 kDa isoform (close in size to that reported for mammalian FAAH [63 or 67 kDa] [Giang and 
Cravatt, 1997]) and a 45 kDa isoform (close to the 46 kDa of amide hydrolase in invertebrates 
[Matias et al., 2001]). Two isoforms of MAGL have also been found in T. thermophila; 40kDa 
and 45kDa (Evagorou et al., 2010). 
 
1.3.3. Receptors in Tetrahymena 
To date, no homologues of CB1, CB2, GPR55 and TRVP1 have been detected in protists. 
However, they do respond to cannabinoids (see 1.6.4 and 1.7.2) suggesting a cellular target 
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is present. Bih et al. (2015) reviewed the literature for evidence of the involvement of other 
receptors that could bind CBD and found seven. Table 1.5 lists these seven receptors and 
evaluates whether they might be present in Tetrahymena.  
Table 1.5: CBD receptors identified by Bih et al., (2015) and whether the receptor, or orthologues, 
are present in Tetrahymena (www.ciliate.org).  
Receptors Cannabinoid ligands  Present in 
Tetrahymena? 
Opioid CBD, AEA, THC Yes, μ Opioid 
Dopamine CBD, AEA Yes, D1 receptor 
Serotonin  CBD, AEA Yes 
Adenosine CBD Possible, produces 
cAMP  




CBD, AEA, 2-AG, CP55940, WIN55,212-2 Possible- possess 
acetylcholinesterase 




1.3.4. Response of Tetrahymena to cannabinoids 
Only two studies have evaluated the effect of cannabinoids on Tetrahymena. McClean and 
Zimmerman (1976) were the first to show that THC caused the cells of T. pyriformis to become 
round and move in a sluggish manner. It was then found that THC caused a dose-dependent 
delay in cell division, with cells being most sensitive in their G2 phase of cell division 
(Zimmerman et al., 1981). In both studies, cells recovered after a few hours.  
In addition to these, there have been two studies on amoebae (see 1.6.2) but as yet, the 





1.4. Cannabinoids and amoebae  
1.4.1. Overview of amoebae 
Amoeba represent an important component of surface-associated communities (biofilms) as 
their trophozoites can only feed on surface-associated prey (Parry, 2004). Free living amoebae 
(FLA) are prevalent in water and soil (Lorenzo-Morales et al., 2013) and although several 
species are opportunistic pathogens, the majority are non-pathogenic (Thomas et al., 2009). 
Amoebae are divided into naked and testate amoebae; testate amoebae possess an external 
shell-like structure (teste) with one compartment and one aperture (Esteban et al., 2014).    
Naked amoebae exist in three forms; a cyst which forms under unfavourable conditions (lack 
of food and osmotic stress), a moving trophozoite (the feeding form) and a ‘floating form’ (a 
non-feeding form suspended in liquid) (Figure 1.8). Also, a fourth form has been identified as 








Figure 1.8:  Life cycle of an amoeba (Smirnov, 2008). 
 
1.4.2. Amoebic response to cannabinoids 
To date, only two studies have examined the response of amoebae to cannabinoids. Pringle 
et al. (1979) studied the growth of Naegleria fowleri for 3 days with/without three 
phytocannabinoids: Delta-9-tetrahydrocannabinol (THC), Cannabidiol (CBD) and Cannabinol 
(CBN). N. fowleri was affected by all treatments and results showed that, at an equivalent 
concentration, THC was more potent than CBN or CBD (Table 1.6). Moreover, THC prevented 
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the trophozoites from transforming into flagellates or cysts, but had no effect on cell shape 
or speed of movement (Pringle et al., 1979).  
Table 1.6: The influence of the phytocannabinoids Delta-9-tetrahydrocannabinol (THC), Cannabidiol 









delta-9-tetrahydrocannabinol (THC) 15.9 47 Grown up from 
1x104-5x104 





159 No growth 
Cannabidiol (CBD) 15.9 73 
31.8 87 
63.6 94 




The second study was carried out by Dey et al. (2010) who tested N-
arachidonoylethanolamine (AEA) and 2-O-arachidonoylglycerol (2-AG) on the growth of three 
amoebae over 3 days: Acanthamoeba castellanii, Willertia magna and Vermamoeba 
(Hartmannella) vermiformis) (Table 1.7). Results indicated that reduced population growth 
occurred with 5.75µM AEA (MIC <5.75µM) and 100% cell death occurred at 57.5µM (Table 
1.7) V. vermiformis was more sensitive to AEA treatment than A. castellanii and W. magna 
with IC50s of 14, 17 and 20µM, respectively. In addition, all amoebae were affected by 2-AG 
at 26.4 µM (only concentration tested) and showed the same pattern of sensitivity as that 
with AEA, i.e., V. vermiformis > A. castellanii > W. magna. This study also demonstrated that 
it was 2-AG per se that caused the reaction (and not its breakdown products) as the same 
reduction in population growth was recorded with 2-AG-ether which is a non-hydrolysable 
form of 2-AG (Table 1.7) (Dey et al., 2010). 
Both studies then, found that two endocannabinoids and three phytocannabinoids reduced 
amoebic population growth after 3 days. Successful population growth of amoebae requires 
successful ingestion and metabolism of prey, yet no study to date has examined the effect of 
cannabinoids on amoebic feeding.  
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Table 1.7: Sensitivity of three amoebae to different doses of N-arachidonoylethanolamine (AEA), 2-O-
arachidonoylglycerol (2-AG) and 2-AG-ether under similar condition (cells were grown up from 2x105 
cells/ml initial dose for 72 h, at 37oC) (Dey et al., 2010). 
Amoeba sp. Cannabinoid Concentration 
(µM) 
% Population growth compared to Control 
Acanthamoeba 
castellanii 
AEA 5.75 Inhibition of growth 
17.0 50 
28.8 68 
57.5 Cell death 
2-AG 26.4 reduction 75.2%  
2- AG ether 27.4 reduction 75.4%  




2- AG 26.4 reduction 56.6%  
2- AG ether 27.4 reduction 56.2%  
Hartmannella 
vermiformis 




2- AG 26.4 reduction 95.6%  
2- AG ether 27.4 reduction 87.8%  
 
1.4.3. Amoebic feeding 
1.4.3.1. General overview 
Amoebic trophozoites use extended pseudopodia for motility and the engulfment of prey via 
phagocytosis (Bogitsh et al., 2018). Phagocytosis refers to a biological process that organizes 
the absorption of particles into cellular vacuoles (phagosomes) from the cell membrane (Levin 
et al., 2016). The mechanism of phagosomal formation and maturation in protists is still 
poorly described but is thought to be similar to that of macrophages. Briefly, the process 
begins when the phagocytic cell recognises the binding ligands of the prey cell in a receptor-
dependent way (Fig. 1.9, stages 1-2). This recognition leads to signal pathways that stimulate 
the re-shaping of the actin cytoskeleton and the extension of pseudopodia to enclose the prey 
in a phagocytic cup (Duhon and Cardelli, 2002; Cosson and Soldati, 2008; Pauwels et al., 2017) 
(Fig. 1.9, stage 3). The complete closing of the phagocytic cup leads to the formation of the 
phagosome (Fig. 1.9, stages 4-5), which is inert until it maturates via a complicated series of 
fusion events with endosomes (to reduce the pH) and then with lysosomes (which contain 
digestive enzymes) (Haas, 2007; Pauwels et al., 2017) (Fig. 1.9, stage 6). The process ends with 
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the defecation of waste materials (Fig. 1.9, stage 7) and the recycling of the phagosome 












Figure 1.9: Diagrammatic representation of membrane dynamics in the phagocytic cycle. 1) Receptors 
and membrane are available for prey uptake and phagosome formation. 2) Binding of prey to 
receptors (e.g. C-type lectins) leads to 3), actin polymerisation and formation of pseudopodia which 
surround the prey. 4) Myosin is recruited to help seal the ends of the pseudopods together. 5) 
Dynamin is recruited to allow detachment of the phagosome into the cytoplasm. 6) The phagosome 
matures via a series of fusions with endosomes and lysosomes and the contained material is digested. 
7) Phagosome membrane fuses with the plasma membrane and releases undigested material. 8) 
Plasma membrane is endocytosed to form vesicles. 9) Vesicles are transported to the site of 
phagocytosis by microtubule ribbons and used to form new phagosomes. Stages 3 to 7 are known to 
be reliant on activation of the Arp2/3 system.  
 
1.4.3.2. Receptor-mediated ingestion of prey (Fig. 1.9, stages 1-2) 
C-type lectins have been shown to be key receptors for prey capture in amoebae (Ravdin and 
Guerrant, 1981; Bracha et al., 1982; Ravdin et al., 1985; Petri et al., 1987; Allen and 
Davidowicz, 1990; Venkataraman et al., 1997; Harb et al., 1998; Garate et al. 2004; Alsam et 
al., 2005; Bär et al., 2015). C-type lectins are glycoproteins that are part of a protein super 
family which includes 17 sub-groups; divided according to phylogenetic and structural 












bind carbohydrate ligands on bacteria, in a calcium dependent manner, via a conserved 
extracellular carbohydrate recognition domain (CDR)  (Kerrigan & Brown, 2009; Hoving et al,. 
2014; Alenton et al., 2017). The carbohydrates they recognize include mannose, N-
acetylglucosamine (GlcNAc), L-fucose, glucose, galactose and N-acetylgalactosamine 
(GalNAc) (Drickamer and Fadden, 2002).  
C-type lectins are functionally diverse and are involved in the recognition of pathogens, 
phagocytosis, activation of platelets, cell binding, transporting substance into the cell and cell 
differentiation (Ramoino et al., 2001; Wormald & Sharon, 2004; Cambi et al., 2005; Roberts 
et al., 2006; Gupta, 2012). The majority of these lectins exist on the cell surface however they 
can also can be found associated with organelles such as the Golgi complex, phagosome and 
nuclear envelope (Ramoino, 1997; Roberts et al., 2006).  
The role of specific C-type lectins in amoebic feeding has been studied using sugar blocking 
experiments whereby the amoeba is pre-incubated with a specific sugar, to block a specific 
receptor, and then the uptake of prey is compared in the presence/absence of the blocking. 
Using this technique, a mannose receptor has long been known play a role in amoebic feeding. 
Bracha et al. (1982) first demonstrated that the uptake of Escherichia coli and Serratia 
marcescens by Entamoeba histolytica was reduced by 66% with 100mM mannose. Alsam et 
al. (2005) also showed that the feeding of Acanthamoeba castellanii on E. coli was reduced 
by 80% in the presence of 100mM mannose. Allen and Davidowicz (1990) tested various 
mannose concentrations on A. castellanii whilst feeding on the yeast Saccharomyces 
cerevisiae and found the IC50 to be 10mM.  
The A. castellanii mannose receptor has been cloned and is a 400-kDa protein, comprising 
multiple 130-kDa subunits (Garate et al. 2004). Despite extensive BLAST searches, this 
receptor lacks sequence identity to any well characterized lectin receptor in other cell types. 
For example, in mammals the mannose receptor is 180-kDa (Stahl and Ezekowitz, 1998). 
Mannose residues are present in many Gram-negative cell wall structures such as O-antigens, 
core polysaccharide, Type I fimbrae, S-layers, capsules, slime (Ofek et al., 1993; Hamrick et 
al., 2000; Lagoumintzis et al., 2003; Veremeichenko et al., 2005; Bradshaw et al., 2018) and 
in the mannose-capped lipoarabinomannan (ManLAM) of Mycobacterium tuberculosis (Kang 
et al., 2005). Gram-positive cells do not possess mannose residues (Mirelman et al., 1980).  
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There is also evidence for a Gal/GalNAc receptor in amoebae. Entamoeba histolytica primarily 
uses this 170 kDa transmembrane lectin as an adherence molecule to bind to host cells 
(Ravdin and Guerrant, 1981; Petri et al., 1987) and it can be blocked with 4.5mM GalNAc and 
56mM galactose (Ravdin et al., 1985). E. histolytica has also been shown to use this lectin to 
bind Gal/GalNAc-rich bacterial strains, e.g. E. coli serotype O55 (Bär et al., 2015). 
Vermamoeba vermiformis possesses a similar 170kDa transmembrane lectin to bind and 
internalize Legionella pneumophila which can be 70-89% blocked with 100mM GalNAc 
(Venkataraman et al., 1997; Harb et al., 1998). In mammalian cells, the membrane galactose 
ligand (MGL) is only ca. 40 KDa but produces dimers and trimers (80-120KDa) (Napoletano et 
al. 2012). It binds only GalNAc and blocking with 100mM GalNAc prevents of the uptake of 
Neisseria gonorrhoeae (van Vliet et al., 2009). GalNAc residues are present in the cell walls of 
both Gram-positive and Gram–negative bacteria where they form part of the 
glycosaminoglycans, teichoic acids, O-antigens, and slime (Speert et al., 1988; 
Abeygunawardana et al., 1989; Michael et al., 2002; Bogomolnaya et al. 2008). 
To date, there have been no reports of true amoebae possessing a GlcNAc receptor. Indeed, 
no specific GlcNAc receptor has been found in professional phagocytes, with GlcNAc 
instead binding to either the mannose receptor (East et al., 2002), Peptidoglycan 
Recognition Proteins (PGRPs) (Liu et al., 2001) or DC-SIGN (van Kooyk and Geijtenbeek, 
2003). To date, there are no reports of protists possessing homologues of PGRPs or DC-
SIGN so GlcNAc might bind to the mannose receptor instead. However, one study has 
argued that a specific GlcNAc receptor is one of three lectins in the slime mould Dictyostelium 
discoideum (which has an amoebic stage in its growth cycle). Here, all three are used for the 
adhesion of cells to a surface (Bozzaro & Roseman, 1983). GlcNAc is one of the main cell 
surface carbohydrates in bacteria which, together with N-acetylmuramic acid, forms the 
peptidoglycan layer of Gram-negative and Gram-positive cells (Rogers et al., 1980). It is 
also found in the core polysaccharide of the lipopolysaccharide layer (van Kooyk and 
Geijtenbeek, 2003).  
In addition to C-type lectins, a recent study by Sattler et al. (2018) has shown that D. 
discoideum possesses homologous receptors to the mammalian class B scavenger receptors, 
LIMP-2 and CD36, i.e. LmpA and LmpB, respectively. Scavenger receptors are another class of 
surface membrane glycoprotein used for the recognition of carbohydrates in phagocytosis 
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(Perún et al., 2016). The Class B scavenger receptors bind to the lipoteichoic acid of Gram-
positive bacteria (Stuart et al., 2005; Hoebe et al., 2005) and the lipid A of the 
lipopolysaccharide layer of Gram-negative bacteria (Baranova et al., 2008). In D. discoideum, 
LmpA was found in endosomes and phagolysosomes and played a role in the binding and 
phagocytosis of bacteria (particularly Gram-positive strains) while LmpB was localized to the 
plasma membrane and early phagosomes and was exclusively involved in the uptake of Gram-
positive bacteria (Sattler et al. 2018).  
1.4.3.3. Phagosome formation and trafficking (Fig. 1.9, stages 3-6) 
Little is known about the formation of phagosomes in protists but it is thought to be similar 
to that of macrophages. Here, phagosome formation is a complex molecular process but in 
its simplest terms: Upon prey-receptor binding, actin polymerisation is activated and two 
pseudopodia extend out from the cell to surround the prey particle. Myosin is then recruited 
to help seal the ends of the pseudopods together and then the recruitment of dynamin leads 
to the detachment of the phagosome from the cell surface to the cytoplasm (Levin et al., 
2016). The whole process (and indeed phagosome trafficking [Duleh and Welch, 2010]) is 
reliant on activation of the Arp2/3 system (Seven-transmembrane-actin-related proteins 2 
and 3) which itself is activated via a plethora of molecules and signalling cascades (Levin et al. 
2016) (see Chapter 5).  
Studies on protists have confirmed that actin, myosin and dynamin play a role in the 
formation of the phagocytic cup, migration of newly formed phagosomes into the cell, 
trafficking of phagosomes within the cell, and their fusion with lysosomes (Tiggemann and 
Plattner, 1981; Tiggemann et al., 1981; Allen and Fok, 1983; Méténier, 1984). In addition, all 
sequenced protists to date have been shown to possess the Arp2/3 complex, including 
amoebae; Acanthamoeba castellanii, Naegleria fowleri, Entamoeba histolytica, E. dispar, E. 
invadens and E. moshkovskii (www.amoebadb.org). Defecation in D. discoideum is also 





1.4.3.4. Defecation and membrane recycling (Fig. 1.9, stages 7-9) 
There is very little information on the recycling of phagosome membrane in amoebae and 
most work has been performed on ciliates; though this is still very little. Ciliates are known to 
possess a limited volume of membrane with which to form phagosomes (Allen, 1974) and the 
constant recycling of ‘old’ phagosome membrane from the cytoproct (cell ‘anus’) to the 
cytostome (cell ‘mouth’) is essential to ensure membrane availability for newly developing 
phagosomes (Allen, 1974). The actual process by which ‘expended’ phagosome membrane is 
recycled has only been studied in the ciliate Paramecium (Allen and Fok, 1980). Here, the 
membrane of a defecated phagosome fuses with the plasma membrane and is then retrieved 
at the cytoproct by endocytosis. The resulting endosomes become flattened and disk-shaped 
(‘discoidal vesicles’). Within 3 min these vesicles become aligned to a bundle of microtubule 
ribbons which join the cytoproct to the cytostome, and the vesicles then travel along it and 
reach the cytostome by 4 min (Allen and Fok, 1980). This is an example of ‘direct recycling’, 
i.e., no involvement of the lysosomal or Golgi systems on the vesicle’s journey back to the 
cytostome (Allen and Fok, 1980). Direct membrane recycling has also been observed in the 
ciliates Tetrahymena (Grønlien et al., 2002) and Ophrydium (Goff and Stein, 1981) but it is 
currently unknown whether amoebae also employ direct membrane recycling. 
 
1.5. Aims of the study 
The overall aim of this study was to evaluate the sensitivity of amoebae to the 
endocannabinoid AEA and the phytocannabinoid CBD by examining their population growth 
and feeding response in their presence. It also aimed to evaluate whether three receptors 
(PPAR, Dopamine, Serotonin) could be involved in their mode of action to investigate the 
evolutionary, and non-receptor-based, functioning of the ECS in amoeba. 
Specific objectives were to: 
1) Determine the extent of AEA and CBD sensitivity within freshwater naked amoebae by 
evaluating population growth in their presence, in a range of species. Determine the 
MIC, IC50 and lethal doses with those sensitive strains.   
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2) Characterise the feeding behaviour of untreated Vermamoeba vermiformis and 
determine whether it possesses C‐type lectin prey‐recognition receptors for mannose, 
N‐Acetyl‐D‐glucosamine (GlcNAc) and N‐Acetyl‐D‐galactosamine (GalNAc).  
3) Compare the feeding behaviour of V. vermiformis in 2) to that in the presence of the 
cannabinoid and evaluate whether any effects (specifically feeding lags and ingestion 
rates) are density‐dependent, and whether cannabinoids interact with the prey‐
recognition receptors. 
4) Determine whether cannabinoids affect phagosome trafficking and defecation in V. 
vermiformis using a pulse‐chase experiment.  
5) Determine whether PPARs are a possible cannabinoid receptor in amoebae.  
a. Evaluate how many amoebic species are sensitive to agonists for the three 
PPAR isoforms (α, β/δ and γ). Determine the MIC, IC50 and lethal doses for 
population growth of the sensitive strains and whether the effects can be 
abolished in the presence of their respective PPAR antagonist (α, β/δ and γ). 
b. Determine whether the PPAR agonists (at their IC50s) mirror the effects of 
cannabinoids on V. vermiformis feeding and whether these effects can be 
abolished with the use of their respective PPAR antagonist. Determine 
whether any of the PPAR antagonists can abolish the cannabinoid feeding 
effect.  
6) Determine whether the Dopamine and/or Serotonin receptors are possible cannabinoid 
receptors in amoebae.  
a. Evaluate whether the AEA/CBD effect on the population growth of sensitive 
strains can be blocked with Haloperidol (a dopamine/serotonin antagonist). 
b. If a responsive strain is something other than V. vermiformis, perform a feeding 
experiment in the presence of the cannabinoid with/without haloperidol. 
c. Using more specific blockers, determine whether any Haloperidol effect is due 






Chapter 2: Methods and Materials  
2.1 Organisms and maintenance 
2.1.1. Escherichia coli 
Escherichia coli (E. coli) DH5α (Dr Karen Tait) was maintained as streak plates on Diagnostic 
Sensitivity Test Agar (DST) containing chloramphenicol at 30 µg/ml (to retain a bacterial 
plasmid containing a gene for a lactonase, which was required for a separate study) (see 
Appendix 1).  The bacterium was grown at 25oC for 3 days prior to an experiment, after which, 
a bacterial suspension was prepared by flooding two plates with sterile distilled water and 
scraping the cells into suspension with a sterile spreader. The number of cells/ml was then 
determined (see 2.3.1). 
2.1.2. Synechococcus sp. (‘Pico’)  
Synechococcus sp. S-KH3 (Dillon and Parry, 2009) was cultured in a flask containing Blue-green 
11 broth (BG11, see Appendix 1). Cells were sub-cultured 3 days prior to an experiment and 
incubated at room temperature (23°C), in a 16:8 natural light: dark cycle, on a rotary shaker 
(0.00118 g). The number of cells/ml was then determined (see 2.3.2). 
 
2.1.3. Amoebae 
Twenty-seven strains of amoeba (Table 2.1) were maintained on Non-Nutrient Agar (NNA, 
see Appendix 1) with a thin streak of E. coli DH5α down the center of the plate.  They were 
sub-cultured by removing a plug of agar from a previously cultured amoeba plate and placing 
this, cell-side-down, on the streak of E. coli on a fresh NNA plate. Plates were incubated at 
room temperature (ca. 23°C) for 7 days prior to an experiment.  Then, the agar plug together 
with any residual E. coli streak and areas with cysts, were removed from the plate prior to 
flooding with Amoeba Saline (AS, see Appendix 1) and suspending the cells using a sterile 
spreader. The suspension was collected in a 50 ml tissue culture flask which was placed on a 
rotary shaker (0.00118 g) to promote the amoebic ‘floating form’ and avoid the formation of 
cysts. When very high concentrations of an amoeba were required (feeding experiments [see 




Table 2.1: Sources of amoebae used in the study. CCAP (Culture Collection of Algae and Protozoa), 
ATCC (American Type Culture Collection).  
 
Amoeba  Source Isolated from… Year 
Acanthamoeba castellanii CCAP1501/1A Soil; California, USA 1957 
Acanthamoeba polyphaga CCAP1501/18 
Freshwater; cooling tower, Lincoln, England, 
UK 1985 
Amoeba borokensis  CCAP1503/7 Freshwater; pond, Borok, Russia 1974 
Allovahlkampfia nedeslanaiensis  CCAP2502/3  Soil; pasture, Veluwe, The Netherlands 2011 
Cochliopodium minus  CCAP1537/1A Freshwater; pond, Madison, Wisconsin, USA 1965 
Dermamoeba algensis  CCAP1524/1  Freshwater; Pond, St Petersburg, Russia 2000 
Echinamoeba silvestris   CCAP1519/1 Soil; Wandlebury Wood, England, UK 1964 
Flamella arnhemensis  
CCAP1525/2 
Freshwater; cooling tower, Arnheim, 
Netherlands 2004 
Hartmannella cantabrigiensis  CCAP1534/8  Freshwater; ditch, Cambridge, England 1972 
Hartmannella cantabrigiensis   CCAP1534/11 Freshwater; ditch, Cambridge, England 1972 
Mayorella cantabrigiensis  CCAP1547/11 Freshwater; Cambridge Univ., England, UK 1981 
Naegleria gruberi NEG-M ATCC30224 No data ? 
Phalansterium filosum  CCAP1576/1 Soil; Khao Yai National Park, Thailand 2001 
Saccamoeba limax CCAP1572/3 Freshwater, Scotland, UK  1977 
Stygamoeba regulata  CCAP1580/1  Brackish; Nivå Bay, The Søund, Denmark 1994 
Tetramitus aberdonicus  CCAP1588/4 Soil; garden, Macauley Institute, Aberdeen, UK 1972 
Thecamoeba quadrilineata  CCAP1583/10 Freshwater; roof gutter, Melsbach, Germany 1998 
Vahlkampfia avara  CCAP1588/1A Freshwater; ditch, Schneider, Indiana, USA 1964 
Vannella placida  CCAP1565/2 Freshwater; stream, Wisconsin, USA 1964 
Vermamoeba vermiformis  CCAP1534/7A Freshwater; Pigeon Lake, Wisconsin, USA 1964 
Vermamoeba vermiformis  CCAP1534/13 Freshwater; sediment, Siegburg, Germany 1967 
Vermamoeba vermiformis  CCAP1534/14 Freshwater; lake, Groβer Barschsee, Germany 2008 
Vermamoeba vermiformis 137 
Dr Sutherland 
McIvor Soil, North Berwick, Scotland, UK  2000 
Vermamoeba vermiformis 172 
Dr Sutherland 
McIvor Soil, Byron Bay, East Australia  2013 
Vermamoeba vermiformis 173 
Dr Sutherland 
McIvor Soil, Byron Bay, East Australia  2013 
Vermamoeba vermiformis 174 
Dr Sutherland 
McIvor Soil, Byron Bay, East Australia  2013 
Vexillifera bacillipedes  CCAP1590/1 Freshwater; Rock River, Wisconsin, USA 1968 
 
2.2. Experimental compounds 
2.2.1 Fluorescent microspheres (‘beads’) 
A suspension of yellow-green fluorescent microspheres of 0.49µm diameter (Fluoresbrite, 
Polyscience Inc.) was stored at 4°C. The number of beads/ml was determined (see 2.3.2). 
32 
 
2.2.2. Agonists  
Stock solutions of all agonists (obtained from TOCRIS) were prepared in ethanol and stored 
at -20oC.  Cannabidiol (CBD), N-oleoylethanolamine (OEA), N-palmitoylethanolamine (PEA), 
GW0742 and Rosiglitazone stocks were 10mM while Anandamide (AEA) was 14.4mM. When 
necessary, stocks were 10-fold diluted in AS prior to use.   
 
2.2.3. Antagonists 
Stock solutions of all antagonists (obtained from TOCRIS) were prepared at 10mM in ethanol 
and stored at -20oC.  These included the PPAR antagonists GW6471 (PPARα), GSK3787 
(PPARβ) and T0070907 (PPARγ), the dopamine receptor antagonists Haloperidol chloride, LE 
300 and L-741,626 and the serotonin receptor antagonist (S)-WAY 100135 dihydrochloride. 
When necessary, stocks were 10-fold diluted in AS prior to use.  
 
2.2.4. Sugars 
Three sugars were used to block amoebic C-type lectin feeding receptors prior to the addition 
of CBD. D (+)-Mannose, N-Acetyl-D-glucosamine (GlcNAc) and N-Acetyl-D-galactosamine 
(GalNAc) (Sigma). Stock solutions (1M) were freshly prepared in sterile water on the day of 
an experiment.  
 
2.3. Counting cells and beads 
  
2.3.1 Counting E. coli cells  
An E. coli suspension (see 2.1.1) was 10-fold diluted in sterile water down to 10-3 in 
eppendorfs (volume 100µL). A drop of the DNA stain, 4 ' 6-dimidino-2-phenylendol (DAPI), 
was added to each dilution and left to stain for 30 min at room temperature. A known volume, 
of a known dilution, was filtered onto a white 0.2µm pore-size filter (Millipore) under low 
suction. The filter was then placed onto a drop of immersion oil on a glass slide. A drop of oil 
was placed on the center of the filter, followed by a coverslip and then a final drop of oil was 
placed on the cover slip. The filter was examined with an epifluorescence microscope (1250x 




A whipple grid (WG) was located in the eye piece of the microscope and cells were counted 
in randomly selected WGs until at least 400 cells had been counted. The average number of 
cells per WG was deduced and multiplied by 23068 to give the number of cells on the filter. 
Knowing the volume and dilution filtered, the concentration of E. coli cells in the undiluted 
sample (cells/ml) could be calculated.   
 
2.3.2 Counting Synechococcus cells and beads  
The same method was performed as described in 2.3.1. but in the absence of DAPI staining 
because Synechococcus cells naturally fluoresce red under green excitation (due to the 
presence of Chlorophyll a) and beads fluoresce yellow under blue excitation. 
 
2.3.3. Counting amoeba cells in suspension 
Two haemocytometer slides, each containing two haemocyometer grids, were loaded with a 
suspension of the amoeba (see 2.1.3.). The number of cells in the medium-sized squares (9 
per grid) were determined (36 squares in total) using a light microscope (x40 magnification). 
The average number of cells per square was multiplied by 10,000 to give the number of 
cells/ml in the suspension.  
 
2.3.4. Counting amoeba cells on agar plates  
All experimental plates, inoculated with amoeba cells, had a piece of acetate glued to the 
back of the plate, which contained 5 counting squares (area of each = 1.44 cm2). When the 
plate was viewed with a light microscope (x40 magnification) the squares were visible, along 
with the amoeba cells on the surface of the plate.  The number of cells were counted in each 
square, divided by 1.44 and then averaged to give the number of amoebic cells/cm2. 
 
2.3.5. Counting fluorescent prey inside Vermamoeba vermiformis cells 
A fixed suspension of the amoeba, obtained in feeding and pulse-chase experiments (see 2.5 
and 2.6), was loaded into a haemocytometer slide and viewed with an epifluorescence 
microscope using a combination of white light (to locate amoeba cells) and either blue or 
green excitation (to count ingested beads and Synechococcus, respectively). The 
haemocytometer grid lines aided the location of the very small cells of V. vermiformis. A total 
of 20 cells in each sample were viewed and the number of ingested prey/cell determined. 
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2.4. Amoeba population growth experiments 
 
2.4.1. Basic experimental protocol  
E. coli was prepared and counted as described in 2.1.1. and 2.3.1. Amoebae were prepared 
and counted as described in 2.1.3 and 2.3.3. All experiments employed NNAg plates (see 
Appendix 1) which was AS solidified with agarose as opposed to agar No2 (which contains a 
carbon source). This prevented the growth of E. coli during the experiment. Furthermore, 
NAAg plates were prepared on a spirit-level-checked surface in the Class 2 cabinet.  
 
The desired starting concentrations of an amoeba and E. coli were 15 cells/cm2 and 5x106 
cells/cm2, respectively. Since the surface area of the agar in the 9 cm diameter Petri dish was 
63.63 cm2, this demanded that the inoculum (which was always 1ml) contained 954 amoebic 
cells and 3.18x108 E. coli cells. For a control inoculum, the amoeba and E. coli were added to 
the eppendorf and the volume was made up to 1ml with AS. For test inocula, the cells and 
compound were added and then made up to 1ml with AS.  
 
All the 1ml inocula were vortexed before pouring onto a NNAg agar plate, swirling the plate 
to ensure full coverage and then leaving the plate to dry on a spirit-level-checked surface in a 
Class 2 cabinet. A piece of acetate containing 5 counting grids was then fixed onto the back 
of the plate and a Tzero count was performed (see 2.3.4) before incubating the plates at 16oC. 
The amoeba cells on the Control plate were counted every day and only when the population 
had divided at least three times were the cells on the Test plates counted (normally 3 days).  
 
2.4.2. Initial screening of amoebae for sensitivity to the agonists  
These experiments employed a very high concentration of each agonist (200µM) with the 
view that, if the amoeba did not respond at this concentration it was unlikely to be sensitive 
to the agonist. Experiments followed that described in 2.4.1. To achieve an agonist 
concentration of 200µM in the 1ml inoculum, 20µL of undiluted CBD, OEA, PEA, GW0742 and 
Rosiglitazone stocks, and 13.9 µL of undiluted AEA stock, were used. These experiments were 
repeated at least twice. Experiments that utilised the same controls were grouped for 
statistical analysis, i.e., (i) CBD and AEA vs a common Control and, (ii) OEA, PEA, GW0742 and 
Rosiglitazone vs a common Control. Each group was analysed using a one-way Analysis of 
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Variance (ANOVA). If P≤0.05, a post-hoc Tukey test was carried out to discern which 
treatment was giving the significant result.  
 
2.4.3. Determining the MIC, IC50 and lethal dose of agonists against sensitive amoebae 
These experiments employed a range of agonist concentrations and the procedure followed 
that described in 2.4.1. Experiments were repeated three times. The %population growth 
(compared to the Control) in each replicate of each test was deduced and plotted against 
agonist concentration in Qtiplot, which calculated the IC50 value and slope.  The MIC and lethal 
dose values were estimated from the graphs by extrapolating the linear decline in % 
population growth to 100% (for MIC) and 0% (for lethal dose) (see Figure 3.2 as an example).  
 
2.4.4. Effect of antagonists on population growth  
These experiments tested AEA/CBD/PPAR agonists at either 2µM or their IC50 value (see 
relevant Chapters), in the presence and absence of 10µM antagonists for PPARs, Dopamine 
and Serotonin receptors. Each antagonist was added 20 mins before the addition of the 
agonist. Experiments were performed three times and the % population growth of the Tests 
(compared to the Control) were analysed with a one-way ANOVA. Those that gave significant 
results (P≤0.05) were subjected to dose-response experiments whereby the antagonist 
concentrations were 10, 1, 0.1, 0.01 and 0.001µM.  These experiments were repeated three 
times and data (% population growth compared to Control) were analysed with a one-way 
ANOVA and those that gave significant results (P≤0.05) were further analysed using a post-
hoc Tukey test.  
 
2.5. Feeding experiments involving Vermamoeba vermiformis 
 
2.5.1. Basic experimental protocol 
The prey used for feeding experiments were either fluorescent microspheres (beads) or 
Synechococcus due their fluorescent characteristics allowing their visualization within 
amoeba cells. Inoculation of experimental plates followed the procedure described in 2.4.1., 
i.e., 1ml inoculum, but the concentration of prey was increased to 3x107 particles/cm² (this 
concentration was optimised to ensure enough prey were consumed/cell in a relatively short 
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time period). Also, a denser suspension of the amoeba was required (see 2.1.3). Test inocula 
were variable and contained the agonist and/or antagonist and/or sugars (see 2.5.2 to 2.5.5).   
As soon as the plates had dried (considered Tzero), four plugs of agar were removed with a 
sterile cork borer (6mm diameter) and placed into a 15ml centrifuge tube contained 1ml of 
AS and 50µL of 10% glutaraldehyde (final conc. 0.5% v/v) to fix the cells. Further samples (4 
plugs) were removed and fixed every 20 min for a given period of time. The cells were 
dislodged from the agar surface into suspension by vortexing for 2 min. The suspension was 
loaded into a haemocytometer slide and the number of prey/cell determined (see 2.3.5).  
 
The average prey/cell was plotted against time (min) to provide a visual depiction of the 
response. The linear portion of the increase in prey/cell, for each treatment, were compared 
with an Analysis of Covariance (ANCOVA). Ingestion rate (prey/cell/min) was determined as 
the gradient of the linear increase of prey/cell over time. The lag phase (min) was estimated 
from the point at which this linear increase crossed the x axis (where prey/cell is zero). 
Ingestion rates and feeding lags were deduced for each replica and then averaged.  
 
2.5.2. Effect of AEA and CBD on V. vermiformis feeding 
The experiment followed that described in 2.5.1. using only AEA and CBD at a concentration 
of 2µM and both beads and Synechococcus as prey. It was only performed once for the latter 
prey so limited statistical analysis were carried out, while it was performed three times for 
former with full statistical analysis of the data.  
2.5.3. Effect of CBD concentration of V. vermiformis feeding 
The experiment followed that described in 2.5.1. using CBD at 0, 0.1, 1, 2 and 5µM and beads 
as the prey. These experiments were performed twice and full statistical analysis was carried 
out. 
2.5.4. Effect of PPAR agonists and antagonists of the feeding of V. vermiformis  
The experiment followed that described in 2.5.1. using CBD at 2µM, beads as the prey, and 
the PPAR agonists (OEA, PEA, GW0742 and Rosiglitazone) at their IC50 values. Experiments 
were performed in the presence/absence of a specific PPAR antagonist at 10µM, added 20 
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min before agonist. These experiments were performed three times, and full statistical 
analysis was carried out. 
2.5.5. Effect of blocking amoeba prey recognition receptors, prior to adding CBD, on V. 
vermiformis feeding  
The experiment followed that described in 2.5.1. except that the amoeba was pre-incubated 
for 20 min with 100mM of D (+)-Mannose, N-Acetyl-D-glucosamine (GlcNAc) and N-Acetyl-D-
galactosamine (GalNAc), to block amoebic C-type lectins. Then, the experiment was 
inoculated as normal with CBD at 2µM and using Synechococcus as the prey. These 
experiments were performed three times and full statistical analysis was carried out.  
2.6. Effect of CBD on phagosome processing and defecation in V. vermiformis  
Pulse-chase experiments were performed to monitor the fate of ingested prey (beads) in the 
presence and absence of 2µM CBD. Two dense suspensions of V. vermiformis (1 ml) were 
mixed with beads (at 5x107 particles/ml) and each poured onto a level NNAg plate. Once dry, 
four plugs of agar were removed from each plate and fixed at 0, 5 and 10 min (see 2.5.1). 
Immediately after this, the chase was performed, i.e., 1 ml of AS was poured onto the surface 
of each plate, the cells were dislodged into suspension then added to 24 ml AS in a tissue 
culture flask. CBD was added to one of these flasks at 2µM (Test). Then, each flask was used 
to inoculate eight large NNAg plates (140 cm diameter) with 1ml of the suspension. The 
suspension was quickly spread across the surface. This dilution into 25ml AS coupled with 
spreading the amoebae across a large area was intended to stop further ingestion of beads 
and only allow only the fate of the pre-ingested prey (up to 10 min) to be monitored. 
A whole plate, for Control and Test, was sacrificed at T = 15, 20, 25 and 30 min, then every 10 
min up to 70 min, by adding 1ml of glutaraldehyde (0.5% v/v) to the plate and dislodging the 
cells into suspension. Twenty cells in each sample were viewed and the number of ingested 
prey/cell recorded (see 2.3.5). This experiment was performed three times and full statistical 
analysis was carried out. Ingestion rates and defecation rates were deduced for each replica 





2.7. Bioinformatic analysis  
Published genome databases were explored to verify whether the gene sequences of 
cannabinoid putative receptors and the degradation enzymes of cannabidiol existed in single-
celled eukaryotes or not. Three databases were used; www.amoebadb.org , www.ciliate.org 





















Chapter 3: Sensitivity of amoebae to CBD and AEA  
 
3.1. Introduction 
The effect of cannabinoids on amoebae has not be extensively researched. There is only one 
publication (Pringle et al. 1979) which has examined the effect of THC and CBD on Naegleria 
fowleri and one (Dey et al., 2010) which has examined the effect of AEA and 2-AG on 
Vermamoeba vermiformis, Acanthamoeba castellanii and Wilertia magna. Some work has 
been performed on the effects of THC and CBD on the slime mould Dictyostelium discoideum 
(Bram and Brachet, 1976; Perry et al. 2020). This mould has an amoebae stage in its growth 
cycle but upon starvation the cells do not forms cysts, as do true amoebae, instead they 
aggregate to form a slug followed by a fruiting body (Hayes et al., 2013).   
 
The first aim of the current study was to evaluate the extent to which true naked amoebae 
respond to cannabinoids. Considering the taxonomy of amoebae is still very fluid (Kang et al., 
2017), it was necessary to obtain strains from reputable culture collections so that if their 
genus/species name changed, their catalogue number would not; allowing others to repeat 
the experiments if necessary. A representative strain of all the 20 species of non-marine 
naked amoebae available in culture (at 2017) were tested here. Two species of 
Acanthamoeba were included as this genus is well studied and of medical significance 
(Thomas et al., 2009). Each amoeba was first subjected to a high concentration (200µM) of 
CBD and AEA to determine whether they were sensitive or insensitive to these compounds. 
Those strains that were sensitive were further tested to deduce their MIC, IC50 and lethal dose 
values.   
 
3.2. Results 
3.2.1 Initial screening of amoebae for sensitivity to AEA and CBD  
Exposure of the 20 species of amoeba (27 strains) to 200µM AEA or CBD resulted in 14 





Table 3.1: Strains considered insensitive to AEA or CBD (at 200µM). ANOVAs for each of two 
experiments show no significant effect of the compounds on population growth, compared to the 
Control (P>0.05).  
Amoeba  ANOVA P values 
Acanthamoeba polyphaga CCAP1501/18 0.08/0.50 
Amoeba borokensis CCAP1503/7 0.14/0.35 
Allovahlkampfia nedeslanaiensis CCAP2502/3  0.68/0.81 
Cochliopodium minus CCAP1537/1A 0.81/0.92 
Dermamoeba algensis CCAP1524/1  0.46/0.50 
Echinamoeba silvestris CCAP1519/1  0.41/0.42 
Mayorella cantabrigiensis CCAP1547/11 0.43/0.68 
Phalansterium filosum CCAP1576/1 0.89/0.99 
Saccamoeba limax CCAP1572/3 0.29/0.92 
Stygamoeba regulata CCAP1580/1  0.14/0.19 
Tetramitus aberdonicus CCAP1588/4 0.12/0.89 
Thecamoeba quadrilineata CCAP1583/10 0.16/0.58 
Vannella placida CCAP1565/2 0.77/0.77 
Vexillifera bacillipedes CCAP1590/1 0.18/0.53 
 
Of the 6 sensitive species (Table 3.2) all strains were sensitive to CBD and all but Flamella 
arnhemensis and Acanthamoeba castellanii were sensitive to AEA.  
 
Table 3.2: Strains considered sensitive to AEA or CBD (at 200µM). ANOVAs for each of two 
experiments were significant (P<0.05) and post-hoc Tukey tests identified which compound affected 
population growth, compared to the control. All were sensitive to CBD and all but two (A. castellanii 
and F. arnhemensis) were sensitive to AEA.  
Amoeba 
Post-hoc (vs Control) P values 
CBD AEA 
Acanthamoeba castellanii CCAP1501/1A 0.001/0.036 0.25/0.90 
Flamella arnhemensis CCAP1525/2 0.002/0.007 0.18/0.29 
Hartmannella cantabrigiensis CCAP1534/8  0.001/0.005 0.001/0.003 
Hartmannella cantabrigiensis CCAP1534/11  0.001/0.001 0.001/0.001 
Naegleria gruberi NEG-M ATCC30224 0.001/0.001 0.001/0.001 
Vahlkampfia avara CCAP1588/1A 0.001/0.007 0.001/0.006 
Vermamoeba vermiformis CCAP1534/7A 0.001/0.001 0.001/0.001 
Vermamoeba vermiformis CCAP1534/13 0.001/0.001 0.001/0.001 
Vermamoeba vermiformis CCAP1534/14 0.001/0.001 0.001/0.001 
Vermamoeba vermiformis 137 0.001/0.001 0.001/0.001 
Vermamoeba vermiformis 172 0.001/0.001 0.001/0.001 
Vermamoeba vermiformis 173 0.001/0.001 0.001/0.001 




There appeared to be no strain differences in amoebic response, with all 7 strains of 
Vermamoeba vermiformis, and both strains of Hartmannella cantabrigiensis, showing the 
same response. Species difference were evident within the genus Acanthamoeba with A. 
castellanii being sensitive to CBD (Table 3.2) while A. polyphaga was not (Table 3.1).  
 
3.2.2. MIC, IC50 and lethal dose values for AEA and CBD against sensitive amoebae  
All 13 sensitive strains (Table 3.2) were subjected to dose response experiments with CBD and 
AEA. There now follows an example of the analysis carried out on each strain, using 









     
  Specific growth rate (/h)  Lag phase (min) 
0uM 0.035±0.002 0 
5uM 0.028±0.001 14.65±2.08** 
10uM 0.022±0.002* 26.79±2.21** 
15uM 0.027±0.002* 21.39±1.54** 
 
 
Figure 3.1: The effect of AEA concentration on the population growth of Vermamoeba vermiformis 
CCAP 1534/7A at 23oC together with calculated specific growth rates (/h) and lag phases (min). 
Significant difference to Control [0µM] *P<0.05, ** P<0.01. 
 
Fig 3.1 shows the population growth of Vermamoeba vermiformis 7A over 3 days in the 
presence of various concentrations of AEA (0 to 25µM). At 5µM, AEA induced a significant lag 

























At 10 and 15µM AEA the specific growth rates were equal (P=0.10) but significantly lower 
than the Control and 5µM AEA (P<0.05). The lag period with these concentrations was also 
equal (P=0.15) and significantly longer than at 5µM AEA (P<0.01). AEA was lethal to the 
amoeba at concentrations of 20µM and above (Fig. 3.1).  
Vermamoeba vermiformis 7A was subjected to further experiments using various AEA 
concentrations and the % survival compared to control (after the control had divided at least 
three times) was plotted against AEA concentration (µM) in QtiPlot (Fig. 3.2). The Qtiplot 
automatically generates two parameters (IC50 and Slope). The MIC and lethal dose (LD) values 
were estimated from this graph (Fig. 3.2 blue lines). The parameter values were; IC50 = 2.63 ± 
1.26µM, Slope = 1.04 ± 0.05, MIC = 0.3µM and LD ≥20µM (Table 3.3). 
 
Figure 3.2: Qtiplot of % population growth (compared to the Control) against AEA concentration (µM) 
for Vermamoeba vermiformis CCAP 1534/7A.  The programme generates values for IC50 (2.63µM) and 
Slope (1.043), while MIC (0.3µM) and lethal dose (20µM) are estimated from where the linear decline 
crosses the the ‘100%’ (MIC) and 0% (Lethal Dose).  
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The above analysis was performed for all sensitive strains and data for the four parameters 
are summarised in Table 3.3 (individual IC50 plots can be found in Appendix 2). Based on 
comparison of IC50 values (Table 3.3) Naegleria gruberi was the most sensitive strain to CBD 
followed by Vahlkampfia avara and Flamella arnhemensis. The least sensitive strain was 
Acanthamoeba castellanii. V. vermiformis and Hartmannella cantabrigiensis strains showed 
varying degrees of sensitivity, with V. vermiformis 173 being the most sensitive and 137 being 
the least sensitive (Table 3.3). 
N. gruberi and V. avara were less sensitive to AEA compared to CBD (Table 3.3) and this was 
also the case for all V. vermiformis and H. cantabrigiensis strains except for V. vermiformis 
173 which displayed equal sensitivity to AEA and CBD (based on IC50) (Table 3.3). 
Table 3.3: Calculated MIC, IC50, lethal dose (µM) and slope values for AEA and CBD acting on 13 strains 
of amoebae. 
Sensitive amoeba strains 
CBD AEA 
MIC IC50 Slope Lethal MIC IC50 Slope Lethal 
Acanthamoeba castellanii CCAP 1501/1A 10 16.37 4.59 >27 N/A N/A N/A N/A 
Flamella arnhemensis CCAP 1525/2 0.4 0.97 2.47 >4 N/A N/A N/A N/A 
Hartmannella cantabrigiensis CCAP 1534/11  15 17.93 18.15 >21 0.1 3.63 0.53 >100 
Hartmannella cantabrigiensis CCAP 1534/8 1.5 4.1 1.96 >13 14 23.71 3.46 >41 
Naegleria gruberi NEG-M ATCC 3022 0.2 0.72 1.63 >3 0.21 1.15 1.25 >6 
Vahlkampfia avara CCAP 1588/1A 0.08 0.78 0.94 >9 2.1 7.52 1.76 >40 
Vermamoeba vermiformis 137 4 7.31 3.77 >14 1.3 9.89 1.01 >50 
Vermamoeba vermiformis 172 0.3 1.78 1.23 >10 5 7.33 5.45 >12 
Vermamoeba vermiformis 173 0.08 0.98 0.87 >10 0.06 0.96 0.72 >13 
Vermamoeba vermiformis 174 1.6 2.98 3.86 >5 1.2 5.41 1.23 >25 
Vermamoeba vermiformis CCAP 1534/7A 0.2 1.99 0.89 >16 0.3 2.63 1.04 >20 
Vermamoeba vermiformis CCAP 1534/13 3 5.05 3.79 >9 1.5 7.69 1.32 >35 
Vermamoeba vermiformis CCAP 1534/14 0.15 1.01 1.05 >8 0.15 2.33 0.74 >30 
 
3.3. Discussion 
This study investigated the sensitivity of 20 amoebic species (27 strains) to the cannabinoids 
CBD and AEA. Fourteen species were insensitive to both, four were sensitive to both and two 
were sensitive to CBD only. Results showed no strain differences within a given species, 
however differences within the genus Acanthamoeba were evident with A. castellanii being 
sensitive to CBD while A. polyphaga was not. Also, the data suggest that amoebae are 
generally more sensitive to CBD than AEA. 
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3.3.1. Differences in sensitivity of amoebae to AEA and CBD 
There appears to be no pattern regarding the phylogenetic position of an amoeba and its 
sensitivity to AEA and CBD. Of those that were sensitive, V. vermiformis, H. cantabrigiensis, 
A. castellanii and F. arnhemensis are within the supergroup Amoebozoa (sub-phylum Lobosa), 
while V. avara and N. gruberi belong to the Excavata (sub-phylum Percolozoa) (Fig. 3.3). Also, 
Echinamoebida and Vermamoeba are within the same order (Echinamoebida) (Fig. 3.3) but 
the former was insensitive to both AEA and CBD while the latter was sensitive.  
 
Figure 3.3: Phylogenetic position of the 19 amoeba genera used in this study (adapted from Smirnov 






Saccamoeba and Hartmannella are within the same family (Hartmannellidae) (Fig. 3.3) yet 
the former was insensitive to AEA and CBD while the latter was sensitive. Allovahlkampfia, 
Tetramitus, Vahlkampfia and Naegleria are also in the same family (Vahlkampfiidae) (Fig. 3.3) 
but the former two were insensitive to AEA and CBD while the latter two were sensitive.  
These is also a difference within the genus Acanthamoeba (not shown in Fig. 3.3) whereby A. 
polyphaga was not sensitive to AEA and CBD while A. castellanii was sensitive to CBD only. In 
addition, V. vermiformis was previously described as Hartmannella vermiformis until 2011, 
when Smirnov et al. described it as a new genus under the newly described order 
Echinamoebida (Figure 3.3). However, both these genera responded similarly to CBD and AEA 
suggesting that they might behave the same and did not warrant such separation (but see 
Chapter 5 were their separation does appear warranted). 
 
Considering their taxonomic position did not appear to govern sensitivity, attention turned to 
the size of the amoebae (Table 3.4) and where they were isolated from (Table 2.1).  
 
Table 3.4: Comparison of cell sizes between amoeba species. Sensitive strains in bold. Adapted from 
Page, 1988; Marciano-Cabral et al., 2003; Garstecki et al., 2005;  Walochnik and Mulec, 2009; Tyml 
et al., 2016; www. microworld; www.nies.go.jp. 
Amoeba   Cell length (µM) 
Phalansterium filosum  6.3-8.5 
Echinamoeba silvestris   7-21 
Hartmannella cantabrigiensis  10-30 
Naegleria gruberi  10-36 
Vexillifera bacillipedes  10-70 
Acanthamoeba castellanii  12-35 
Flamella arnhemensis  13-34 
Vermamoeba vermiformis  14-31 
Vahlkampfia avara  14-33 
Cochliopodium minus  16-42 
Stygamoeba regulata  19-38 
Allovahlkampfia sp.  20-40 
Acanthamoeba polyphaga  25-40 
Tetramitus aberdonicus  30-65 
Thecamoeba quadrilineata  35-80 
Saccamoeba limax 35-85 
Vannella placida  40-75 
Dermamoeba algensis  50-100 
Mayorella cantabrigiensis  55-180 
Amoeba borokensis  210-545 
46 
 
Cell measurements of the strains in the current study were not determined but Table 3.4 
indicates (using published data) that those susceptible strains (in bold) are generally at the 
lower end of the cell size spectrum. However, if cell size was a determinant of sensitivity, a 
concentration of 200µM would have been expected to significantly affect the very small cells 
of P. filosum and E. silvestris (Table 3.4), but they did not.  
There was also no obvious relationship between the source of the amoebae with regards to 
freshwater vs soil, country of origin or year of isolation (see Table 2.1). For example, V. 
vermiformis strains were isolated from both soil and freshwater in four countries, between 
the years 1964 and 2013, and all were susceptible to CBD and AEA (see Table 2.1).  
It was interesting to note that even though there were no strain differences in the responses 
of different strains of V. vermiformis or H. cantabrigiensis to CBD/AEA there was a difference 
in response observed between species of Acanthamoeba. Here, the similarly sized (Table 3.4) 
A. castellanii was sensitive to CBD while A. polyphaga was not. The author cannot find 
evidence from previous studies of the former being sensitive to a compound while the latter 
was not, but differences between these species in their response to a particular compound 
has been reported. For example, Henriquez, et al. (2008) showed that A. castellanii was more 
sensitive to chlorhexidine (IC50 1.56-3.13μM) compared to A. polyphaga (IC50 3.13-6.25μM). 
Also, McBride et al. (2005) found that A. castellanii was far more sensitive to hexadecyl-PC 
and octadecyl-PC (IC50s both 3.91-7.81 μM) compared to A. polyphaga (IC50s of 31.25-62.5μM 
and 15.63-31.25μM, respectively). So, there is evidence that they are ‘different’ but in the 
current study their difference with regards to susceptibility to CBD was very striking. 
 
 
3.3.2 Dose-dependent effect of AEA and CBD on amoebic growth 
The MICs of CBD ranged from 0.08 to 15µM, IC50s from 0.72 to 18µM and lethal doses from 
ca. 3 to 21µM (Table 3.3). Comparison to previously published work is limited, as only one 
study has examined the effect of CBD on amoebae. Pringle et al. (1979) found that the 
population growth of Naegleria fowleri (LEE) was suppressed by 47% and 73% after 3 days 
incubation with 15.9µM THC and CBD, respectively. In the current study, a concentration of 
15.9µM CBD would be lethal to N. gruberi NEG-M (Lethal dose ≥3µM, Table 3.3) suggesting 




The MICs of AEA ranged from 0.06 to 14µM, IC50s from 0.96 to 24µM and lethal doses from 
ca. 6 to 100µM (Table 3.3). Once again, only one study has examined the effect of AEA on 
amoebae. Dey et al. (2010) showed that the population growth of three amoebae, after 3 
days, was negatively affected by AEA, 2-AG but not 2-AG-ether. The latter is a non-
hydrolysable form of 2-AG therefore showing that it was the 2-AG itself, and not a breakdown 
product, that caused this negative effect. The IC50s of V. vermiformis (Ax.5.2e4b), A. castellanii 
(By 02.2.4) and Wilertia magna c2c Maky (ATCC PTA-7824) with AEA were 14, 17 and 20 µM, 
respectively (Dey et al., 2010). Their IC50 for V. vermiformis (14µM) is outside the range of that 
recorded for the seven V. vermiformis strains tested in the current study (0.96-9.89µM, Table 
3.3). Also, the A. castellanii used in the current study (CCAP1501/1A) was not sensitive to AEA 
(Tables 3.2 and 3.3), unlike the strain of Dey et al. (2010). This difference might be due to the 
use of a different strain, although in the current study there was no difference recorded 
between several strains of V. vermiformis and H. cantabrigiensis. However, there is evidence 
of strain differences in susceptibility to Polyhexamethylene biguanide (PHMB) within the 
species A. castellanii (Huang et al., 2015). 
 
Data showed that, in general, amoebae were more sensitive to CBD than AEA. With such little 
amoebic data with which to make comparisons, amoebic sensitivity was compared to those 
of mammalian cells (Table 3.6). Firstly, it appears that the CBD and AEA concentrations 
required to elicit a response in amoebae are of the same order as those required to elicit a 
response in mammalian cells (Table 3.6). Secondly, there is some evidence to suggest that 
mammalian cells are more sensitive to CBD than AEA. For example, Grimaldi et al. (2006) 
showed that 10µM AEA was not toxic to MDA-MB-231 breast cancer cells (after 24h) but 
Sultan et al. (2018) recorded CBD-induced apoptosis in these cells (after 24h), with an IC50 of 
2.2µM (Table 3.6). Ligresti et al. (2006) also found these cells to be sensitive to CBD at 8.2µM 
(after 4d) (Table 3.6). Studies on C6 glioma cells (Table 3.6) have shown that CBD-induced 
apoptosis occurs (after 4d) with an IC50 of 8.5µM (Ligresti et al., 2006) while a concentration 






Table 3.6: The effect, and the effective concentrations, of CBD and AEA on mammalian cells. 
Cannabinoid 
 

























T-47D h-breast cancer 
 
IC50 = 2.2µM 
 








































MDA-MB-231 h-breast IC50 = 8.2µM Induced 
apoptosis 
4d Ligresti et 
al., 2006 
 
C6 cells of glioma 
 
 















































H460   h- lung cancer 20µM Induced 
apoptosis  
2h Athanasiou 
et al., 2007 
h- melanoma IC50 = 5.8µM  Induction of 
cytotoxicity 
24h Adinolfi et 
al., 2013 
MDA-MB-231 h-breast 10µM No effect  24h Grimaldi et 
al., 2006 
 



















This study set out to determine the sensitivity of 20 naked amoeba species to CBD and AEA. 
Fourteen species (70%) were insensitive while 6 species (30%) were sensitive. There appeared 
to be no correlation between sensitivity and phylogenic position, cell size or habitat. For the 
sensitive strains, (i) CBD and AEA reduced population growth over 3 days in a dose-dependent 
manner and, (ii) higher concentrations proved lethal but lower concentrations induced a lag 
followed by reduced growth rate which was dose-dependent.  
Chapter 4 now looks at one strain in more detail (Vermamoeba vermiformis CCAP 1534/14) 
with regards to the effect of AEA and CBD on its feeding behaviour, to see if disrupted feeding 
is the reason for the lag phase followed by reduced population growth in the presence of 

















Chapter 4: Effect of CBD and AEA on feeding in Vermamoeba vermiformis  
4.1. Introduction 
The results of Chapter 3 indicated that CBD and AEA reduces the population growth of 
sensitive amoebae in a dose dependent manner. Vermamoeba vermiformis CCAP 1534/7A 
(Fig 3.1) showed two features that are evident during the early stage of cannabinoid (at sub-
lethal concentrations). Firstly, there is a lag phase with no effect on subsequent population 
growth and then there is a longer lag phase accompanied by a reduction in population growth.  
Successful amoebic population growth requires successful ingestion and metabolism of prey, 
so this part of the study examined whether it was the amoebic feeding process which was 
being affected by the cannabinoids and causing the lag and reduced growth rates. The feeding 
process in amoebae was described in Section 1.6.3 but a brief summary follows. The process 
begins when the phagocytic cell recognises the binding ligands of the prey cell in a receptor-
dependent manner. In protists, these receptors have been identified as C-type lectins which 
bind carbohydrate residues (e.g. mannose, GalNAc, GlcNAc) on the bacterial cell (e.g. Allen 
and Davidowicz, 1990; Venkataraman et al., 1997). Actin polymerisation is activated and two 
pseudopodia extend out from the cell to surround the prey particle then myosin is recruited 
to help seal the ends of the pseudopodia together (Levin et al., 2016).  The recruitment of 
dynamin leads to the detachment of the phagosome from the cell surface and into the 
cytoplasm (Levin et al., 2016) where it maturates via a complicated series of fusion events 
with endosomes and lysosomes (Haas, 2007; Pauwels et al., 2017). Fusion of the phagosome 
membrane with the outer membrane then leads to the defecation of any undigested material 
and then the spent phagosome membrane is endocytosed and used to make new 
phagosomes (Allen and Fok, 1980). 
Although V. vermiformis strain 173 was the most sensitive to CBD and AEA (Table 3.3), feeding 
experiments employed the second most sensitive strain, V. vermiformis CCAP 1534/14, as it 
is held within a culture collection and available to other researchers. Two fluorescent prey 
were used: live Synechococcus sp. S-KH3 (Dillon and Parry, 2009) and polystyrene 
microspheres (beads); both of which are indigestible to V. vermiformis (Pickup et al., 2007). 
The concentration of CBD/AEA was 2µM which is close to the IC50 values of both cannabinoids 




4.2.1. Effect of AEA and CBD (2µM) on V. vermiformis feeding on indigestible beads and 
Synechococcus (‘Pico’) 
These experiments were only performed once, alongside each other, with three replicas (see 
2.5.2). The same controls were used for Fig. 4.1a and b. 
 
Figure 4.1: Effect of a) AEA and b) CBD (both at 2µM) on the feeding of Vermamoeba vermiformis 























































Although it appears from Fig. 4.1 that V. vermiformis CCAP1534/14 ingests beads to a lesser 
extent than Synechococcus (in the Controls), there was no significant difference in their 
uptake (P=0.91). Estimated ingestion rates were ca. 0.26 and 0.28 prey/cell/min for beads 
and Synechococcus, respectively.  
AEA induced a lag in feeding (Fig 4.1a); ca. 31 min for beads and ca. 21 min for Synechococcus, 
yet surprisingly only the latter was significantly different to the Control (P<0.05). After this, 
feeding in the presence of AEA was higher than the Control with both beads and 
Synechococcus (P<0.01), which was also surprising. This disruption of feeding (firstly a 
negative effect followed by a positive effect) appeared unlikely to be the reason for reduced 
population growth of V. vermiformis with AEA (Fig. 3.1) but before removing AEA from the 
feeding study, this experiment was repeated a further two times with beads as the prey (Fig. 
4.2). Composite data, and a full statistical analysis, confirmed that AEA did not induce a 
significant lag phase (P=0.17) and did not result in an elevated ingestion rate, compared to 
the Control (P=0.77). AEA was therefore considered to have no significant effect on V. 
vermiformis feeding and experiments with AEA ceased.  
 
Figure 4.2: Effect of AEA (2µM) on the feeding of Vermamoeba vermiformis CCAP1534/14 on beads. 































CBD caused a significant (P<0.01) lag in the uptake of both beads (ca. 86 min) and 
Synechococcus (ca. 59 min) followed by a resumption of feeding, at rates equivalent to the 
Control, with Synechococcus (P=0.37) but lower than the Control, with beads (P<0.05) (Fig. 
4.1). This disruption in feeding might therefore contribute to reduced population growth of 
V. vermiformis in the presence of CBD after 3 days so further studies on CBD were performed. 
 
4.2.2. Effect of CBD concentration on the feeding lag and ingestion rate of V. vermiformis  
V. vermiformis CCAP1534/14 was fed with beads at 3x107 particles/cm2 in the absence and 
presence of CBD (0.1-5µM) (see 2.5.3) and the number of beads/cell recorded over time (Fig. 
4.3). This experiment was performed twice. Ingestion rates (prey/cell/min) and feeding lags 
(min) were deduced for each replicate (n=6) and averaged. In these experiments the Control 
showed a ca. 42 min lag in feeding (Fig. 4.3) so this was subtracted from Test lag times to 
provide net lag times (Fig. 4.4a).  
Figure 4.3: Consumption of beads (as beads/cell) by Vermamoeba vermiformis CCAP1534/14 in the 




































Figure 4.4a shows that CBD did not induce a significant feeding lag until 1µM (P<0.05), after 
which the lag duration appeared to be dose-dependent. The ingestion rates at 0.1 and 1µM 
were not significantly different to the Control (P=0.89), but those at ≥2µM were significantly 




















Figure 4.4: Effect of CBD concentration (0.1-5.0µM) on a) the feeding lag (min) and b) subsequent 
ingestion rates (beads/cell/min) of Vermamoeba vermiformis CCAP1534/14 feeding on beads. 


























































Plotting the net lag phase against ingestion rate (Fig. 4.5) shows a strong inverse relationship, 
whereby the longer the lag the lower the subsequent ingestion rate. Data therefore suggest 
that the immediate negative effect of CBD is to stop feeding completely, i.e., induce a lag, 
then when feeding resumes it does so at a slower rate. A complete cessation in feeding could 
be due to CBD (i) blocking ingestion mechanisms such as feeding receptors and/or the 
formation of new phagosomes or, (ii) blocking the trafficking of phagosomes in the cell so that 
no membrane becomes recycled to form new phagosomes. The latter was tested first (see 
4.2.3) 
 
Figure 4.5: Relationship between the duration of a CBD-induced feeding lag and subsequent 
ingestion rate in Vermamoeba vermiformis CCAP1534/14 feeding on beads. 
 
4.2.3. Effect of CBD on phagosome trafficking within V. vermiformis  
Pulse-chase experiments were performed three times, using beads as the prey, in the absence 
and presence of CBD at 2µM (see 2.6). This CBD concentration yields a ca. 36 min lag in 
feeding (Fig. 4.4a). During the first 10 min (no CBD in either treatment), ingestion of the beads 
was evident and by 10 min V. vermiformis CCAP1534/14 cells contained ca. 23 beads. At 10 
min, both treatments were diluted (to prevent further uptake of beads) and CBD was added 
to one treatment (Test). The loss of beads in pre-formed phagosomes over time was then 
monitored. If CBD stopped phagosome processing and defecation inside the cell for ca. 36 
min the graphical response would mirror that shown by the orange dotted line (Fig. 4.6). It 
did not. And although the presence of CBD appeared to ‘empty’ the amoeba of beads quicker 




























Net lag phase before feeding (min)
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than the Control, with defecation rates of 4.17±0.46 and 3.74±0.37 beads/cell/min for Test 
and Control respectively, these rates were not significantly different (P=0.50). It therefore 
appears that CBD does not affect the trafficking and defecation of phagosomes, so attention 
turned to its potential effect on the ingestion process.  
 
Figure 4.6: Effect of CBD on the defecation of beads in phagosomes formed over the first 10 min in 
Vermamoeba vermiformis CCAP1534/14. The amoeba was diluted at 10 min and CBD (2µM) added to 
one treatment. If CBD halted phagosome trafficking and defecation, the loss of beads would begin at 
ca. 46 min; it did not. Experiment repeated three times. 
 
4.2.4. Interaction between CBD and the feeding receptors of V. vermiformis 
V. vermiformis CCAP1534/14 was incubated for 20 min with 100mM of D (+)-mannose, N-
Acetyl-D-glucosamine (GlcNAc) or N-Acetyl-D-galactosamine (GalNAc), to block C-type lectins, 
before performing feeding experiments with Synechococcus in the absence and presence of 
CBD (2µM) (see 2.5.5).  These experiments were performed three times (Fig. 4.7). Any feeding 
































Figure 4.7: Feeding of Vermamoeba vermiformis CCAP1534/14 on Synechococcus (Pico) in the absence 
(Control) and presence of CBD (at 2µM) with/without a 20-minute pre-incubation with a) GalNAc b) 






























































































CBD alone caused a significant lag which was quite variable (50.32-74.41 min) (Table 4.1) but 
the subsequent ingestion rates were less variable (0.104-0.112 pico/cell/min) (Table 4.1). 
These ingestion rates were significantly lower (by 44-58%) than those of the Controls 
(P<0.01).  
The presence of the sugars alone caused no significant lag phase but did significantly reduce 
ingestion rate (Table 4.1) suggesting that all three are involved in the feeding process of this 
amoeba. The presence of GalNAc, GlcNAc and mannose significantly (P<0.01) reduced prey 
ingestion rate by 53%, 73% and 66%, respectively (compared to the Control). GalNAc alone 
reduced ingestion rate to the same level as CBD alone (P=0.25) while GlcNAc and mannose 
alone caused a significantly lower ingestion rate than with CBD alone (P<0.01).  
Table 4.1: Feeding lags (min) and subsequent ingestion rates (prey/cell/min) of Vermamoeba 
vermiformis CCAP1534/14 feeding on Synechococcus in the presence/absence of CBD (2µM) 
with/without a 20-minute pre-incubation with a sugar (GalNAc, GlcNAc or mannose) at 100mM. 
Significant difference (P<0.05) to *Control, “sugar alone, ^CBD alone.  
Sugar/Parameter Control CBD alone Sugar alone Sugar then CBD 
GalNAc 
Net lag phase (min) 0 65.62±11.51*” 11.02±1.06 74.61±6.39*” 
Ingestion rate (prey/cell/min) 0.205±0.004 0.112±0.022* 0.096±0.006* 0.065±0.007*^ 
GlcNAc 
Net lag phase (min) 0 50.32±7.71*” 0 101.25±3.48*”^ 
Ingestion rate (prey/cell/min) 0.247±0.014 0.104±0.007*” 0.066±0.001*^ 0.087±0.010* 
Mannose 
Net lag phase (min) 0 74.41±7.70*” 5.71±4.21 53.38±5.88*” 
Ingestion rate (prey/cell/min) 0.190±0.012 0.106±0.009*” 0.065±0.003*^ 0.018±0.001*”^ 
 
The effect of pre-incubating the amoeba with sugars, and then adding CBD, differed with each 
of the sugars (Fig. 4.7). The CBD-induced lag phase was not affected by pre-incubating with 
GalNAc (P=0.76) or mannose (P=0.44) (Table 4.1) but it was significantly (P<0.01) increased 
(2-fold) upon pre-incubation with GlcNAc (Table 4.1).  
Addition of CBD had no effect on the ingestion rates of GalNAc- and GlcNAc-pre-treated cells 
as rates (with CBD) were equivalent to those in the presence of the sugar alone (P=0.35, 
P=0.81, respectively) (Table 4.1). However, addition of CBD to mannose-pre-treated cells 
significantly (P<0.05) reduced ingestion rate compared to both mannose alone and CBD alone 
(Table 4.1).   
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To summarise, all three sugar treatments significantly reduced the ingestion rate of V. 
vermiformis to varying degrees (GlcNAc [by 73%], mannose [by 66%], GalNAc [by 53%]) but 
none induced a lag phase.  A lag phase was only induced in the presence of CBD and pre-
blocking the GalNAc and mannose receptors had no effect on its duration whereas blocking 
the GlcNAc receptor doubled its duration. CBD did not affect the ingestion rates of GalNAc- 
and GlcNAc-pre-treated cells but did significantly reduce that of mannose-pre-treated cells.  
4.3. Discussion 
4.3.1. Effect of particle type on V. vermiformis ingestion rates  
V. vermiformis CCAP1534/14 was able to successfully ingest 0.49µm diameter beads (0.065 
µm3 volume) and live Synechococcus S-KH3 cells (1.04 µm3 volume, Dillon and Parry, 2009) at 
equivalent rates (Fig. 4.1). In these, and subsequent experiments (see later Chapters), 
ingestion rates only ranged from 0.17 to 0.28 prey/cell/min (or 11.4-16.8 prey/cell/h) 
irrespective of particle type (at 3x107 particles/cm2, 23oC); further suggesting no effect of prey 
type.  
These rates are within the range of some previously published ingestion rates (Table 4.2), 
although data are scarce on the ingestion of Synechococus. However, one study (Dillon and 
Parry, 2009) recorded an ingestion rate of 1.68 prey/cell/h when Echinamoeba sp. fed on 
Synechococcus S-KH3 (at 1x107 cells/cm2, 23oC), which is the same prey used in the current 
study. Their ingestion rate is lower than that obtained here with V. vermiformis CCAP1534/14 
which might be due to their lower prey concentration and/or the smaller size of Echinamoeba 
(7-21µm) compared to V. vermiformis (14 x 31µm) (Table 3.4).  
The author cannot find a study which has directly compared the ingestion rates of beads 
verses live prey in amoebae. However, such studies have been performed with other protists, 
with differing results. Some studies have shown that ciliates and flagellates ingest beads at a 
lower rate than live or heat-killed bacteria (Sherr et al., 1987; Nygaard et al., 1988; Jürgens 
and Šimek, 2000; Boenigk et al., 2001a; Parry et al., 2001) while other studies have shown 
they are consumed at equivalent rates (Sherr et al., 1987; Dolan and Šimek, 1997; Boenigk et 
al. 2001b).   
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Table 4.2: Published ingestion rates (IR) of various amoebae. Adapted from Rogerson et al., 1996; 
Butler and Rogerson, 1997; Mayes et al., 1997; Heaton et al., 2001; Huws et al., 2004, Xinyao et al., 
2006; Pickup et al., 2007; Dillon and Parry, 2009. 
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4.3.2. Effect of AEA on the feeding of V. vermiformis  
AEA (2µM) was found to have no significant effect on the feeding of V. vermiformis 
CCAP1534/14,  even though a slight lag was evident in its presence (Fig. 4.2). And, although it 
was removed from the current feeding studies there may be merit in revisiting this because 
the AEA concentration might have been too low to give a significant result. A concentration 
of 2µM AEA and CBD was chosen as this value was close to their IC50 values and would allow 
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a direct comparison of their effect.  But, 2µM is above the IC50 for CBD (IC50 = 1.01µM) and 
below the IC50 for AEA (IC50 = 2.33µM) (Table 3.3). Experiments should be repeated with 
higher concentrations of AEA to confirm/deny any effect on feeding in this amoeba.    
4.3.3. Overall effect of CBD on the feeding of V. vermiformis 
CBD (at 2µM) induced a significant feeding lag followed by a reduced ingestion rate when V. 
vermiformis CCAP1534/14 fed on beads (Fig. 4.4) and Synechococcus (Table 4.1). The effect 
of CBD was dose-dependent, with the lag being induced at a lower CBD concentration (1µM) 
then the reduction in feeding (2µM) (Fig 4.4); a response also recorded with populate growth 
(Fig. 3.1). A longer lag resulted in lower ingestion rates (Fig. 4.5); implying there are connected 
in some way. It also suggests that the effect of CBD is long-lasting; >260 min at 5µM. This 
contrasts to the response of the ciliate Tetrahymena pyriformis, whereby the effect is 
relatively short-lived; 40-60 min at 4µM (Parry, personal communication).  
It is unknown whether these protists differ in their ability to degrade CBD, which might affect 
its longevity in their cells. In all human cells, CBD is metabolised by cytochrome P450 oxidases, 
sulfotransferases and glucuronyl transferases (Ujváry and Hanus, 2016). Most work has been 
performed on P450 oxidases (CYPs) which are enzymes necessary for the metabolism of drugs 
(Šrejber et al., 2018). Even though more than 50 CYP enzymes exist, only six of them (CYP1A2, 
CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) are responsible for metabolising 90% of 
medicinal drugs (Lynch and Price, 2007). Of these, CYP2C9 metabolises THC and CBN, 
CYP2C19 metabolises CBD, and CYP3A4 can metabolise all three (Stout and Cimino, 2014). 
Interestingly, Tetrahymena thermophila possesses 102 CYP homologues (www.ciliate.org), 
the slime mould Dictyostelium discoideum possesses 9 (www.dictybase) whilst 
Acanthamoeba castellanii possesses only 1 and Entamoeba spp. and Naegleria fowleri 
possess none (www.amoebadb.org). None of the above protists possess glucuronyl 
transferases but they all possess sulfotransferases, although there is very little information 
on the latter with regards to metabolism of CBD/THC (Ujváry and Hanus, 2016). Therefore, it 
might be that V. vermiformis, like other amoebae, possesses a limited ability to degrade CBD 
within their cells and this might explain the longevity of the drug action on V. vermiformis, 
compared to T. pyriformis.  
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Whether CBD is metabolised or not, amoebic feeding was affected by this phytocannabinoid, 
but which stage of the feeding process was being targeted (Fig. 4.8 [same as Fig. 1.9 but 












Figure 4.8: Diagrammatic representation of membrane dynamics in the phagocytic cycle. 1) Receptors 
and membrane are available for prey uptake and phagosome formation. 2) Binding of prey to 
receptors (e.g. C-type lectins) leads to 3), actin polymerisation and formation of pseudopodia which 
surround the prey. 4) Myosin is recruited to help seal the ends of the pseudopods together. 5) 
Dynamin is recruited to allow detachment of the phagosome into the cytoplasm. 6) The phagosome 
matures via a series of fusions with endosomes and lysosomes and the contained material is digested. 
7) Phagosome membrane fuses with the plasma membrane and releases undigested material. 8) 
Plasma membrane is endocytosed to form vesicles. 9) Vesicles are transported to the site of 
phagocytosis by microtubule ribbons and used to form new phagosomes. Stages 3 to 7 are known to 
be reliant on activation of the Arp2/3 system.  
 
4.3.4. Effect of CBD on phagosome trafficking and defecation (Fig. 4.8, stages 6-7) 
Pulse-chase experiments with V. vermiformis CCAP1534/14 showed that CBD did not affect 
the processing of pre-formed phagosomes (Fig. 4.8, stages 6-7), i.e., they were trafficked 
through the cell and defecated at the same rate as the Control (Fig. 4.6). The vacuole passage 












upon the chase at 10 min. Published VPTs are rare for comparison, but Thurman and Parry 
(2010) reported that the VPT in the ciliate T. pyriformis, feeding on Synechococcus sp. S-KH5, 
was variable but that the minimum VPT was 30 min.  Ciliates possess a single rudimentary 
mouth (cytostome) at one end of the cell, where all the ingestion of prey takes place, and a 
single rudimentary anus (cytoproct) at the other end of the cell, where undigested material is 
expelled from the cell. Because phagosomes travel along the whole length of the cell, it will 
take time, and because there is only one exit point, pre-formed phagosomes have to queue 
before their contents are expelled which results in variable VPTs (Thurman and Parry, 2010). 
Amoebae, on the other hand, have no defined cytostome and cytoproct and appear to ingest 
and defecate prey at any point in their outer membrane (Page, 1988), which might explain 
their shorted VPT. However, the slime mould D. discoideum exhibited a VPT of 80 min when 
feeding on the yeast Cryptococcus neoformans (Watkins et al. 2018).  
The lack of effect of CBD on phagosome trafficking and defecation (Fig. 4.8, stages 6-7) mirrors 
the results obtained with T. pyriformis (Parry, personal communication), and suggests that 
CBD’s target is something involved with the initial stages of prey ingestion. The potential 
target(s) could be, (i) prey capture (Fig. 4.8, stages 1-2), (ii) formation of the phagosome (Fig. 
4.8, stages 3-5) and/or, (iii) phagosome membrane recycling after defecation (Fig. 4.8, stages 
8-9). Separating these out is difficult as if just one of these processes fails, no ingestion of prey 
takes place; and this is what was measured in all experiments (as prey/cell). 
4.3.5. Effect of CBD on phagosome formation (Fig. 4.8, stages 3-5) 
Upon prey-receptor binding, actin polymerisation is activated and two pseudopodia extend 
out from the cell to surround the prey particle. Myosin is then recruited to help seal the ends 
of the pseudopods together and then the recruitment of dynamin leads to the detachment of 
the phagosome from the cell surface to the cytoplasm (Levin et al., 2016). The whole process 
(and indeed phagosome trafficking [Duleh and Welch, 2010]) is reliant on activation of the 
Arp2/3 system (Seven-transmembrane-actin-related proteins 2 and 3) which itself is activated 
via a plethora of molecules and signalling cascades (Levin et al. 2016) (discussed further in 
Chapter 5).  
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Phagosome formation therefore appears to use the same cytoskeletal machinery, and the 
same Arp 2/3 complex, as that used for phagosome trafficking and defecation, which were 
not affected by CBD in V. vermiformis CCAP1534/14.  This implies that at least the machinery 
for phagosome formation might have been fully functional in the presence of CBD in this 
amoeba. In addition, CBD is known to become incorporated into the plasma membrane of 
cells and increase membrane fluidity (Watkins, 2019). Increased membrane fluidity, by 
decreasing the saturated:unsaturated fatty acid ratio, has been shown to increase 
phagocytosis in both macrophages (Schumann, 2016) and A. castellanii (Avery et al., 1995). 
Thus, one might have expected an increase in feeding in the presence of CBD, with functional 
machinery present, but this was not recorded. However, even functional machinery would 
only be able to form phagosomes if the prey recognition receptors were fully functional 
and/or there was enough membrane available at the site of prey-receptor binding.   
4.3.6. Effect of CBD on phagosome membrane recycling (Fig. 4.8, stages 8-9) 
The constant recycling of phagosome membrane in ciliates is essential to ensure membrane 
availability for newly developing phagosomes (Allen, 1974). Ciliates use ‘direct recycling’, i.e., 
no involvement of the lysosomal or Golgi systems on the vesicle’s journey from the cytoproct 
to the cytostome (Allen and Fok, 1980; Goff and Stein, 1981; Grønlien et al., 2002). 
It is currently unknown whether direct recycling occurs in amoebae but a membrane recycling 
process has been shown to be imperative for the correct formation of pseudopodia (for 
locomotion) in D. discoideum (Zanchi et al. 2010). Here, SecA mutants (with no ability to 
defecate) became paralysed within minutes and cells shrunk in size. This was because the 
block in defecation resulted in a net endocytosis of plasma membrane and an accumulation 
of small vesicles that remained close to the plasma membrane. This ultimately reduced the 
outer cell membrane area, reducing cell size and restricting pseudopodia expansion (Zanchi 
et al. 2010). This does imply then, that membrane recycling would also be imperative for 
phagosome formation, as expansion of pseudopodia around a particle is part of the process 
(Fig. 4.8). If this recycling was somehow affected by CBD, there would be limited membrane 
available for the functional cytoskeletal machinery to form phagosomes.  
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Observations of CBD-treated V. vermiformis CCAP1534/14 cells in feeding experiments did 
not show an obvious difference in cell size between the Control cells and those treated with 
CBD. No difference in cell size has also been recorded for Control and CBD-treated T. 
pyriformis cells (Parry, personal communication). In both cases, the CBD-treated cells of these 
protists would have been defecating normally (known from pulse-chase experiments) and 
thus, constantly adding membrane to the outer plasma membrane. If subsequent endocytosis 
(Fig. 4.8, stage 8) was blocked (with no phagocytosis was taking place) the cells would be 
expected to increase in size; but they did not. So, endocytosis might therefore be functional 
and, in the presence of CBD, the cell size would not be expected to change (which was 
recorded). But this lack of cell size change does not clarify whether the endosomes remain at 
the site of defecation or whether they are transported to the site of new phagocytosis, i.e., 
whether the transport system is functional (Fig. 4.8, stage 9), as cell size would not change in 
either case. However, with such little published information on stage 9 it is difficult to discuss 
this further. 
4.3.7. Pre-phagosome membrane availability at the site of phagocytosis (Fig. 4.8, stage 1) 
An observation made throughout the current study was that the CBD-induced lag phase 
durations in V. vermiformis CCAP1534/14 were highly variable between experiments. This has 
also been observed with T. pyriformis (Parry, personal communication) possibly indicating 
that CBD’s target is highly variable in the cells at the start of an experiment. This might be due 
to the amount of membrane available at the site of phagocytosis. For example, in well-fed 
cells the majority of membrane might already be used up in pre-existing phagosomes, leaving 
only a small volume for new phagosomes; which would be demonstrated by a low ingestion 
rate in Control cells. Conversely, if the cell is ‘empty’ of pre-existing phagosomes, there would 
be more membrane available for new phagosomes (yielding a high ingestion rate in Control 
cells). Indeed, others have observed that starved cells feed faster than well-fed cells and the 
accepted explanation is that it is due to variations in the nutritional and physiological 
conditions of the protist at the start of the experiment (Boenigk et al., 2001).  
Although V. vermiformis was prepared in the same way for each experiment (grown to 
stationary phase for 7 days on a streak of E. coli), these cells would not be exactly the same 
between experiments and their membrane availability for phagocytosis might have differed. 
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Indeed, ingestion rates of V. vermiformis Control cells ranged from 0.17 to 0.28 prey/cell/min, 
with 3x107 prey/cm2, which is not a great deal but does suggest that membrane availability 
might have been different at the start of each experiment. When these ingestion rates (as a 
proxy for membrane availability) are plotted against the lag phase duration in corresponding 
CBD-treated cells, there is a small trend towards shorter CBD-induced lag times occurring 
when more membrane is available. This is opposite to what was expected, but it might be 
suggesting a dose-response at the molecular level whereby binding of CBD to a larger area of 
nascent phagosome membrane might be diluting its effectiveness. However, this is just 
speculation at present.  
 
Figure 4.9: Relationship between ingestion rate of Control Vermamoeba vermiformis CCAP1534/14 
cells (as a proxy for the level of membrane available in the cells for the formation of phagosomes) 
against the length of a 2µM-CBD-induced lag phase (min). High ingestion rate is a proxy for low 
membrane availability and vice versa.  
 
4.3.8. Effect of CBD on receptor-mediated prey uptake (Fig. 4.8, stages 1-2) 
4.3.8.1. Prey uptake in the absence of CBD  
Previous studies have shown that C-type lectins are involved in the ingestion of prey by 
amoebae, particularly lectins for mannose (Bracha et al., 1982; Allen and Davidowicz, 1990; 
Garate et al. 2004; Alsam et al., 2005) and GalNAc (Ravdin and Guerrant, 1981; Ravdin et al., 
1985; Petri et al., 1987; Venkataraman et al., 1997; Harb et al., 1998; Bär et al., 2015). The 
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current study found that ingestion of Synechococcus by V. vermiformis CCAP1534/14 was 
reduced in the presence of mannose, GalNAc and GlcNAc, but no lag phase was induced.  
GlcNac was the most potent sugar blocker (73% reduction in feeding), followed by mannose 
(66% reduction) and then GalNac (53% reduction). This might suggest that either, (i) this 
amoeba possesses three distinct receptors for these sugar ligands, as does D. discoideum 
(Bozzaro & Roseman, 1983) or, (ii) it might only have only two receptors (mannose and 
GalNAc), as do professional phagocytes, because although the mannose receptor 
preferentially binds mannose (and fucose) it can, to a lesser extent, bind GlcNAc (Largent et 
al., 1984; Iobst and Drickamer, 1994; Roseman and Baenziger, 2000).  
The binding of GlcNAc led to the strongest inhibition of ingestion in V. vermiformis suggesting 
it was not only binding ‘weakly’ to a mannose receptor but also/instead binding ‘strongly’ to 
its own receptor. In addition, blocking with GlcNAc affected the duration of the CBD-induced 
lag phase whereas blocking with mannose did not (Table 4.1).  These data therefore support 
the case for three distinct sugar receptors in V. vermiformis, as has been suggested for D. 
discoideum (Bozzaro & Roseman, 1983) and more recently, for T. pyriformis (Boboc, 2019).  
The location of carbohydrate-binding receptors in cells can be visualized with fluorescent 
derivatives of plant lectins such as ConcanavalinA (ConA) which binds D-mannose (Goldstein 
et al., 1965), wheat germ agglutinin (WGA) which binds GlcNAc (Wright, 1992), and peanut 
agglutinin (PNA) which binds GalNAc (Macartney, 1986). A handful of studies have used such 
techniques to detect these receptors in ciliates and dinoflagellates. The mannose receptor 
has been shown to be associated with the whole feeding process, i.e., prey capture, 
phagosome formation, phagosome trafficking, defecation and membrane recycling (Scott and 
Hufnagel, 1983; Wilks and Sleigh, 2004; Roberts et al., 2006; Wootton et al., 2007; Dürichen 
et al., 2016). Wilks and Sleigh (2004) showed a distinct series of events of ConA staining in 
Euplotes mutabilis, starting with the staining of the cytostome only, then simultaneous 
staining of the cytostome and phagosomes, then staining of the phagosomes only, followed 
by no staining. In T. pyriformis, the mannose receptor has been shown to affect phagosome 
trafficking by detecting the nature of the internalised prey, i.e., inducing early exocytosis or 
full trafficking (Dürichen et al., 2016) and has also been shown to be important in defecation 
(preventing membrane defecation alongside the cargo) and the endocytosis of plasma 
membrane at the cytoproct (Scott and Hufnagel, 1983). 
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Staining ciliates with WGA (binds to GlcNAc) has shown it to be associated with early 
phagosomes near the cytostome (Wilks and Sleigh, 2004; Dürichen et al., 2016). In T. 
pyriformis, WGA bound to patches of these early phagosome membranes whereas ConA 
bound to the whole membrane (Dürichen et al., 2016). Its role in prey capture is less clear as 
Wilkes and Sleigh (2004) detected WGA binding at the cytostome of E. mutabilis but Roberts 
et al. (2006) and Dürichen et al. (2016) did not detect cytostome binding in Euplotes vannus 
and T. pyriformis, respectively. With regards to GalNAc, Roberts et al. (2006) found that the 
binding of PNA occurred only in the phagosomes of E. vannus whereas Wilks and Sleigh (2004) 
recorded binding at the cytostome in addition to phagosomes of E. mutabilis. 
4.3.8.2. Prey uptake in the presence of CBD  
The most striking feature of CBD was its ability to completely arrest feeding in V. 
vermiformis CCAP1534/14 for 50-74 min; but not arrest subsequent phagosome trafficking. 
Addition of mannose, GalNAc and GlcNAc alone did not induce such a lag phase suggesting 
that these are not the receptors involved in inducing a lag. Pre-blocking cells with mannose 
or GalNAC prior to adding CBD did not affect this CBD-induced lag suggesting no interaction 
with CBD. Indeed, receptors for both GalNAc and mannose are associated with the full life-
span of a phagosome (Wilkes and Sleigh, 2004; Roberts et al., 2006; Dürichen et al., 2016), 
and the mannose receptor itself is important for defecation and membrane recycling (Scott 
and Hufnagel, 1983), yet the trafficking and defecation of these phagosomes were not 
affected by CBD; further suggesting no interaction between these receptors and CBD.  
The GlcNAc receptor on the other hand, is not associated with mature phagosomes and 
defecation and is only associated with newly formed phagosomes at the cytostome (Wilkes 
and Sleigh, 2004; Dürichen et al., 2016). When GlcNAc was added to V. vermiformis prior to 
the addition of CBD, the lag phase was doubled, suggesting some level of interaction 
between the GlcNAc receptor and CBD during the stage of phagosome formation. The 
GlcNAc receptor itself appeared to be the dominant feeding receptor in V. vermiformis. 
When it was blocked, feeding was reduced by 73% compared to the blocking of the 
mannose and GalNAc receptors which reduced feeding by 66% and 53%, respectively. 
However, is unknown whether the GlcNAc was binding to the GlcNAc receptor alone, or 
whether it was also binding weakly to the mannose receptor (to yield a culminative 73% 
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reduction in feeding). Addition of CBD after blocking with GlcNAc did not affect this 
reduced feeding rate.  
One could therefore make an initial assumption that CBD might possibly be binding to the 
GlcNAc receptor (to cause a reduction in feeding rate) and to a yet unidentified ‘other’ 
receptor (to cause a lag). When both receptor types are available, CBD binds to both and 
causes a 50 min lag with a 53% reduction in feeding. When the GlcNAc receptor is blocked 
with GlcNAc, CBD can only bind to the ‘other’ (giving a longer lag) and the reduction in 
feeding is due to GlcNAc binding to the GlcNAc receptor. However, this is highly speculative 
and there is already evidence against this theory.  
Firstly, there is no evidence to date that C-type lectins can bind cannabinoids. Secondly, if 
CBD does not bind to the GalNAc or mannose receptors (as hypothesised) it would only be 
able to bind to the ‘other’ receptor and this should have yielded a lag of 100 min, but it did 
not. Thirdly, a CBD-induced lag (and reduced feeding) was recorded when the prey were 
polystyrene beads and these do not possess surface carbohydrate moieties for recognition by 
C-type lectins. Indeed, the mannose receptor has been shown not to be involved in the uptake 
of beads in A. castellanii (Allen and Davidowicz, 1990); no data on GlcNAc and GalNAc 
receptors.   
However, in slight defense of the theory, there is some evidence that C-type lectins can bind 
lipids (Cummings and McEver, 2006). For example, the macrophage inducible C-type lectin 
(Mincle) typically binds mannose and glucose residues but possesses hydrophobic pockets 
which can bind lipids (Chiffoleau, 2018). To the authors knowledge, no-one has actually 
tested whether cannabinoids can bind to C-type lectins so it is not known for certain whether 
they can or not. There have also been a couple of reports of C-type lectins being involved in 
the uptake of beads in professional phagocytes, via hydrophobic interactions, specifically the 
mannose receptor (Ichinose and Sawada, 1996) and the GlcNAc receptor (Shinzaki et al., 
2016); no reports of the GalNAc receptor being involved.  
4.3.9. Working hypothesis on how CBD affects feeding in V. vermiformis 
A hypothesis is proposed whereby CBD only binds to ‘another’ receptor and does not bind 
to the GlcNAc receptor. It does however require an acknowledgement that the process of 
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phagosome formation is not necessarily controlled by those receptors that capture prey 
and move them into the phagosome. To the author’s knowledge, this has not been properly 
discussed in the literature to date and ‘ingestion rate’ has been used as an all -
encompassing term which combines both processes. Here, we separate them out and 
suggest that the receptors for CBD and GlcNAc are involved with phagosome formation 
whereas receptors for mannose and GalNAc are involved with prey capture and 
phagosome filling.  
It is proposed that CBD only binds to a yet unidentified receptor which firstly stops 
phagosome formation completely and then causes phagosome formation to proceed at a 
slower rate than normal, i.e., at ca. half the rate seen in Control cells. Even though C-type 
lectins, which do not bind CBD, may have bound many prey cells, they can only fill the 
phagosome at the same rate at which it is being formed; so CBD is governing overall 
‘ingestion rate’. Now, if any of these C-type lectins are blocked by their respective sugar 
there will be less prey captured and phagosomes will be filled with less prey. If this is 
coupled with a reduced phagosome formation rate due to the presence of CBD, one would 
expect a synergistic negative effect on ingestion rate, and this is what was observed when 
the mannose and GalNAc receptors were blocked (Table 4.1). Ingestion rates for cells 
treated with both the sugar and CBD were significantly lower than rates with CBD alone in 
both cases, and lower than rates with the sugar alone (but this was only significant for 
mannose, Table 4.1).  
As for the GlcNAc receptor, it is proposed that this is predominantly involved in controlling 
phagosome formation rate. When blocked with GlcNAc, no lag was formed but the 
formation rate was reduced by 73% that of the Control; more so than with CBD alone (after 
its lag). In the presence of both GlcNac and CBD there was a lag which was twice the 
duration of that with CBD alone, suggesting some level of synergistic negative effect on lag 
duration. However, it is proposed that the CBD-induced lag itself was not prolonged but 
that instead, the combination of a 73% reduction in phagosome formation rate (by blocking 
with GalNAc) together with a 50% reduction in rate due to the presence of CBD led to a 
phagosome formation rate that was so slow there was very limited ingestion occurring, 
and so it appeared as if the CBD-induced lag had been prolonged. Why after 100h this 
combined ‘lag’ was lost, and phagosome formation rate reverted to that equivalent to 
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blocking with GalNAc alone, is currently unclear as the action of CBD would be expected to 
persist as it did in experiments involving mannose and GalNAc. 
A feature which lends weight to the GlcNAc receptor being specifically associated with 
phagosome formation is the observation of Dürichen et al. (2016) whereby WGA (for 
GlcNAc) bound to patches of early phagosome membranes whereas ConA (for mannose) 
bound to the whole membrane. This implies some level of specificity as to the location of 
GlcNAc receptors in phagosome membranes. It is also interesting that both Wilks and Sleigh 
(2004) and Dürichen et al. (2016) only found GlcNAc receptors to be associated with early 
phagosomes, after which they disappeared (unlike mannose and GalNAc receptors). Where 
do GlcNAc receptors go? Are they recycled to nascent vesicles to help control the formation 
of new phagosomes? 
As for the identity of the CBD receptor, this could be anything involved in stages 9 through to 
5 (Fig. 4.8). However, further observations suggest it is not involved with stages 4 (phagosome 
closure) and 5 (phagosome detachment into the cytoplasm). The reason for this is that, if 
these were the targets, phagosomes would still have developed and become filled with prey, 
in the presence of CBD. This would have been observed and prey/cell counts would have 
increased; this was not the case.  
With regards to phagocytic cup formation (Fig. 4.8, stage 3), it was noted that phagosome 
formation and trafficking utilise the same cytoskeletal machinery and considering the latter 
was unaffected by CBD it implied that V. vermiformis had the functional machinery in place 
to form phagosome. However, no evidence of phagocytic cup formation was recorded 
which might suggest that this machinery was not activated between stages 2 and 3 (Fig. 
4.8).  Actin polymerisation is reliant on activation of the Arp2/3 system which itself is 
activated via a plethora of molecules and signalling cascades; cascades which can differ 
depending on cytoskeletal function/location in the cell (Levin et al. 2016). So, because CBD 
stopped phagocytic cup formation (Fig. 4.8, stage 3), components of the signalling cascade 






V. vermiformis CCAP1534/14 was able to ingest inert beads and live Synechococcus at 
equivalent rates. These rates were reduced in the presence mannose, GalNAc and GlcNAC 
suggesting that this amoeba possesses three corresponding C-type lectins. It was proposed 
that the former two receptors are involved with prey capture and phagosome filling while the 
latter is involved with controlling phagosome formation rate.  
AEA had no effect on V. vermiformis feeding but CBD induced a feeding lag (MIC <1µM) 
followed by a reduced ingestion rate (MIC <2µM). The longer the lag, the lower the 
subsequent ingestion rate suggesting they are coupled in some way.  The long-term effect of 
CBD on V. vermiformis, compared to T. pyriformis, was thought to be due to a reduced 
capacity for metabolizing CBD within the amoebic cell (possibly due to the lack of CYPs).  
It was proposed that CBD’s target was not the C-type lectins but a yet unidentified receptor. 
Based on experimental evidence, this receptor was not considered to be involved in the 
following stages of feeding (Fig. 4.8): phagosome closure (stage 4), phagosome detachment 
(stage 5), phagosome trafficking (stage 6), phagosome defecation (stage 7) and endocytosis 
(stage 8). So, the current hypothesis is that CBD acts on a target between stages 8 and 3 (Fig. 
4.8) and that it is involved in controlling phagosome formation rather than prey capture and 
phagosome filling. Further speculation now stops until additional evidence is obtained. In 
Chapters 5 and 6 the effects of blocking putative CBD receptors is performed to see if this 
eliminates the effects of CBD and which could offer clues as to the mechanism by which CBD 








Chapter 5: Involvement of Peroxisome Proliferator-Activated Receptors 
(PPARs) in the mode of action of CBD against Vermamoeba vermiformis  
5.1. Introduction 
The working hypothesis from Chapter 4 was that, at sub-lethal concentrations, CBD acts on 
Vermamoeba vermiformis CCAP1534/14 by binding to a yet unidentified receptor which 
leads to a complete cessation of ingestion followed by a reduced ingestion rate. It  was 
considered that CBD acted on phagosome formation (along with the GlcNAc receptor), 
rather than prey capture and phagosome filling. Phagosome formation relies on effective 
membrane recycling to the site of phagocytosis (Fig. 4.8, stage 9), effective prey-receptor 
binding (Fig. 4.8, stages 1-2) and the activation of actin polymerisation via a signalling 
cascade (in-between stages 2 and 3), for the formation of the phagocytic cup (Fig. 4.8, stage 
3). The target for CBD is considered to lie somewhere between these stages.  
As for the identity of the CBD receptor, 11 receptors for CBD have been reported in the 
literature (Bih et al., 2015). Protists are already known not to possess homologues of the main 
receptors CB1, CB2, GPR55 and TRPV1 (McPartland et al., 2006), which reduces the number 
of potential receptors to seven, i.e., receptors for Nicotinic Acetylcholine, Adenosine, Glycine, 
Opioids, Serotonin, Dopamine, and Peroxisome Proliferation. Homologues of the latter, 
Peroxisome Proliferator-Activated Receptors (PPARs), have not been identified in protists to 
date but protists do possess peroxisomes (Ludewig-Klingner et al., 2017) and PPARs in animals 
are known to be involved in controlling their feeding behaviour (Romano et al., 2015; Satta et 
al., 2018). Since feeding in V. vermiformis was affected by CBD (in Chapter 4) these receptors 
were investigated first. 
In animals, the predominant ligands for PPARs are the endocannabinoids Oleoylethanolamide 
(OEA) and Palmitoylethanolamide (PEA) (Sullivan, 2016). OEA and PEA are known to be 
synthesised by the ciliate Tetrahymena thermophila (Anagnostopoulos et al., 2010) and the 
slime mould Dictyostelium discoideum (Hayes et al., 2013). OEA has a strong anorexiant effect 
on mice, i.e., it can stop feeding completely and then reduce food intake; PEA is less potent 
than OEA and AEA has no effect on feeding at all (Rodríguez de Fonseca et al., 2001; Diep et 
al., 2011). The effect of OEA on mice is remarkably similar to the effect of CBD on V. 
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vermiformis, in that feeding completely stops and then resumes at a slower rate (and AEA has 
no effect) (Chapter 4). Although PPARs exist in three isoforms (α, β/δ and γ), OEA and PEA 
have highest affinities for PPARα (Romano et al., 2015) while CBD binds to PPARγ (O'Sullivan, 
2016).  
OEA’s mode of action in animals is not completely understood, but elevated concentrations 
of OEA appear to ‘trick’ animals into thinking they are full (satiated), which stops them feeding 
(Rodríguez de Fonseca et al., 2001; Diep et al., 2011). This mode of action might also be 
pertinent to protists, in that, if membrane is limited for phagosome formation (at satiation), 
or there are defunct receptor-driven signalling cascades, protists cannot produce 
pseudopodia to feed (Boenigk et al., 2001).  
The following experiments tested the involvement of ‘PPARs’ in the creation of the CBD-
induced feeding lag and reduced feeding rate in V. vermiformis CCAP1534/14, which 
ultimately leads to a reduced population growth rate. It involved the use of four known PPAR 
agonists, OEA and PEA (for PPARα), GW0742 (for PPARβ/δ) and Rosiglitazone (for PPARγ) to 
see if they gave the same amoebic response as that exhibited with CBD. The latter two 
agonists are synthetic. Rosiglitazone is a member of a Thiazolidinediones (Lehmann et al., 
1995) and, because only break-down products of endocannabinoids activate PPARβ/δ, 
GW0742 has been specifically manufactured as a selective agonist for this receptor 
(Sznaidman et al. 2003). Experiments then blocked the PPAR receptors with antagonists 
specific for each PPAR isoform to see if this alleviated the effect of the PPAR agonists and 
CBD. All amoebae (20 species) were subjected to 3-day growth experiments whereas feeding 
experiments were only performed with V. vermiformis CCAP 1534/14. 
5.2. Results 
5.2.1. Growth experiments 
5.2.1.1. Response of all amoebae to four PPAR agonists  
All amoebae that had been tested for their sensitivity to AEA and CBD in Chapter 3 (Table 3.1) 
were subjected to 200µM of OEA, PEA, GW0742 and Rosiglitazone, and amoebic growth after 
three divisions (normally 3 days) was compared to the Control (no agonist). Experiments were 
performed twice (for AEA/CBD sensitive strains) and once (for AEA/CBD non-sensitive strains).  
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All the strains which had been shown to be insensitive to CBD and AEA at 200µM (Table 3.1) 
were also found to be insensitive to the four PPAR agonists (Table 5.1). However, some of 
those strains that were sensitive to AEA/CBD, were insensitive to the four PPAR agonists, i.e., 
Naegleria gruberi, Vahlkampfia avara, Flamella arnhemensis, Acanthamoeba castellanii and 
Hartmannella cantabrigiensis (Table 5.1, bold). 
Table 5.1: Amoebae that proved insensitive to PPAR agonists OEA, PEA, GW0742 and Rosiglitazone 
(at 200µM). One-way ANOVA P values shown. Experiments performed once (for strains not sensitive 
to AEA/CBD) or twice (for strains sensitive to AEA/CBD – in bold).  
Amoeba  ANOVA P value 
Acanthamoeba castellanii CCAP1501/1A 0.08/0.72 
Acanthamoeba polyphaga CCAP1501/18 0.47 
Amoeba borokensis CCAP1503/7 0.99 
Allovahlkampfia nedeslanaiensis CCAP2502/3  0.74 
Cochliopodium minus CCAP1537/1A 0.96 
Dermamoeba algensis CCAP1524/1  0.69 
Echinamoeba silvestris CCAP1519/1  0.63 
Flamella amhemensis CCAP1525/2 0.33/0.48 
Hartmannella cantabrigiensis CCAP1534/8  0.16/0.57 
Hartmannella cantabrigiensis CCAP1534/11  0.89/0.90 
Mayorella cantabrigiensis CCAP1547/11 0.79 
Naegleria gruberi NEG-M 0.71/0.75 
Phalansterium filosum CCAP1576/1 0.53 
Saccamoeba limax CCAP1572/3 0.9 
Stygamoeba regulata CCAP1580/1  0.75 
Tetramitus aberdonicus CCAP1588/4 0.77 
Thecamoeba quadrilineata CCAP1583/10 0.89 
Vahlkampfia avara CCAP1588/1A 0.45/0.55 
Vannella placida CCAP1565/2 0.99 
Vexillifera bacillipedes CCAP1590/1 0.58 
 
Only strains of V. vermiformis showed a response to the four PPAR agonists (Table 5.2). All 
strains were sensitive to 200µM OEA, PEA (PPARα) and GW0742 (PPARβ/δ) and all but two 





Table 5.2: All V. vermiformis strains were sensitive to PPAR agonists at 200µM (One-way ANOVA, 
P<0.01). Subsequent post-hoc Tukey test P values show which agonist affected which strain (P<0.05) 
and which ones did not (P>0.05 – in bold). The effect on the majority of strains was ca. 0% survival, 
except for CCAP1534/7A where Rosiglitazone and PEA yielded 53% and 60% survival, respectively*. 
Vermamoeba vermiformis strain 
Post-hoc (vs Control) P values 
GW742 Rosiglitazone OEA PEA 
CCAP1534/7A 0.001/0.001 0.003/0.003* 0.001/0.001 0.013/0.009* 
CCAP1534/13 0.010/0.003 0.107/0.840 0.011/0.005 0.050/0.039 
CCAP1534/14 0.001/0.015 0.001/0.012 0.001/0.012 0.013/0.016 
137 0.001/0.001 0.097/0.061 0.001/0.001 0.013/0.004 
172 0.001/0.001 0.001/0.001 0.025/0.001 0.001/0.001 
173 0.001/0.001 0.001/0.001 0.001/0.001 0.001/0.001 
174 0.001/0.001 0.001/0.001 0.001/0.001 0.001/0.001 
 
Further growth experiments, with each V. vermiformis being subjected to different 
concentrations of each PPAR agonist (except for CCAP1534/7A with Rosiglitazone and PEA, 
Table 5.2*), were performed to deduced the MIC, IC50, slope and lethal dose (Table 5.3). 
Individual IC50 graphs can be found in Appendix 3.  
Table 5.3: Calculated MIC, IC50, lethal dose (µM) and slope values for four PPAR agonists (OEA, PEA, 
GW0742, Rosiglitazone) acting on the population growth of 7 strains of Vermamoeba vermiformis.  
 OEA PEA 
Vermamoeba vermiformis strain MIC IC50 Slope Lethal MIC IC50 Slope Lethal 
CCAP 1534/7A 0.6 0.94 1.17 >6 ND ca.200 ND ND 
CCAP 1534/13 0.20 2.60 0.85 >23 0.75 2.87 1.69 >10 
CCAP 1534/14 0.19 0.81 1.51 >5 0.25 2.55 0.91 >23 
137 0.08 2.12 0.67 >35 3.10 4.79 5.78 >8 
172 2.70 4.28 8.79 >9 2.70 3.68 7.00 >5 
173 0.04 0.63 0.81 >10 0.04 0.50 0.85 >8 
174 1.00 4.77 1.32 >24 3.20 4.62 6.89 >7 
  GW0742 Rosiglitazone 
Vermamoeba vermiformis strain MIC IC50 Slope Lethal MIC IC50 Slope Lethal 
CCAP 1534/7A 2.5 6.31 2.24 >17 ND ca.200 ND ND 
CCAP 1534/13 0.29 2.50 1.01 >20 ND ND ND ND 
CCAP 1534/14 0.60 1.75 2.10 >5 0.16 0.78 1.41 >3 
137 2.00 1.80 1.83 >20 ND ND ND ND 
172 0.25 1.89 1.09 >14 4.00 6.2 5.5 >9 
173 0.01 0.48 0.5 >20 0.14 1 1 >8 




The most sensitive strain to the PPAR agonists (based on IC50 data) was strain 173 followed 
by CCAP 1534/14 which was the same pattern as with AEA and CBD sensitivity (Table 3.3). 
Apart from this, there was no obvious patterns between strains or between agonists.  
5.2.1.2. Response of all V. vermiformis strains to PPAR agonists in the presence and absence 
of specific PPAR antagonists 
Antagonists (blockers) specific for each of each PPAR isoform (α, β/δ and γ), at 10µM, were 
tested against all the V. vermiformis strains in the presence/absence of the four agonists at 
their IC50 value (Table 5.3). Experiments were performed three times. Results for V. 
vermiformis CCAP 1534/14 are shown in Figure 5.1 (data for other strains are in Appendix 4).  
 
Figure 5.1: Three-day population growth (compared to the Control) of Vermamoeba vermiformis 
CCAP1534/14 in the presence of a) OEA, b) PEA, c) GW0742 and d) Rosiglitazone (each at their IC50 value 
[Table 5.3]), with/without a pre-incubation with 10µM of the PPAR antagonists GW6471 (blocks PPARα), 
GSK3787 (blocks PPARβ/δ) and T007 (blocks PPARγ).  Growth in the presence of each antagonist alone is 
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None of the antagonists on their own had a significant negative effect on amoebic growth, 
compared to the Control (P=0.12) (Fig. 5.1). The negative action of OEA and PEA on V. 
vermiformis growth was only blocked by GW6471 (P<0.01), the specific PPARα antagonist (Fig. 
5.1. a-b). The blocking was 100% effective with GW6471 + OEA or PEA being equivalent to 
GW6471 alone (P=0.59 and 0.25, respectively). This response was recorded with all V. 
vermiformis strains (Appendix 4).    
The action of Rosiglitazone was only blocked by T007 (P<0.01), the specific PPARγ antagonist 
(Fig. 5.1 d). The blocking was also 100% effective with Rosiglitazone in the presence of T007 
being equivalent to T007 alone (P=0.33). This response was recorded with all V. vermiformis 
strains (Appendix 4).  
The action of GW0742 was expected to be blocked by GSK3787 only, the specific PPARβ/δ 
antagonist, but it was blocked by this and T007 (P<0.01), the PPARγ antagonist (Fig 5.3 c). In 
both cases, the blocking was 100% effective with GW0742 in the presence of GSK3787 and 
T007 being equivalent to GSK3787 and T007 alone (P=0.44 and 0.25, respectively). This 
response was recorded with all V. vermiformis strains (Appendix 4). 
5.2.1.3. Response of all V. vermiformis strains to AEA and CBD in the presence and absence 
of specific PPAR antagonists   
Each V. vermiformis strain was pre-incubated with 10µM of each PPAR antagonist to see if it 
blocked the negative effect of AEA and CBD (at 2µM). Experiments were performed three 
times. Results for V. vermiformis CCAP 1534/14 are shown in Figure 5.2 (data for other strains 
are in Appendix 5).  
The action of CBD was only blocked by 10µM GW6471 (PPARα) (P<0.01) (Fig. 5.2 a). Blocking 
was 100% effective as there was no difference between GW6471 with or without CBD 
(P=0.33). This response was recorded with all V. vermiformis strains (Appendix 5) and suggests 
an interaction between CBD and a PPARα-like receptor for this species.  
The action of AEA was also significantly blocked by GW6471 (P<0.01), but is was far from being 
100% blocked (as with CBD) (Fig 5.2 b). The interaction between AEA and these antagonists 
was only tested on V. vermiformis CCAP 1534/14 as AEA was not the major cannabinoid being 
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studied (based on data from Chapter 4). Further work on its interaction with PPAR antagonists 




Figure 5.2: Three-day population growth (compared to the Control) of Vermamoeba vermiformis 
CCAP1534/14 in the presence of a) CBD and b) AEA (each at 2µM), with/without a pre-incubation with 
10µM of the PPAR antagonists GW9471 (blocks PPARα), GSK3787 (blocks PPARβ) and T007 (blocks 
PPARγ).  Growth in the presence of each antagonist alone is also shown. *Significant difference to 
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5.2.1.4. Response of all V. vermiformis strains to CBD in the presence of varying 
concentrations of specific PPAR antagonists   
Dose-response experiments with V. vermiformis CCAP 1534/14, and all antagonists, 
confirmed that there was only an interaction between CBD and PPARα (Fig. 5.3) and no 
interaction between CBD and GSK3787 (ANOVA P=0.67) and T007 (ANOVA P=0.24) (Appendix 
5).  The action of CBD was blocked at all GW6471 concentrations except 0.01µM (P=0.35) and 
0.001µM (P=0.09) (Fig. 5.3) suggesting an MIC <0.1µM.  There was a strong dose response 
with each antagonist concentration (+CBD), being significantly different to each other 
(P<0.05). A concentration of 10µM GW6471 completely blocked the effect of CBD (GW6471 
with and without CBD, P=0.84). All other V. vermiformis strains showed the same dose-
response as that exhibited by strain CCAP1534/14, i.e., all gave 100% blocking at 10µM and 









Figure 5.3: Population growth (compared to the Control) of Vermamoeba vermiformis CCAP1534/14 
in the presence of CBD (at 2µM), with/without a pre-incubation with different concentrations (0.001-
10µM) of the PPARα antagonist GW6471.  Growth in the presence of each concentration of GW6471 
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5.2.2. Feeding experiments with V. vermiformis CCAP 1534/14  
The feeding of V. vermiformis on beads was monitored in the presence of CBD (2µM) and the 
four PPAR agonists, OEA, PEA, GW0742 and Rosiglitazone (at their IC50 concentration), in the 
presence and absence of their respective PPAR antagonist (at 10µM). Experiments were 
performed three times. 
Figure 5.4 shows that all the agonists had a negative effect of amoebic feeding, i.e., they 
induced a lag phase and then a reduced ingestion rate, compared to the Control. These effects 


































































Figure 5.4: Feeding of Vermamoeba vermiformis CCAP1534/14 on beads in the presence/absence of 
a) OEA, b) PEA, c) GW0742, d) Rosiglitazone (each at their IC50 value [Table 5.3]) and e) CBD (at 2µM), 
with/without a pre-incubation with 10µM of the PPAR antagonist GW6471 (blocks PPARα), GSK3787 



























































































All PPAR agonists induced a feeding lag with an equivalent duration (Table 5.4, P=0.46) at their 
IC50 values for reduced population growth (OEA, PEA, GW0742, Rosiglitazone at 0.81, 2.55, 
1.75 and 0.78 µM, respectively). However, visual examination of the graphical data (Fig. 5.4) 
clearly showed that CBD completely stopped feeding for up to 40 mins (at 2µM) whilst the 
PPAR agonists (at 0.78-2.55µM) allowed some level of feeding to occur.  
Table 5.4: Significant (P<0.01) feeding lags in Vermamoeba vermiformis CCAP1534/14, induced by each 
agonist alone. No significant difference between the agonist-induced lag times (P=0.46). No lags were 
recorded in the Control, blocker (antagonist) alone and agonist with blocker. GW6471 = blocker for CBD, 
OEA and PEA (PPARα), GSK3787 = blocker for GW0742 (PPARβ/δ) and T007 = blocker for Rosiglitazone 
(PPARγ).   
Treatment 
Lag phase (min) 
OEA PEA GW0742 Rosiglitazone CBD 
Control 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Blocker alone 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
Agonist alone 19.66±5.31 22.97±2.26 26.65±3.64 26.71±5.18 34.42±1.58 
Agonist and blocker 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
 
With regards to subsequent ingestion rates, all PPAR agonists significantly reduced ingestion 
rate compared to the Control (Table 5.5); a response that was also recorded with CBD.  This 
negative effect was 100% blocked with the respective antagonist (Figure 5.4, Table 5.5). 
Table 5.5: Significant reductions (compared to the Control) in ingestion rates of Vermamoeba 
vermiformis CCAP1534/14, induced by each agonist alone (*P<0.05, **P<0.01). No reduction in rate 
was recorded with blocker (antagonist) alone and agonist with blocker. GW6471 = blocker for CBD, 
OEA and PEA (PPARα), GSK3787 = blocker for GW0742 (PPARβ/δ) and T007 = blocker for Rosiglitazone 
(PPARγ).   
Treatment 
Ingestion rate (beads/cell/min) 
OEA PEA GW0742 Rosiglitazone CBD 
Control 0.211±0.006 0.169±0.003 0.183±0.004 0.166±0.011 0.185±0.009 
Blocker alone 0.183±0.004 0.163±0.002 0.172±0.006 0.153±0.005 0.178±0.014 
Agonist alone 0.105±0.004** 0.139±0.021* 0.151±0.009** 0.141±0.010** 0.079±0.003** 





In order to compare the effect of each agonist on amoebic ingestion rate, between 
experiments (although the agonist concentrations used were variable), ingestion rate was 
converted to % ingestion rate compared to the relevant Control in each experiment (Fig. 5.5) 
and data were analysed using a one-way ANOVA. Feeding in the presence of CBD (2µM) and 
OEA (0.81µM) were equivalent (P=0.90) suggesting that, in reality, OEA is more detrimental 
to feeding than CBD. Feeding in the presence of OEA and CBD was significantly (P<0.01) lower 
than with PEA (2.55µM), Rosiglitazone (0.78µM) and GW0742 (1.75µM), which were 
themselves equivalent (P=0.79); although it is unknown whether Rosiglitazone (at ca. 2µM) 








Figure 5.5: % ingestion rates of Vermamoeba vermiformis, compared to the Control, in the presence 
of PEA, Rosiglitazone (ROS), GW0742 and OEA (each at their IC50 value [Table 5.3]) and CBD (at 2µM). 
All were significantly (P<001) lower than the Control. Rates with OEA and CBD were equivalent 
(P=0.90) but significantly (P<0.01) lower than those with PEA, Rosiglitazone and GW0742 (which were 
themselves equivalent P=0.79). 
 
5.3. Discussion  
5.3.1. Sensitivity of amoebae to PPAR agonists 
All those amoebae that were not sensitive to AEA and CBD (Table 3.1) were also not sensitive 
to the four PPAR agonists. This suggests that they might not be susceptible to any form of N-
acylethanolamine (NAE), although it remains to be seen whether they are susceptible other 






































N-acylserotonin, Fatty acids amides of amino acids (FAAAs) or COX2-derivatives (Piscitelli, 
2015). But this is future work.  
Of those species that were sensitive to AEA/CBD, only V. vermiformis strains were sensitive 
to the PPAR agonists. Those that were not, were: Naegleria gruberi and Vahlkampfia avara 
(both in the sub-Phylum Percolozoa), Flamella amhemensis (in the sub-Phylum Conosa), 
Acanthamoeba castellanii (in the sub-phylum Lobosa, Class Discosea) and Hartmannella 
cantabrigiensis (in the sub-Phylum Lobosa, Class Tubulinea, alongside V. vermiformis) (Fig. 
3.3). V. vermiformis was previously described as Hartmannella vermiformis until it was 
reclassified in 2011 due to (i) differences in shape, length/breadth ratio and its tendency to 
branch when changing the direction of locomotion and, (ii) the fact that it always grouped 
with Echinamoeba, and not with other hartmannellids, in published phylogenetic trees 
(Smirnov et al., 2011). Now, we have recorded that these genera also differ in their response 
to PPAR agonists which lends further weight to the re-classification of H. vermiformis to V. 
vermiformis.  
A recent phylogenomic study of amoeba, comparing 325 protein genes from 98 taxa, has 
resulted in some slight changes to the amoeba taxonomic tree (as depicted in Fig. 3.3), but 
Vermamoeba is still most closely related to Echinamoeba and distinct from Hartmannella 
(Kang et al., 2017). There is also no evidence to suggest that Vermamoeba has evolved earlier 
or later than other genera (Kang et al., 2017) so why it is the only genus that is susceptible to 
PPAR agonists remains a mystery. However, it might not be the only genus, but without any 
trend whatsoever in susceptibility/non-susceptibility one would have to test every single 
genus of amoeba to confirm this. This study has already tested all the available genera of non-
marine naked amoebae available in culture; other genera are currently unculturable.    
All V. vermiformis strains responded to AEA, CBD, OEA and GW0742 but there were strain 
differences with regards to their susceptibility to PEA and Rosiglitazone. Strains CCAP1534/13 
and 137 were not sensitive to Rosiglitazone (at 200µM) and CCAP1534/7A required very high 
concentrations of PEA and Rosiglitazone to elicit a response (Table 5.3). All these 
combinations were deemed ‘insensitive’. Of those sensitive combinations, strain differences 
were evident with regards to MIC, IC50 and lethal dose (Table 5.3) but values were within the 
same range and were similar to those obtained for CBD (Table 3.3). For example, IC50 values 
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ranged from 0.63-4.77µM (OEA), 0.5-4.79µM (PEA), 0.48-6.31µM (GW0742) and 0.78-6.2µM 
(Rosiglitazone) (Table 5.3) while those for CBD were 0.98-7.31µM (CBD) (Table 3.3); all were 
below 10µM.  
5.3.2. Response of V. vermiformis to PPAR antagonists 
5.3.2.1. Growth experiments 
There were no V. vermiformis strain differences evident in their responses to PPAR 
antagonists blocking the action of an agonist. In all cases the action of OEA and PEA was 100% 
blocked with 10µM GW6471 only, the specific PPARα antagonist, Rosiglitazone was 100% 
blocked with 10µM T007 only, the specific PPARγ antagonist but, GW0742 was unexpectedly 
100% blocked by both GSK3787, the specific PPARβ/δ antagonist, and T007 (at 10µM). Lee et 
al. (2002) examined T007 binding selectivity using adipocyte differentiation assays in HEK293 
cell lines and found it blocked the effect of Rosiglitazone with an IC50 of 0.01µM but could also 
block the action of PPARα ligands (IC50 of 0.85μM) and PPARβ/δ ligands (IC50 of 1.8 µM). Since 
this antagonist was used at 10µM it might be expected to block all agonists but it did not. 
And, if higher concentrations are required to block amoebic PPARs then one would expect 
T007 to possibly block PPARα before PPARβ/δ, but it did not. This unexpected result is 
discussed further below. 
The results might suggest that the majority of V. vermiformis strains contain three PPAR 
isoforms but this is difficult to believe as to date, the three isoforms have only been reported 
in bony fish, mammals, birds and amphibians; not invertebrates (Zhou et al. 2015). 
Phylogenetic analysis has also shown that PPARα and PPARβ/δ cluster together, whereas the 
branch of PPARγ is distinct, suggesting the latter is the earliest ancestor of the PPAR gene 
family (Zhou et al., 2015). However, not all V. vermiformis strains responded to Rosiglitazone 
and if PPARγ was the ancestral form of PPAR, one would expect this isoform to be present in 
all these primitive cells. It is therefore more likely that V. vermiformis possesses a single 
promiscuous PPAR-like molecule which can bind each PPAR agonist and each PPAR 
antagonist.  
Structurally, a PPAR molecule is divided into five distinct functional regions; a DNA-binding 
domain (DBD), a ligand-binding domain (LBD), activation function 1 (AF1), activation function 
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2 (AF2), and a variable hinge region (Zhou et al., 2015). The LBD is unusually large and spacious 
in PPARs and, as a consequence, they are relatively promiscuous (O’Sullivan, 2007; Itoh et al., 
2008). It might therefore be that the PPAR agonists/antagonists bind to the amoeba’s PPAR-
like molecule at different sites in the LBD. For example, the PPARα antagonist might bind to 
the same site(s) as OEA and PEA and the PPARβ/δ antagonist might bind to the same site as 
GW0742. However, the PPARγ antagonist (which also seems to block GW0742 as well as 
Rosiglitazone) might span the binding sites of both Rosiglitazone and GW0742 in this ‘PPAR’.  
The agonists themselves can also be promiscuous. For example, in addition to binding to 
PPARα, PEA can bind to the CB2 receptor (Facci et al., 1995) and OEA can bind to TPRV1 and 
GPR119 (Overton et al., 2006; Kleberg et al., 2014; Piscitelli, 2015). A very promiscuous 
agonist is CBD which, to date, has 11 reported receptors (Bih et al., 2015). In the current study, 
all V. vermiformis strains showed the same response with CBD in that its action was 100% 
blocked with 10µM GW6471 only (PPARα antagonist) and there was a dose-response, yielding 
an MIC of <0.1µM. CBD is not known to bind to PPARα in animals, instead it is reported to 
bind to PPARγ with an IC50 of 5µM (O’Sullivan et al., 2009b); a concentration within the range 
of IC50 values (0.98-7.31 µM) reported for CBD binding to ‘PPARα’ in the current study. 
The IC50 values for CBD with V. vermiformis were shown to be within the same range as those 
concentrations required to elicit a response in mammalian cells (see 3.3.2) and indeed, the 
IC50s for the four PPAR agonists are also within the same range as mammalian cells. For 
example, Lueneberg et al. (2011) showed that 0.1µM of OEA caused no cell death in mouse 
granule neuron cells over 24h while the same concentration of PEA induced 50% cell death. 
Di Marzo et al. (2001) showed that 5µM PEA caused a 30-40% decrease in MCF-7 breast 
cancer cells after 4 days of treatment. OEA has also been found to suppress the migration of 
metastatic tumour cells in mice at 2-100μM (Sailler et al., 2014). Girroir et al. (2008) tested 
the effect of GW0742 on the growth of human UACC903 melanoma cells after 4 days of 
treatment and 1µM caused a 77% reduction while 10µM caused 100% cell death. With 
regards to Rosiglitazone, many studies have investigated the effect of this PPARγ agonist on 
human cancer cells such as bladder cancer and colorectal cancer cells (e.g. Miao et al., 2011; 
Cerbone et al., 2012; Xu et al., 2017), with all studies agreeing that concentrations higher than 
10μM cause 100% cell death.  
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5.3.2.2. Feeding experiments 
The unique characteristic of CBD in Chapter 4 was that it caused an immediate lag/cessation 
in V. vermiformis CCAP 1534/14 feeding whereas the addition of sugars (to block feeding 
receptors) did not. However, in this Chapter, it has been shown that a lag can also be induced 
with agonists for the three PPAR isoforms (Table 5.4) at their IC50 concentration. These 
concentrations were variable (OEA, PEA, GW0742, Rosiglitazone at 0.81, 2.55, 1.75 and 0.78 
µM, respectively) and therefore a true comparison to CBD (at 2µM) cannot be made. 
However, at these IC50 concentrations the lag times were equivalent to each other (Table 5.4) 
and to that with CBD which was close to its IC50 of 1.01µM (Table 3.3). After this lag, CBD and 
all the PPAR agonists caused a reduction in ingestion rate compared to the Control (Table 5.5) 
but OEA was the most potent, followed by CBD. In addition, these negative effects could be 
abolished by 10µM of their respective PPAR antagonist. The action of CBD was only blocked 
by GW6471 (for PPARα). 
Therefore, it appears that the whole PPAR-like molecule (α, β/δ and γ binding sites) in V. 
vermiformis might be involved, in some way, in the feeding process of V. vermiformis and that 
CBD behaves most like the ligands that bind the α-site, particularly OEA. Indeed, there are 
striking similarities between OEA and CBD with regards to their mode of action in animals and 
V. vermiformis. 
 
Firstly, OEA has an anorexiant effect in mice, i.e., it can stop feeding completely and then 
reduce food intake (Rodríguez de Fonseca et al., 2001; Diep et al., 2011). The same response 
was recorded in V. vermiformis with all PPAR agonists and CBD. Secondly, PEA is significantly 
less potent than OEA and AEA has no effect (Rodríguez de Fonseca et al., 2001; Diep et al., 
2011). This response was also recorded with V. vermiformis. Thirdly, administration of OEA in 
mice causes a dose-dependent delay in the feeding onset (Gaetani et al., 2003; Karimian 
Azariet al., 2014). The effect of CBD on the feeding lag and ingestion rates of V. vermiformis 
was dose-dependent (dose-responses of PPAR agonists were not performed). Fourthly, OEA 
does not reduce feeding in animals if they lack a functional PPARα gene, suggesting that 
PPARα activation is crucial for mediating its hypophagic actions (Fu et al., 2003). In the current 
study, all agonist-induced lags and reduced feeding rates were abolished with PPAR 
antagonists, and for OEA and CBD, this was the blocking of the PPARα receptor only.  
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It is also interesting to note that OEA only evokes a delayed feeding onset and reduced meal 
size in food-deprived rats (only the former in well fed mice) (Gaetani et al., 2003; Karimian 
Azariet al., 2014). In the current study, V. vermiformis would have also been food-deprived 
after 7 days culturing prior to experiments. It would be interesting to repeat experiments with 
well-fed cells to see if only a lag phase is induced.   
 
The underlying mechanisms of OEA-induced anorexia in animals is currently unclear although 
much work is being carried out as it has potential therapeutic uses for the treatment of 
obesity (Fernández-Ruiz et al., 2015). OEA acts as a satiety signal, which is generated in the 
intestine upon the ingestion of fat (Provensia et al., 2013). It then induces a ‘satiation status’ 
signalling pathway which is transferred to the hypothalamic nuclei of the brain where 
different neuronal pathways, including oxytocinergic, noradrenergic, and histaminergic 
neurons, seem to mediate its hypophagic action (Romano et al., 2015). It is considered that 
upon binding to PPARα, it induces ‘several transcriptional changes’ to activate this signaling 
cascade (Romano, et al., 2015), suggesting that it is a PPAR genomic response (see 1.2.4.1).   
However, the observed effects of PPAR agonists and CBD in both V. vermiformis (current 
study) and T. pyriformis (Parry, personal communication) appear to be instantaneous; a 
feature which is considered too rapid to be attributed to the biosynthesis of mRNA or protein 
in the classical PPAR genomic response (Falkenstein et al., 2000). In addition, no homologues 
of RXR have been found in protists to date (see 1.2.4.1). It is therefore possible that a non-
genomic PPAR response might be occurring in these protists, although this has not been 
studied as extensively as the genomic response to date.  
 
5.3.3 PPAR-induced non-genomic response  
PPAR non-genomic responses are rapid (Falkenstein et al., 2000) and do not involve the 
binding of PPARs to RXR, but instead, PPARs bind to other proteins (Unsworth et al. 2018).  
Non-genomic functions occur if PPARs are associated with the cytosol, plasma membrane or 
intracellular organelles, such as mitochondria, whilst genomic functions are restricted to 
when they are localized in the nucleus (Unsworth et al. 2018).  
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Most work on the PPAR-induced non-genomic responses have been performed on anucleate 
platelets and the mechanism of action of PPARα and PPARβ/δ appears to be very similar 
whilst that of PPARγ is distinct (Figure 5.6). The former two isotopes inhibit ADP-stimulated 
platelet activation by binding to PKCα (Protein Kinase C α) which then limits its availability to 
facilitate downstream signalling events; which then increases the level of cAMP (Ali et al, 
2006, 2009a). PPARβ/δ can also be activated by the prostaglandin PGI2 (Ali et al., 2009b) but 
its involvement in platelet inactivation has yet to be tested (Unsworth et al. 2018).  
 
Figure 5.6: Non-genomic regulation of platelets by PPAR ligands. PPARα and PPARβ/δ ligands cause a 
reduction in intracellular calcium mobilization and platelet activation. This inhibition is due to the 
attenuation of PKCα through its interaction with PPARα or PPARβ/δ, which limits its availability to 
facilitate signalling downstream. Treatment with PPARγ ligands inhibits the phosphorylation of Syk 
and LAT that mediate signalling initiated by the collagen receptor GPVI (Unsworth et al. 2018).  
 
Activation of PPARγ, on the other hand, inhibits collagen-stimulated platelet function through 
modulation of signalling downstream of the collagen receptor GPVI (Moraes et al., 2010). 
Specifically, in its un-ligated state, PPARγ interacts with Syk (Spleen tyrosine kinase) and LAT 
(a transmembrane adaptor protein Linker for Activation of T-cells) and their phosphorylation 
leads to the activation of proteins downstream, e.g. PI3-K (Phosphoinositide 3-kinase). Upon 
ligation of PPARγ, an interaction with Syk and LAT is prevented, so no phosphorylation takes 
place and downstream signalling stops (Moraes et al., 2010). The authors have yet to discover 
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if PPARγ is recruited to a signalling protein complex (with both Syk and LAT) or whether 
interaction with Syk and LAT occurs independently.  
What is interesting is that Syk, LAT and PKC are involved in the initial stages of phagosome 
formation in macrophages; specifically the signaling cascade between stages 2 and 3 (Fig. 4.8).  
 
5.3.4. Signalling cascades responsible for phagosome cup formation (Fig. 4.8, stage 2-3) 
 
Current evidence suggests that a non-genomic response can occur via binding of PPARα or 
β/δ to PKCα and binding of PPARγ to Syk, LAT or a Syk-LAT complex. Considering V. 
vermiformis might possess one promiscuous PPAR molecule, evidence for the involvement of 
these four molecules (PPAR, Syk, LAT and PKCα) in phagocytosis is reviewed.  
 
5.3.4.1. Opsonized phagocytosis in macrophages  
 
Syk is the first of the four molecules to be involved in phagosome formation in macrophages 
(Figure 5.7, Stage ii) and is particularly associated with the activation of feeding receptors 
(Levin et al., 2016).  Upon ligand binding to the receptor binding domain, the receptor tail 
(which extends into the cytostol) initiates the signaling cascade which culminates in the 
extension of pseudopods (Levin et al., 2016). Receptor tails contain tyrosine residues within 
a tyrosine-based activation motif (ITAM) and it is the phosphorylation of these residues by 
Src-family tyrosine kinases (SFKs) that starts the signaling cascade (Fitzer-Attas et al., 2000). 
To safeguard their phosphorylation, receptors move laterally within the membrane via 
cytoskeletal remodeling (Jaumouillé et al., 2014) and cluster together in order to exclude 
Protein Tyrosine Phosphatases (PTPs) such as SHP-1 and SJP-2 (Yamauchi et al., 2012).   
 
Phosphorylated tyrosines then serve as a docking site for the tandem SH2 domains of Syk 
(Johnson et al., 1995). Syk amplifies signaling by (i) further phosphorylating nearby tail 
tyrosine residues (Mócsai at al., 2010) and (ii) by recruiting and phosphorylation adapter 
proteins such as growth factor receptor bound protein 2 (Grb2), Grb2-associated-binding 
protein 2 (Gab2), the Src homology 3 (SH3) domain-binding protein 2 (SH3BP2) and linker of 
activated T cells (LAT) (Tridandapani et al., 2000; Yu et al., 2006). It is these adapter proteins 
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that then recruit cytosolic effectors to carry out the extensive lipid and cytoskeletal 
remodeling that accompanies the phagocytic process (Levin et al., 2016). 
 
 
Figure 5.7. Cellular events that lead to vacuole formation in macrophages (Levin et al., 2016). See text for details 
of stages ii and iii.  
 
One of the first major lipid-remodeling events to occur is a local increase in 
phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2] (Botelho et al., 2000), mediated by 
phosphatidylinositol 4-phosphate 5-kinases (PIP5Ks) whose recruitment is bolstered by the 
local activation of phospholipase D (Iyer et al., 2004). Shortly after accumulating however, 
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PtdIns(4,5)P2 is significantly depleted from sites of phagosome formation through its 
conversion into PtdIns(3,4,5)P3 by phosphoinositide 3-kinases (PI3K) (Marshall et al., 2001).  
 
PtdIns(4,5)P2 can also be broken down into diacylglycerol (DAG) and inositol (1,4,5)-
trisphosphate (IP3) by phospholipase Cc (PLCc) (Marshall et al., 2001). DAG and intracellular 
calcium regulate a number of effectors involved in phagocytosis, including members of the 
protein kinase C (PKC) family and myosin light chain kinase (Larsen et al., 2002). PKC has a 
range of downstream targets that are implicated in phagocytosis. For example, plekstrin, the 
major PKC phosphorylation target in platelets, is expressed in macrophages and recruited to 
the phagosome membrane during receptor-mediated phagocytosis (Brumell et al., 1999), 
although its role there is unknown.  
The culmination of this signaling cascade downstream of receptor tails, together with the 
generation of lipid intermediates at the site of receptor engagement, leads to the spatial and 
temporal activation of Arp2/3 by the local recruitment of nucleation-promoting factors (NPFs) 
(Goley et al., 2004). Specifically, Arp2/3 binds to both PtdIns(4,5)P2 and Rho-family GTPases 
particularly Cdc42 or Rac (Levin et al., 2016). These GTPases are activated locally by GEFs, 
which are themselves recruited by signals at the plasma membrane such as PtdOH and PtdIns 
(3,4,5)P3. This then gives rise to the elaborate branched actin networks associated with 
phagocytosis (Levin et al., 2016).  
The above signaling cascade describes that which is induced upon ligand binding to Fc 
receptors, which are single span transmembrane proteins involved in opsonized phagocytosis 
(Huber et al., 1976). Opsonized phagocytosis involves Fc receptor-binding to particles coated 
with opsonins, i.e., soluble molecules such as antibodies, surfactant proteins, mannose 
binding proteins (Stuart and Ezekowitz, 2005). Compared to opsonized phagocytosis, non-
opsonized phagocytosis has received far less attention but it is the type of phagocytosis 
carried out by protists.  
5.3.4.2. Non-opsonized phagocytosis in macrophages  
Non-opsonised phagocytosis involves the internalisation of particles via the direct recognition 
of bacterial ligands (Pathogen-Associated Molecular Patterns [PAMPs]) without the need of 
enhanced stimuli given by opsonins (Zeng et al., 2016). Two main families of receptors are 
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involved in non-opsonic phagocytosis: C-type lectins (Harb et al., 1998) and Scavenger 
Receptors (Peruń et al., 2016). Most information on the signaling cascade, post receptor 
binding, is available for the mannose receptor (MR/CD206) which exists in both macrophages 
(Drickamer and Fadden, 2002) and amoebae (Allen and Davidowicz, 1990). However, even 
though activation of PKC by MR-ligand binding has been known for some time (Allen and 
Aderem, 1996) details of the other components of the signalling cascade have only come to 
light recently (Rajaram et al., 2017).  
The MR is a type I 180-kDa transmembrane C-type lectin that consists of five domains which 
includes a binding domain and a tail (Stahl et al., 1980). The tail is crucial for phagocytic 
functions and its removal can significantly reduce the uptake of prey (Ezekowitz et al., 1990). 
The MR cytoplasmic tail does not contain an ITAM motif and possesses only one tyrosine 
residue. However, a FcRγ-chain (which contains an ITAM motif) is constitutively bound to it 
(Schweizer et al., 2000) (Fig. 5.8).  
 
Figure 5.8: Main components of the signaling cascade induced upon the binding of Mycobacterium 




In a study by Rajaram et al. (2017), it was thought that Src kinase-mediated phosphorylation 
of the tyrosine residues was occurring in the MR, but this was not confirmed. However, the 
authors did confirm that Syk became phosphorylated and co-localized with the MR early upon 
MR activation. They considered that Syk might be activated by a recruited Src kinase or 
alternatively by binding to a constitutively-bound FcRγ-chain. The study then went on to show 
that the adaptor protein Grb2 (see Fig. 5.7ii) was recruited and phosphorylated by Syk. 
Another 47 proteins were detected but their identity was undisclosed (Rajaram et al., 2017) 
so it is unknown at present whether one of these might have been LAT. The study also 
confirmed that Grb2 activated the Rac-1, Cdc42 and PAK-1 which are important for F-actin 
polymerization (Rajaram et al., 2017).  
So, it is beginning to look as if the signaling cascades induced by receptors involved in both 
opsonized and non-opsonized phagocytic cup formation are similar and involve Syk and PKC 
(and possibly LAT). What is also interesting, is that the ligand Rajaram et al. (2017) used for 
activating the MR was Mycobacterum tuberculosis (M.tb) (Fig. 5.8) and there are reports of 
PPARγ being involved in enhancing its survival within host cells. 
5.3.4.3. Phagocytosis of Mycobacterium spp. and the involvement of PPAR  
Mycobacterium tuberculosis infection begins with entry into macrophages where they 
multiply within the phagosomes, by preventing phagosome fusion with lysosomes (Armstrong 
and d’Arcy Hart, 1971). The mannose-capped lipoarabinomannan (ManLAM) from the M. 
tuberculosis cell surface has mannose and GlcNAc residues and interacts strongly with the 
mannose receptor (Kang et al., 2005).  
Rajaram et al. (2010) were the first to identify a ‘MR-mediated signaling pathway’ in 
macrophages that linked engagement of the mannose receptor by M. tuberculosis (or 
ManLAM) with PPARγ activation; alongside the activation of the p38 MAPK pathway (Fig. 5.9). 
PPARγ activation enhanced bacterial growth within the phagosome (Rajaram et al., 2010) 
while PPARγ silencing decreased it (Mahajan et al., 2012). The latter response was also 
confirmed to occur in vivo, using a macrophage-specific PPARγ knock out mouse model 
(Guirado et al., 2018). Thus, PPARγ activation in macrophages increases the susceptibility of 




Figure 4.9: A model proposing mannose receptor/PPARγ crosstalk in Mycobacterium tuberculosis 
infection (Rajaram et al., 2010). 
 
More recently, Diaz Acosta et al. (2018) studied the infection of Schwann cells (SCs) with 
Mycobacterium leprae. An active crosstalk between the mannose receptor (CD206) and 
PPARγ was detected that led to the induction of lipid droplet (LD) formation and prostaglandin 
E2 (PGE2), which are fundamental players in bacterial pathogenesis (Diaz Acosta et al., 2018). 
A model proposing a key role for the phenolic glycolipid I (PGL I)-induced CD206 (mannose 




Figure 5.10: A model proposing a key role for the phenolic glycolipid I (PGL I)-induced CD206 (mannose 
receptor)/PPARγ crosstalk in Mycobacterium leprae neuropathogenesis (Diaz Acosta et al., 2018). See 
text for details. 
 
The model states that the recognition of M. leprae ManLAM by baseline levels of CD206 
allows some bacterial entry and weak activation of PPARγ (Diaz Acosta et al., 2018). Then, 
CD206 is up-regulated, more bacteria are sensed which triggers a stronger signal (‘signal 2’, 
Fig. 5.10), where internalized M. leprae promotes the amplification of CD206/ PPARγ crosstalk 
(Diaz Acosta et al., 2018).  Details of the signalling cascades are absent or vague in this study 
but the insinuation is that as PPARγ is upregulated, so too is the phagocytosis of M. leprae.  
 
Indeed, stimulation of PPARγ with the agonist MDG548 has been shown to increase 
phagocytosis in the murine microglial cell line MMGT12 and increase the levels of the 
mannose receptor and a scavenger receptor (CD68) (Lecca et al., 2018). Interestingly, when 
cells were not pre-stimulated with bacterial lipopolysaccharide (LPS), PPARγ activation 
increased phagocytosis of necrotic neurons but not latex beads. Only when cells were pre-




In the current study, activation of the V. vermiformis PPAR-like molecule with known agonists, 
and CBD, did not result in increased phagocytosis; quite the opposite. The reason for this is 
currently unknown. However, it is interesting that both models (Figs. 5.9 and 5.10), and the 
study of Lecca et al. (2018), involve a PPAR-induced genomic response in the nucleus and 
therefore appear to be describing PPAR activation via mechanism 3 (See 1.2.4.1. and Fig. 1.4). 
There has been no mention to date of a possible link between the mannose receptor (or 
indeed any other receptor) and a PPAR-induced non-genomic response, which we 
hypothesise to occur in protists. This might be the reason for the different responses obtained 
here although this will require further study.   
5.4. Conclusions 
Of the 19 amoeba genera tested, it was only V. vermiformis that responded to PPAR agonists. 
All seven V. vermiformis strains were susceptible to OEA and GW0742 but there were strain 
differences with regards to their susceptibility to PEA and Rosiglitazone. Each PPAR agonist 
induced the same feeding response as CBD, i.e., a feeding lag followed by reduced ingestion 
rate. These negative responses were eliminated by blocking the PPAR with a specific 
antagonist. Only the blocking with the PPARα antagonist eliminated the negative effect of 
CBD.  
It is hypothesised that V. vermiformis does not contain three separate PPAR isoforms but 
contains a promiscuous PPAR-like molecule which can bind PPAR agonists and antagonists; 
and CBD at the α-binding site. It is also hypothesised that, due to the instantaneous effect of 
PPAR activation of amoebic feeding, PPAR induces a non-genomic response whereby PPAR 
does not bind to RXR in the nucleus but binds to other proteins outside the nucleus. From the 
limited information available on this response, potential proteins for PPAR-binding included 
Syk, LAT and PKC which are all involved in the very early stages of receptor-mediated 
phagocytosis (whether opsonized or non-opsonized).  
 
Amoebae feed by non-opsonized phagocytosis and receptors for mannose, GalNAc and 
GlcNAc exist in V. vermiformis but CBD did not appear to interact directly with any of them 
(Chapter 4). There is however evidence for cross-talk between the mannose receptor and 
PPARγ in macrophages, with the activation of both leading to increased phagocytosis, possibly 
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via a PPAR-induced genomic response (information on GalNAc and GlcNAc receptors is 
unavailable). However, in V. vermiformis, activation of PPAR did not increase phagocytosis, it 
completely stopped feeding for a given period of time. Therefore, the nature of any cross-talk 
between a feeding receptor and a PPAR in an amoeba appears to be different and might be 
due to it being a non-genomic response.  It might be that un-ligated PPAR binds to a given 
protein (Syk/LAT/PKC) allowing its phosphorylation and downstream signaling to occur, but 
on ligation this binding is prohibited, no phosphorylation takes place and the signalling 
cascade, which would normally culminate in actin polymerisation and phagocytic cup 




























Chapter 6: Involvement of the dopamine and serotonin receptors in the mode 
of action of CBD against amoebae  
6.1. Introduction 
The serotonin and dopamine receptors are neurotransmitters that are involved in 
physiological processes such as appetite, emotion, movement and cognition (de Pedro et al., 
1998a, b; Frazer and Hensler, 1999; Mishra et al., 2018). There are at least seven distinct 
serotonin receptor families (5-HT₁ up to 5-HT₇) (Frazer and Hensler, 1999) with all but 5-HT3 
(a ligand-ion channel) being GCPRs (Mazák et al., 2009). CBD has been shown to bind to 5-
HT1A (De Gregorio et al., 2019) while AEA has been shown to bind 5-HT3 (Racz et al., 2008). 
Dopamine receptors are all GPCRs and the family consists of D1, D2, D3, D4 and D5 receptors 
(Rashid et al., 2007). AEA and CBD have been shown to bind to D2 (Beltramo et al., 2000; 
Seeman, 2016) while THC has been shown to bind to D1 (Miyamoto et al., 1996).   
Dopamine receptor D1 has been identified in the ciliate Tetrahymena thermophila and 
serotonin receptors have been identified in Tetrahymena pyriformis (Csaba et al., 2010; Ud 
Daula et al., 2012). So, this part of the study evaluated whether amoebae might have them, 
and whether they played a role in the AEA/CBD-induced reduction in population growth 
(observed in Chapter 3) and CBD-induced feeding lag and reduced ingestion rate (observed in 
Chapters 4 and 5).   
The following experiments used four blockers. Haloperidol is considered ‘general’ blocker, as 
it blocks both receptor types. However, it does possess a higher affinity for serotonin 
receptors (particularly 5-HT2) over dopamine receptors (Kroeze et al., 2003; Li et al., 2016). It 
also exhibits selectivity for D2-like dopamine receptors with Ki values of 1.2, 1.7, 2.3, 80 and 
100nM for D2, D3, D4, D1 and D5, respectively (Lindsley and Hopkins, 2017). Two blockers 
were specific for dopamine receptors. The first, LE 300, is a potent D1 antagonist with Ki 
values of 0.08-1.9nM and 6-45nM for D1 and D2, respectively, although it does also display a 
moderate affinity for the 5-HT2A receptor (Ki value of of 20nM) (Kassack et al., 2002). The 
second was L741,626, which exhibits a strong antagonistic affinity for D2 with Ki values of 2.4, 
100 and 220nM for D2, D3 and D4, respectively (Strange, 2008). The final blocker was (S)-WAY 
100135 dihydrochloride, a potent and selective inhibitor of the serotonin receptor 5-HT1A (IC50 
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of 15nM) with very little sensitivity towards 5-HT1B, 1C, 2, α1, α2 and D2 (IC50 > 1000nM) 
(Fletcher et al., 1993). 
6.2. Results 
6.2.1. Growth experiments with Haloperidol 
All strains that were sensitive to AEA and/or CBD (Table 3.2) were subjected to population 
growth experiments (with AEA and CBD at their IC50, Table 3.3) in the presence/absence of 
10µM Haloperidol (added 20 min prior to agonist). Haloperidol was slightly toxic to amoebae 
at this concentration and induced a significant (P<0.05) 5-10% reduction in growth, compared 
to the Control, in most amoebae. The only exceptions were Acanthamoeba castellanii, 
Flamella arnhemensis, Hartmannella cantabrigiensis (CCAP1534/11) (see Appendix 7) and 
Naegleria gruberi (Fig. 6.1).  
Only N. gruberi showed 100% blocking (P<0.01) by Haloperidol of the negative effect of CBD; 
it did not block the negative effect of AEA (Fig. 6.1) (data for other strains in Appendix 7).   
 
 
Fig 6.1: Blocking putative dopamine and serotonin receptors in Naegleria gruberi with Haloperidol 
(10µM) pre-incubation abolished the negative effect of CBD (at 0.72µM) on population growth but did 








































A dose response experiment, performed three times, showed that the population growth of 
N. gruberi with CBD alone (0.72µM) was significantly lower than in the presence of 10µM and 
1µM Haloperidol (P<0.01) but was equivalent in the presence of 0.1µM Haloperidol (P=0.75), 










Figure 6.2: Population growth (compared to the Control) of Naegleria gruberi in the presence of CBD 
(at 0.72µM), with/without a pre-incubation with different concentrations (0.001-10µM) of 
Haloperidol. Growth in the presence of Haloperidol alone is also shown. **Significant difference 
(P<0.01) to CBD alone. 
 
6.2.2. Feeding experiment with Haloperidol 
The feeding of N. gruberi on beads was monitored in the presence of CBD (0.72µM) 
with/without 10µM Haloperidol. Experiments were performed three times. CBD induced a lag 
of 24 min (Fig. 6.3) and then ingestion rate was significantly lower compared to the other three 
treatments (P<0.01). The presence of Haloperidol, with CBD, abolished the lag phase and 
alleviated the negative effect on ingestion rate, although it was not 100% alleviated as rates 
for Haloperidol alone and Haloperidol with CBD were significantly different (P<0.01).  
Thus, either the blocking of the dopamine receptor or serotonin receptor (or both) were 
considered responsible for this alleviation of the negative effect of CBD. Experiments went on 








































Treatment Ingestion rate 
(prey/cell/min) 
Lag Phase (min) 
Control 0.217±0.001 0.00±0.00 
Haloperidol only 0.211±0.009 0.00±0.00 
CBD 0.150±0.006** 24.16±2.72** 
CBD + Haloperidol 0.190±0.008 0.00±0.00 
  
Figure 6.3:  Feeding of Naegleria gruberi on beads in the presence/absence of CBD (at 0.72µM), 
with/without a pre-incubation with 10µM Haloperidol.  Feeding in the presence of Haloperidol alone 
is also shown. Calculated specific ingestion rates (prey/cell/min) and lag phases (min) also shown. 
**Significant difference (P<0.01) to Control [0µM]. 
 
6.2.3. Growth experiments with separate dopamine and serotonin receptor blockers 
Growth experiments were carried out with N. gruberi and CBD (0.72µM) in the 
presence/absence of three blockers at concentrations ranging from 0.001 to 10µM. 
Experiments were performed three times. Experiments with LE300, specific for dopamine D1, 
were unsuccessful because the blocker itself was toxic to N. gruberi even at 0.001µM. At this 



























































Figure 6.4: Effect of different concentrations of a) LE300 (dopamine D1 blocker), b) L741,626 
(dopamine D2 blocker) and c) (S)-WAY 100135 (serotonin 5-HT1A blocker) on Naegleria gruberi 














































































































L741,626, which specifically blocks D2, was also toxic to N. gruberi and yielded a 40-50% 
population growth, compared to the Control, in the presence of 10, 1 and 0.1µM (Fig 6.4b). It 
was less toxic at 0.01 and 0.001µM which allowed some level of statistical analysis to carried 
out. It appeared that blocking this receptor at 0.001-0.01µM had no significant effect on the 
action of CBD (ANOVA P=0.11).  
The final blocker was (S)-WAY 100135 dihydrochloride which is a potent and selective 5-HT1A 
antagonist (Fig. 6.4c). This blocker was not as toxic to N. gruberi as the dopamine receptor 
blockers but it did significantly reduce population growth by 15% at 10 and 1µM S-WAY 
(P<0.01) but not at 0.1µM (P=0.11). CBD alone (at 0.72µM) reduced population growth by 
50% and this was alleviated by S-WAY concentrations of 10 to 0.01µM (P<0.01) but not at 
0.001µM (P=0.54) suggesting an MIC <0.01µM. The blocking of CBD by S-WAY was 100% 
effective at concentrations of 10 and 1µM with no significant difference between the effect 
of S-WAY alone and S-WAY+CBD (P = 0.27 and 0.69, respectively). Blocking was not 100% 
effective at 0.1µM and 0.01µM, indicating that a dose-response exists here.  
 
6.3. Discussion 
6.3.1. Effect of CBD on N. gruberi feeding 
The feeding of un-treated N. gruberi showed no feeding lag and gave an ingestion rate of 
0.217±0.001 beads/cell/min (Fig. 6.3).  This is within the range recorded for the similar-sized 
(Table 3.4) V. vermiformis feeding on the same concentration of beads (0.17-0.28 
prey/cell/min, Chapters 4 and 5). The presence of CBD (at 0.72µM) induced a feeding lag of 
ca. 24 min and reduced the ingestion rate compared to the Control (Fig. 6.3). The lag was 
shorter than those recorded by V. vermiformis, but these themselves were highly variable 
(34.42-74.41, Chapters 4 and 5); a feature of the response that is currently unexplainable.  
However, what this experiment showed was that CBD’s negative effect on feeding occurs in 
a different species to V. vermiformis and so evidence is starting to build up that the reduction 
in amoebic population growth over three days might be primarily due to its effect on feeding. 
However, this cannot be said for AEA, as demonstrated by a lack of effect on V. vermiformis 
feeding with this cannabinoid (Figure 4.2).  
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6.3.2. Blocking experiments 
6.3.2.1. Suitability of the chosen receptor blockers 
Of the four blockers used in this study, data from only two were reliable enough for robust 
statistical analysis, i.e., Haloperidol and S-WAY.  The dopamine receptor blockers were very 
toxic to N. gruberi and induced a reduction in population growth at concentrations of 
0.001µM (LE 300) and 0.01µM (L741,626). These were lower than the toxic concentrations of 
S-WAY (0.1µM) and Haloperidol (10µM). The supplier’s safety data sheet (TOCRIS) has no 
available data on the toxicity of LEE 300, L741,626 and S-WAY but classifies Haloperidol (the 
least toxic to amoebae) as being acutely toxic. Although these experiments gave encouraging 
results with regards to the presence of a putative serotonin receptor in N. gruberi, less toxic 
dopamine receptor blockers should be sought in order to repeat these experiments.  
6.3.2.2. Population growth of amoebae in the presence of AEA and CBD with/without 
Haloperidol  
The population growth of 6 amoeba species (13 strains, Table 3.3) were monitored in the 
presence of AEA/CBD with/without 10 µM Haloperidol. Only one species, N. gruberi, showed 
an alleviation of the CBD effect, but not the AEA effect (Fig. 6.1). Haloperidol blocking was 
then shown to act in a dose-dependent manner (MIC >0.1≤1µM, Fig. 6.2). This was a species 
that had not been responsive to PPAR agonists (Table 5.1). Conversely, all seven V. 
vermiformis strains responded PPAR blocking (see 5.2.1.2) but none responded to 
Haloperidol.  
This might suggest an either/or situation with regards to what cannabinoid receptor is present 
in amoebae, as opposed to their cells possessing multiple targets, but it is far too early to say 
for definite. But it was expected that V. vermiformis would show a response to Haloperidol 
because there are some studies which have reported a link between OEA, PPARα and the 
dopamine receptor (Melis et al., 2008; Luchicchi et al. 2010; Tellez et al. 2013; Hankir et al. 
2017). The proposed mechanism also involves a non-genomic effect whereby PPARα receptor 
activation by OEA, activates protein kinases responsible for the phosphorylation status of the 
nicotinic acetylcholine receptors (nAChRs). This then modifies the response of dopaminergic 
neurons to nicotine (Melis et al. 2008; Luchicchi et al. 2010). Considering the action of CBD 
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on V. vermiformis was most like OEA, it involved ‘PPARα’ and we considered PPAR-induced 
non-genomic effects to occur in amoebae (Chapter 4), this study expected a concomitant 
dopamine receptor to be present, but it was not. However, it would be worth testing this 
amoeba species again with specific (non toxic!) dopamine receptor blocker as Haloperidol, 
even though it can block dopamine receptors, has a much higher affinity for serotonin 
receptors (Kroeze et al., 2003; Li et al., 2016); and it was a putative serotonin receptor that 
was identified in N. gruberi with both Haloperidol and S-WAY.  
Also, Haloperidol is described as a classic antipsychotic that employs its action mainly via 
dopamine D2 receptor antagonism and slow receptor dissociation kinetics (Li et al., 2016). In 
addition, Haloperidol is a subtype-selective N-methyl-D-aspartate antagonist that belongs to 
the first generation of antipsychotic drugs which can be classified into different chemical 
classes such as phenothiazines (Samara et al., 2014), thioxanthenes (Fux and Belmaker, 1991) 
and diphenylbutylpiperidines (Gunduz-Bruce et al., 2013). It is the most common 
antipsychotics drug used in the treatment of patients diagnosed with chronic or acute 
schizophrenia disorder (Geddes et al., 2000). Haloperidol is also used in the therapy of other 
disorders, for instance, psychosis, bipolar and behavioural disorders (i.e. hyperactivity) (Kudo 
and Ishizaki, 1999). However, there is evidence that it does not alleviate the effect of CBD in 
patients. Zuardi et al. (1995) studied the administering of Haloperidol in patients with 
schizophrenia who had been given CBD. Haloperidol had no effect on the antipsychotic action 
of CBD.  
6.3.2.3. Population growth of N. gruberi in the presence of CBD with/without S-WAY 
A putative serotonin receptor was identified in N. gruberi based on the fact that Haloperidol 
and S-WAY both blocked the negative effect of CBD on population growth. This was an 
interesting result because CBD is known to bind to 5-HT1A in animals (De Gregorio et al., 2019) 
and S-WAY is a potent and very selective inhibitor of 5-HT1A (Fletcher et al., 1993). Indeed, De 
Gregorio et al. (2019) showed that rats treated with a repetitive low dose of CBD exhibited a 
reduction in anxiety symptoms after activation of the 5-HT1A receptor, and that this anti-
anxiety effect was alleviated by a potent 5-HT1A  antagonist (WAY 100635). Others have found 




Considering a serotonin receptor has been reported to be present in Tetrahymena pyriformis 
(Csaba et al., 2010) it is not inconceivable that N. gruberi might possess one too. The study of 
Csaba et al. (2010) however is vague, and little can be gained regarding any direct cellular 
effect of receptor-ligand binding. Phagocytes of the immune system possess serotonin 
receptors and have been studied more extensively; although there is still very little with 
regards to their role in phagocytosis. Macrophages possess serotonin receptors of the 5-HT2 
class (Sternberg et al., 1986) while monocytes possess receptors from five of the seven 
families (5-HT₁ up to 5-HT5) (Hellstrand and Hermodsson, 1993; Dürk et al., 2005). With 
regards to feeding, Nannmark et al. (1992) showed that direct treatment of 
polymorphonuclear leukocytes with serotonin suppressed zymosan-induced phagocytosis. In 
contrast, Northover (1961) showed that serotonin stimulated polymorphonuclear leukocyte 
phagocytosis of staphylococci and Schuff-Werner and Splettstoesser (1999) went on to show 
that this was dose-dependent. And, in vivo, CBD has been shown to stop the hyperphagia 
behaviour in rats that is activated by 5-HT1A receptor agonist 8-OH-DPAT (Scopinho et al., 
2011).  
6.4. Conclusions 
Of the 6 amoeba species (13 strains) tested, it was only N. gruberi that responded to the 
antagonistic action of Haloperidol and S-WAY, in the presence of CBD. Both blockers abolished 
the effect of CBD on population growth at 10 and 1µM, but not at 0.1µM. CBD induced a 
feeding lag and reduced ingestion rates, as had been previously recorded with V. vermiformis. 
This now shows that the feeding of at least two amoeba species is affected by CBD, and is the 
possible reason for reduced population growth over three days.  Haloperidol abolished the 
feeding lag and reduced ingestion rate at 10µM. It is hypothesised that CBD is binding to the 








Chapter 7: General Discussion 
Endocannabinoids, e.g. Anandamide (AEA), are lipid compounds which together with their 
receptors (e.g. CB1, CB2), and metabolizing enzymes, form the human endocannabinoid 
system (ECS) (Greydanus et al. 2013); affecting mood, cognition, appetite, pain, memory etc. 
Similar effects are activated by Cannabis due to Δ9-tetrahydrocannabidiol (THC, psychoactive) 
and cannabidiol (CBD, non-psychoactive) receptor-binding. However, many of their effects 
cannot be attributed solely to binding to these receptors and another 63 molecular targets 
have been proposed (Bih et al. 2015). Further knowledge regarding these alternative targets 
could increase the potential therapeutic use of phytocannabinoids. 
Single-celled protists such as amoebae and ciliates do not possess any of the main 
cannabinoid receptors (CB1, CB2, GPR55 and TRPV1) (McPartland et al. 2006) yet they 
respond to cannabinoids, often showing a reduction in motility and arrest in cell division 
(McClean & Zimmerman 1976; Pringle et al. 1979; Zimmerman et al. 1981; Dey et al. 2010).  
Accordingly, these protists offer an opportunity to examine the role of alternative molecular 
targets in the action of cannabinoids on cells. This study therefore evaluated the role of three 
such targets (PPAR, Dopamine, Serotonin) on the action of CBD and AEA on naked amoebae.  
7.1. Amoebic sensitivity to AEA and CBD 
A total of 27 amoeba strains, which comprised 20 species, were tested for their sensitivity to 
AEA and CBD. Fourteen species (70%) were insensitive while 6 species (30%) were sensitive. 
All 6 were sensitive to CBD but only 4 were also sensitive to AEA. There appeared to be no 
correlation between sensitivity and phylogenetic position, with differences in sensitivity being 
evident within a single order (e.g. Order Echinamoebida - Vermamoeba “sensitive”, 
Echinamoeba “not sensitive”). Also, differences within a single family were recorded (e.g. 
family Hartmannellidae - Hartmannella “sensitive”, Saccamoeba “not sensitive”) and even a 
difference within the same genus (e.g. Acanthamoeba – A. castellanii “sensitive”, A. 
polyphaga “not sensitive”).  
Regarding cell size, in general, the susceptible strains were at the lower end of the cell size 
spectrum (Table 3.4), However, the very high concentration used (200µM) would have been 
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expected to significantly affect the very small cells of P. filosum and E. silvestris if cell size was 
a compounding factor, but it did not.  
Lastly, there was no relationship between sensitivity and the source of the amoeba, for 
example, V. vermiformis strains were isolated from different environments (soil and 
freshwater) in four different countries and all were sensitive to CBD and AEA. 
For those sensitive strains, CBD and AEA reduced population growth over 3 days in a dose-
dependent manner and, higher concentrations proved lethal. Lower concentrations induced 
a lag followed by reduced growth rate which was dose dependent. It was discovered that, for 
CBD, this reduction in population growth was due to the disruption of amoebic feeding 
(Section 7.3) however, this was not the case for AEA (Section 7.2). 
7.2. Amoebic response to AEA 
AEA, at 2µM, had no significant effect on V. vermiformis feeding, although a slight lag was 
evident. However, the AEA concentration might have been too low to give a significant result. 
A concentration of 2µM AEA (and CBD) was chosen as this value was close to their IC50 values 
and would allow a direct comparison of their effect.  But, 2µM is above the IC50 for CBD (IC50 
= 1.01µM) and below the IC50 for AEA (IC50 = 2.33µM) (Table 3.3). Experiments should be 
repeated with higher concentrations of AEA to confirm/deny any effect on feeding in this 
amoeba.   
AEA, at 2µM, did have a significant effect on V. vermiformis population growth however, and 
considering this is not due to reduced feeding the reason for this remains unknown. 
Population growth relies on successful ingestion and assimilation of prey so the mode of 
action of AEA might be at the assimilation stage, and not the ingestion phase. 
Assimilation is the process by which digested material in the food vacuole/phagosome is 
absorbed into the cytoplasm of the cell to generate progeny (Verma, 2001). In protists, 
assimilation efficiency, or more commonly termed Gross Growth Efficiency (GGE), is defined 
as the volume of carbon produced (in protists) from the volume of prey consumed (Rose et 
al., 2009). GGEs are always <100% because protists notoriously convert much of the organic 
carbon, nitrogen and phosphorus in their prey to inorganic forms, then release them in a 
process known as remineralisation (Coull and Chandler, 2001). 
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GGE estimates for amoebae are rare but one study (Butler and Rogerson, 1996) provided 
estimates for 10 species at 20oC which is close to the 23oC used in the current study. GGEs 
ranged from 13.7% to 56% with variations within a genus being evident: 13.7-20.8% 
(Stereomyxa ramose, Dactydamoeba sp., Rhizamoeba sp.), 26.6-36.1% (Vannella caledonica 
Paraflabellula reniformis, Vahlkampfia baltica) and 41.1-56% (Clydonella rosenfieldi 
Platyamoeba sp., Vahlkampfia damariscottae, Vannella sp.) (Butler and Rogerson, 1996). 
Zubkov and Sleigh (1998) recorded a GGE of 60% for Vannella septentrionalis but no 
temperature was stated, and it is known that GGEs increase with increasing temperature 
which suggests that amoebae convert food into biomass with increased efficiency at higher 
temperatures (Butler and Rogerson, 1996).  
The energy required for assimilation and cellular respiration is provided by mitochondria. It 
has been reported the AEA can directly inhibit the function of mitochondria in rats and 
decreased the sensitivity of   Ca2+ in a dose-dependent manner (Catanzaro et al., 2009). The 
study continued to indicate that these effects are not due to AEA receptor binding, but due 
to its direct effect on mitochondria and it was accompanied with decreasing of membrane 
potential and increasing the fluidity of the membrane. Moreover, AEA has been proposed to 
inhibit the synthesis of ATP (Zaccagnino et al., 2011). In addition, treatment with AEA reduced 
the respiration of mouse brain mitochondria by 30% mediated by CB1 receptor (Bénard et al., 
2012). Anandamide also inhibited the activity of complexes I, II/III and IV of transport chain in 
pig brain mitochondria (Singh et al., 2015). Other studies indicate that AEA negatively affects 
the function of mitochondria in different tissues such as the nerve cells and sperm resulting 
in an inability to perform their functions properly (Rossato et al., 2005; Zaccagnino et al., 
2011). In addition, AEA has been shown to reduce oxygen consumption and decrease the 
potential of the mitochondrial membrane, and its permeability, in rats (Epps et al., 1982; 
Athanasiou et al., 2007).  
Considering amoeba possess mitochondria, they could be a possible target for AEA. Further 
studies on the effect of AEA on mitochondria in amoebae should be performed to evaluate 
whether AEA is targeting the mitochondria or not, and this could be carried out by measuring 
the ATP molecules produced and the activity of the ATPase enzyme.  Zaccagnino et al. (2011) 
examined the effect of AEA on mitochondria by direct measurements of mitochondrial FoF1 
ATP synthase complex. This study concluded that AEA inhibited the oxidative phosphorylation 
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and reduced the releasing of ATP, resulting in dysfunction of mitochondria. Repeating such a 
study Including measurements of oxygen consumption with amoeba would be beneficial  
Alternatively, AEA might directly target the cell cycle of amoeba as it has been reported to 
cause anti-proliferation action on mammalian carcinoma cells (Xie et al., 2012). This study 
indicated that AEA caused inhibition of proliferation in the Huh7 cell line by causing cell cycle 
arresting at the G1 phase and stimulated apoptosis. In addition, AEA can inhibit cancerous 
cells in the gastric gland to arresting the cell cycle in the G2/M phase (Dong et al., 2014). 
Furthermore, other cannabinoids such as CBD have been shown to have anti-proliferation 
and anti-differentiation effects on Dictyostelium discoideum (Bram et al., 1976). 
Whatever the mode of action, it did not appear to involve the binding of AEA to receptors for 
PPAR, Dopamine or Serotonin, as when these receptors were blocked with antagonists there 
was no alleviation of the AEA-induced reduction in population growth. AEA therefore seems 
to act on cells in a very different manner to CBD and future work should look at whether any 
of the other molecular targets summarised in Bih et al (2015), such as opioid and 
acetylcholine, are involved. 
7.3. Effect of CBD on amoebic feeding 
7.3.1. Amoebic feeding in the absence of CBD 
Feeding experiments with V. vermiformis showed that it could ingest inert beads and live 
Synechococcus at equivalent rates. These rates were reduced in the presence mannose, 
GalNAc and GlcNAC suggesting that this amoeba possesses three corresponding C-type 
lectins. 
Many studies have indicated that C-type lectin receptors are involve in the feeding of amoeba, 
particularly lectins for mannose (Bracha et al., 1982; Allen and Davidowicz, 1990; Garate et 
al. 2004; Alsam et al., 2005) and GalNAc (Ravdin and Guerrant, 1981; Ravdin et al., 1985; Petri 
et al., 1987; Venkataraman et al., 1997; Harb et al., 1998; Bär et al., 2015). The current study 
recorded a reduction in ingestion of Synechococcus by V. vermiformis in the presence of 
mannose, GalNAc and GlcNAc, however, no lag phase was induced.  GlcNac was the most 
potent sugar blocker (73% reduction in feeding), followed by mannose (66% reduction) and 
then GalNac (53% reduction).  
113 
 
Treatment with GlcNAc led to the strongest inhibition of ingestion in V. vermiformis 
suggesting it was not only binding ‘weakly’ to a mannose receptor but also/instead binding 
‘strongly’ to its own receptor. In addition, blocking with GlcNAc affected the duration of the 
CBD-induced lag phase whereas blocking with mannose and GalNAc did not.  These data 
therefore support the case for presence of three distinct sugar receptors in V. vermiformis, as 
has been suggested for D. discoideum (Bozzaro & Roseman, 1983) and more recently, for T. 
pyriformis (Boboc, 2019).  Future work could look at other amoebae and see if this is a 
common feature between them. 
In addition to C-type lectins, another group of receptors (Scavenger receptors, SRs), that are 
also surface membrane glycoproteins, are used for the recognition of carbohydrates in prey 
to facilitate phagocytosis (Perún et al., 2016). The Class B scavenger receptors bind to the 
lipoteichoic acid of Gram-positive bacteria (Hoebe et al., 2005; Stuart et al., 2005) and the 
lipid A of the lipopolysaccharide layer of Gram-negative bacteria (Baranova et al., 2008). In 
2018, Sattler et al reported that D. discoideum possesses homologous receptors to the 
mammalian class B scavenger receptors, LIMP-2 and CD36, i.e. LmpA and LmpB, respectively. 
The LmpA was found in endosomes and phagolysosomes and played a role in the binding and 
phagocytosis of bacteria (particularly Gram-positive strains) while LmpB was localized to the 
plasma membrane and early phagosomes and was exclusively involved in the uptake of Gram-
positive bacteria (Sattler et al. 2018).  
An unpublished study in Lancaster university also investigated the participation of SRs in the 
feeding of protist, specifically, in the ciliate T. pyriformis (Parry, unpublished). The study 
concluded that SRs were not involved in the uptake of Pseudomonas aeruginosa however, 
they appear to be involved in the uptake of live Synechococcus cells. Since the current study 
employed the same prey (live Synechococcus cells) in amoebic feeding experiments, it would 
be interesting to see if CBD interacts with these receptors in V. vermiformis (using Dextran 
Sulphate to block the scavenger receptors).   
7.3.2. Amoebic feeding response in the presence of CBD 
CBD induced a feeding lag followed by a reduced ingestion rate in both V. vermiformis and N. 
gruberi. This should be tested on the other 4 susceptible amoeba strains to confirm that this 
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is the inherent effect of CBD on amoebae (and not just the specific effect on these two 
species).  
The long-term effect of CBD on V. vermiformis, compared to T. pyriformis, was thought to be 
due to a reduced capacity for metabolizing CBD within the amoebic cell (possibly due to the 
lack of CYPs). It is unknown whether these protists differ in their ability to degrade CBD, which 
might affect its longevity in their cells. In all human cells, CBD is metabolised by cytochrome 
P450 oxidases, sulfotransferases and glucuronyl transferases (Ujváry and Hanus, 2016). Most 
work has been performed on P450 oxidases (CYPs) which are enzymes necessary for the 
metabolism of drugs (Šrejber et al., 2018). Even though more than 50 CYP enzymes exist, only 
six of them (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) are responsible for 
metabolising 90% of medicinal drugs (Lynch and Price, 2007). Of these, CYP2C19 metabolises 
CBD, (Stout and Cimino, 2014). Interestingly, Tetrahymena thermophila possesses 102 CYP 
homologues (www.ciliate.org), the slime mould Dictyostelium discoideum possesses 9 
(www.dictybase) whilst Acanthamoeba castellanii possesses only 1 and Entamoeba spp. and 
Naegleria fowleri possess none (www.amoebadb.org). Although there is very little 
information on the amoeba with regards to metabolism of CBD (Ujváry and Hanus, 2016), it 
might be that V. vermiformis, like other amoebae, possesses a limited ability to degrade CBD 
within their cells and this might explain the longevity of the drug action on V. vermiformis, 
compared to T. pyriformis.  
Moreover, the longevity of drug in the cell is depending on the efficiency of dissociation of 
drug from its corresponding receptor (Vauquelin and Charlton, 2010). Therefore, the rate of 
dissociation is considered a crucial element to determine the effectiveness of drugs, the 
slower the dissociation rate, the longer the effect will last (Holdgate,2017). This rate depends 
on different factors including temperature and the existence of the catalysis enzymes 
(Cooper, 2000).  
The enzymes responsible for catalysis and metabolism of lipids are present dominantly in the 
endoplasmic reticulum (ER) (Raff et al., 2002). Since CBD is a lipid molecule, it raises the 
possibility that the effect of CBD on amoeba might be occurring within the ER, leading to a 
slow dissociation of this cannabinoid and long lasting activity in these cells. Also, it has been 
reported that CBD causes apoptosis of Hepatic stellate cells (HSC) in mice by evoking stress 
115 
 
activity on the ER by stimulating Protein kinase R-like endoplasmic reticulum kinase (Lim et 
al., 2011).   Thus, a study to examine the effect of CBD on the ER in amoeba would be 
interesting step to evaluate the extent of CBD potency on them. 
The fact that a longer feeding lag resulted in a lower subsequent ingestion rate suggested the 
two responses are coupled in some way.  CBD did not appear to directly interact with V. 
vermiformis’s feeding receptors, so it was proposed that CBD’s target was a yet unidentified 
receptor. When the C-type lectins were individually blocked (mannose, GalNAc and GlcNAc) 
in the presence of CBD, there was no interaction between mannose and GalNAc receptors 
and CBD. However, the GlcNAc receptor ‘interacted’ with CBD, as blocking this receptor in the 
presence of CBD led to double the duration of feeding lag. It was hypothesised that the 
unidentified CBD receptor and GlcNAc receptor were both involved with controlling 
phagosome formation rate whereas receptors for mannose and GalNAc are involved with 
prey capture and phagosome filling. No other studies have been carried out on this process 
to which the results of this study can be compared. 
7.4. Mode of action of CBD in V. vermiformis 
There are many stages involved in the successful formation and processing of phagosomes 
and a ‘CBD-receptor’ could be involved in any of these stages. But, based on experimental 
evidence, this receptor was not considered to be involved in phagosome closure, detachment, 
trafficking, defecation and endocytosis. Instead, it was considered to be involved in 
phagosome formation) and/or membrane recycling.  
The mechanism of phagosome formation and maturation in protists is still poorly described 
but is considered to be similar to that of macrophages. the process begins when the 
phagocytic cell recognises the binding ligands of the prey cell in a receptor-dependent way 
(Levin et al., 2016). This recognition leads to signal pathways that stimulate the re-shaping of 
the actin cytoskeleton and the extension of pseudopodia to enclose the prey in a phagocytic 
cup (Duhon and Cardelli, 2002; Cosson and Soldati, 2008; Pauwels et al., 2017). The complete 
closing of the phagocytic cup leads to the formation of the phagosome, which is inert until it 
maturates via a complicated series of fusion events with endosomes and then with lysosomes 
(which contain digestive enzymes) (Haas, 2007; Pauwels et al., 2017). The final stage is the 
defecation of waste materials and the recycling of the phagosome membrane to make new 
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phagosomes (Allen and Fok, 1980; Gotthardt et al., 2002). It has been highlighted that Syk, 
LAT and PKC are involved in the initial stages of phagosome formation in macrophages; in 
specific, the signaling cascade in the recognition of prey and signalling pathway of extension 
of pseudopodia to form the phagocytic cup (Unsworth et al. 2018). 
As far as the possible identity of the CBD-receptor was concerned, three potential targets 
were evaluated (PPAR, Serotonin, Dopamine). Of the three, only the blocking of PPARα 
resulted in the alleviation of the CBD effect in V. vermiformis. This was a very specific 
interaction as, out of all. 20 amoebic species tested, it was only V. vermiformis that responded 
to PPAR agonists. All seven V. vermiformis strains were susceptible to OEA and GW0742 but 
there were strain differences with regards to their susceptibility to PEA and Rosiglitazone. 
Each PPAR agonist induced the same feeding response as CBD, i.e., a feeding lag followed by 
reduced ingestion rate. These negative responses were eliminated by blocking the PPAR with 
a specific antagonist. Only the blocking with the PPARα antagonist eliminated the negative 
effect of CBD. 
PPARs have been shown to interact with Syk, LAT and PKC proteins in the Non-genomic 
regulation of platelets (Unsworth et al. 2018), whereas PPARα and PPARβ ligands result in a 
decrease in intracellular mobilization of calcium and activation of platelets (Unsworth et al. 
2017). This inhibition is due to the reduction of PKCα potency through its interaction with 
PPARα or PPARβ, which determines its availability to facilitate downstream signalling (Ali et 
al., 2009). Treatment with PPARγ ligands inhibit Syk and LAT phosphorylation that mediate 
signaling initiated by the GPVI collagen receptor (Unsworth et al. 2018).  
Therefore, it is hypothesised that V. vermiformis contains a promiscuous PPAR-like molecule 
which can bind PPAR agonists and antagonists, and CBD at the α-binding site. Due to the 
instantaneous effect of CBD on amoebic feeding, it suggests that PPAR induces a non-genomic 
response whereby PPAR binds to proteins outside the nucleus. Potential proteins for PPAR-
binding included Syk, LAT and PKC which are all involved in the early stages of receptor-
mediated phagocytosis. It might be that un-ligated PPAR binds to this protein allowing its 
phosphorylation and downstream signaling to occur, but on ligation this binding is prohibited, 
no phosphorylation takes place and the signalling cascade, which would normally culminate 
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in actin polymerisation and phagocytic cup formation, becomes non-functional (in the lag) 
and less functional (after the lag). 
Protein phosphorylation is a distinctive sign of signalling cascades and has a crucial role in 
different biological activities in the cell, such as detection of activation and deactivation of 
receptors (McCance and Huether, 2014).  Therefore, further studies to confirm the 
highlighted hypothesis should be performed on this amoeba by detecting the protein 
phosphorylation and measure its level using a suitable protein detecting method such as 
Kinase Activity Assays or ELISA. Also, sequencing could give a deeper understanding on what 
this amoeba has in its genome. 
Although protists do not perform opsonised phagocytosis, complement proteins (CPs) have 
been found in the cytoplasm of single-cell eukaryotes (Elvington et al., 2016). Vinculin is one 
such CP, and is an actin binding protein which plays an important role, with Talin and F-actin, 
in forming stable cell matrix adhesion (De Beco et al., 2012). Vinculin is also a key factor for 
phagosome formation, and interacts with cascades involving Syk, FAK, Pyk2, and Src (Allen 
and Aderem, 1996; Jaumouillé et al., 2019). Moreover, it has been indicated that the 
mechanism of action of alpha-M beta-2 integrins couple to actin cytoskeleton to form the 
phagocytic cup is mediated by Talin and Vinculin (Allen and Aderem, 1996). 
Interestingly, V. vermiformis possesses a gene for the Vinculin (Kang et al., 2020) and there is 
some evidence in other cells, that Vinculin interacts with CBD (Elbaz et al.,2015). Thus, it could 
be that CBD interacts with Vinculin in V. vermiformis, resulting in an inhibition of phagosome 
formation but this requires testing.   
7.5. Comparison of V. vermiformis response to cells of higher animals  
There are significant similarities between OEA and CBD with regards to their mode of action 
in animals and V. vermiformis. These similarities can be summarised in that OEA has an 
anorexiant effect in mice, i.e., it can stop feeding completely and then reduce food intake 
(Rodríguez de Fonseca et al., 2001; Diep et al., 2011). The same response was recorded in V. 
vermiformis with all PPAR agonists and CBD. Moreover, PEA is significantly less potent than 
OEA and AEA has no effect (Rodríguez de Fonseca et al., 2001; Diep et al., 2011). This response 
was also recorded with V. vermiformis. Furthermore, administration of OEA in mice causes a 
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dose-dependent delay in the feeding onset (Gaetani et al., 2003; Karimian Azariet al., 2014). 
Also, the effect of CBD on the feeding lag and ingestion rates of V. vermiformis was dose-
dependent (dose-responses of PPAR agonists were not performed). In addition, OEA does not 
reduce feeding in animals if they lack a functional PPARα gene, suggesting that PPARα 
activation is crucial for mediating its hypophagic actions (Fu et al., 2003). Similarly, in the 
current study, all agonist-induced lags and reduced feeding rates were abolished with PPAR 
antagonists, and for OEA and CBD, this was the blocking of the PPARα receptor only.  
It is also interesting to note that OEA only evokes a delayed feeding onset and reduced meal 
size in food-deprived rats (only the former in well fed mice) (Gaetani et al., 2003; Karimian 
Azariet al., 2014). In the current study, V. vermiformis would have also been food-deprived 
after 7 days culturing prior to experiments. It would be interesting to repeat experiments with 
well-fed cells to see if only a lag phase is induced. 
However, the mode of action of OEA in animals is not completely understood, but it has been 
reported that an elevated concentration of OEA appears to ‘trick’ animals into thinking they 
are full (satiated), which stops them feeding (Rodríguez de Fonseca et al., 2001; Diep et al., 
2011). This mode of action might also be pertinent to protists, in that, if membrane is limited 
for phagosome formation (at satiation), or there are defunct receptor-driven signalling 
cascades, protists cannot produce pseudopodia to feed (Boenigk et al., 2001).  
7.6. Involvement of serotonin receptors in the mode of action of CBD against 
amoebae  
Only N. gruberi responded to the antagonistic action of Haloperidol and S-WAY, in the 
presence of CBD. Both blockers abolished the effect of CBD on population growth at 10 and 
1µM, but not at 0.1µM. CBD induced a feeding lag and reduced ingestion rates, as had been 
previously recorded with V. vermiformis. This showed that the feeding of at least two amoeba 
species is affected by CBD, and is the possible reason for reduced population growth over 
three days. 
There is very little on the role of serotonin receptors and phagocytosis, however, serotonin 
has been found to increase the phagocytic action of macrophages in mouse; mediated by the 
5-HT1A receptor (Freire‐Garabal et al., 2003). Moreover, CBD has been shown to stop the 
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hyperphagia behaviour in rats when the 5-HT1A receptor is activated by the agonist 8-OH-
DPAT (Scopinho et al., 2011). The current study proposed that N. gruberi possesses a 5-HT1A 
serotonin receptor but due to lack of time, the current study could not continue studying the 
effect of serotonin receptor and CBD on the feeding of N. gruberi. This needs further 
examination to understand the mechanism in which serotonin receptors mediated feeding 
processes in this amoeba.  
7.7. Conclusions 
Overall, the study concludes that CBD is more potent against amoebae than AEA and that 
there is no correlation between sensitivity and amoebic phylogeney. CBD affects amoebic 
feeding (by targeting vacuole formation/membrane recycling) while AEA might possibly affect 
processes involved with the assimilation of prey. The study suggests that V. vermiformis 
possesses a promiscuous PPAR-like molecule that can bind CBD at a potential alpha-type  site 
and instigate a non-genomic response which prevents phagocytic cup formation.  It is 
hypothesised that N. gruberi possesses a 5-HT1A serotonin-type receptor which can bind CBD 
but the phagocytic stage which is targeted has yet to be confirmed.  
The study has therefore identified that at least two ‘alternative’ CBD receptors proposed by 
Bih et al. (2015) are involved in amoebic feeding and population growth. These simple, and 
easy to culture, cells now provide a viable cell model for further studies on the interaction of 
these receptors with CBD; as these cells do not possess the ‘complication’ of having 
cannabinoid receptors CB1/2, GPR55 and TRPV1, as do other eukaryotic cells. In addition, 
further work on these amoebae will provide important information on the ancestry of the ECS 
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APPENDIX 1: Media formulations 
 
Amoeba Saline (AS)  
Stock 1:                                    
NaCl              12.0g  
 MgSO4. 7H20     0.4g  
 CaCl2. 6H20     0.6g 
 Distilled water    500ml   
Stock 2: 
 Na2HPO4    14.2g                            
 KH2PO4    13.6g 
 Distilled water    500ml 
 
Prepare stocks and store at 4oC. Add 5ml stock 1 and 5ml stock 2 to 990ml distilled water. 
Autoclave at 121oC for 15 min. 
 
BG11 Broth 
Stock 1:  
NaNO3      15.0g  
K2HPO4      4.0g  
MgSO4·7H2O     7.5g  
CaCl2·2H2O      3.6g  
Citric acid      0.6g  
Ammonium ferric citrate green   0.6g  
EDTANa2     0.1g  
Na2CO3     2.0g  
Distilled water    1000 ml 
Stock 2: 
H3BO3      2.86g  
MnCl2·4H2O      1.81g  
ZnSO4·7H2O      0.22g  
Na2MoO4·2H2O    0.39g  
CuSO4·5H2O     0.08g  
Co(NO3)2·6H2O     0.05g  
Distilled water    1000ml 
 
Prepare stocks and store at 4oC. Add 10ml stock 1 and 1ml stock 2 to 989 ml distilled water. 
Adjust pH to 7.1 with 1M NaOH or HCl. Autoclave at 121°C for 15 minutes. 
 
Diagnostic Sensitivity Test (DST) agar with chloramphenicol (at 30 µg/ml) 
Add 37.5g of Diagnostic Sensitivity Test agar (MAST laboratories) to 1L distilled water. 
Autoclave at 121°C for 15 min. Cool to ca. 50oC before adding 1ml of filter sterilized 
chloramphenicol solution (30 mg/ml). 
Non-Nutrient Agar with agar (NNA) or agarose (NNAg) 
Add 15g of either Agar No 2 (for NNA) or agarose (for NNAg) to 1L Amoeba Saline (AS). 
Autoclave at 121oC for 15 min. 
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Appendix 2: IC50 graphs of all sensitive amoeba strains with AEA and CBD 
(Section 3.2.2) 
Acanthamoeba castellanii CCAP1501/1A (CBD only). 









Flamella arnhemensis CCAP1525/2 (CBD only).  








        Vermamoeba vermiformis CCAP 1534/7A (CBD only, AEA in Fig. 3.2) 










Hartmannella cantabrigiensis CCAP1534/8  
 
CBD: estimated MIC =1.50, IC50=4.10, Slope= 1.96, Lethal dose >13                 AEA: estimated MIC =14.00, IC50=23.10, Slope= 3.46, Lethal dose >41       
Naegleria gruberi NEG-M  
CBD: estimated MIC =0.20, IC50=0.75, Slope=1.63 , Lethal dose >3                       AEA: estimated MIC =0.21, IC50=1.15, Slope=1.25, Lethal dose >6 
 
Vahlkampfia avara CCAP 1588/1A  




Vermamoeba vermiformis 137 
CBD: estimated MIC =4.00, IC50=7.31, Slope=3.77 , Lethal dose >14                   AEA: estimated MIC =1.30, IC50=9.89, Slope=1.01, Lethal dose >50 
 
Vermamoeba vermiformis 172 
 
CBD: estimated MIC =0.30, IC50=1.78, Slope=1.23 , Lethal dose >10                    AEA: estimated MIC =5.00, IC50=7.33, Slope=5.45, Lethal dose >12  
 
Vermamoeba vermiformis 173 
 




Vermamoeba vermiformis 174 
 
CBD: estimated MIC =1.60, IC50=2.98, Slope=3.86 , Lethal dose >5                   AEA: estimated MIC =1.20, IC50=5.41, Slope=1.23, Lethal dose >25 
 
Vermamoeba vermiformis CCAP 1534/13 
CBD: estimated MIC =3.00, IC50=5.05, Slope=3.79, Lethal dose >9                   AEA: estimated MIC =1.50, IC50=7.69, Slope=1.32, Lethal dose >35  
 
Vermamoeba vermiformis CCAP 1534/14 




Appendix 3: IC50 graphs of all sensitive amoeba strains with OEA, PEA, 
GW0742 and Rosiglitazone (Section 5.2.1.1) 
Vermamoeba vermiformis 137 
OEA: estimated MIC = 0.08, IC50=2.12, Slope=0.67, Lethal dose >35               PEA: estimated MIC =3.10, IC50=4.79, Slope=5.78, Lethal dose >8  
 



















Vermamoeba vermiformis 172 

























Vermamoeba vermiformis 173 
















Vermamoeba vermiformis 174 
OEA: estimated MIC =1, IC50=4.77, Slope=1.32, Lethal dose >24                     PEA: estimated MIC =3.20, IC50=4.62, Slope=6.89, Lethal dose >7  
 
 




























Vermamoeba vermiformis CCAP 1534/13 




































Vermamoeba vermiformis CCAP 1534/14 
 OEA: estimated MIC =0.19, IC50=0.81, Slope=1.51, Lethal dose >5                    PEA: estimated MIC =0.25, IC50=2.55, Slope=0.91, Lethal dose >23 
 
 











Vermamoeba vermiformis CCAP 1534/7A 















Appendix 4: Response of Vermamoeba vermiformis strains to PPAR agonists in 
the presence and absence of specific PPAR antagonists (Section 5.2.1.2)  
V. vermiformis 137 
OEA                                                                                                    PEA 


















































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007
GW0742 GW0742+6471 GW0742+3787 GW0742+T007
159 
 
V. vermiformis 172  
OEA                                                                                                           PEA 
 
 











































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007








































































Control GW6471 GSK3787 T007
Ros. Ros.+6471 Ros.+3787 Ros.+T007
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V. vermiformis 173  
OEA                                                                                                          PEA 
                         











































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007
Ros. Ros.+6471 Ros.+3787 Ros.+T007
161 
 
V. vermiformis 174 
OEA                                                                                                        PEA 
 
GW0742                                                                                       Rosiglitazone 
 










































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007







































































Control GW6471 GSK3787 T007
Ros. Ros.+6471 Ros.+3787 Ros.+T007
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V. vermiformis CCAP 1534/13 





















































Control GW6471 GSK3787 T007



































Control GW6471 GSK3787 T007








































V. vermiformis CCAP 1534/7A 















































Control GW6471 GSK3787 T007








































Appendix 5: Response of Vermamoeba vermiformis strains to CBD in the 
presence and absence of three PPAR antagonists (Section 5.2.1.3)  
V. vermiformis 137                          V. vermiformis 172  
 
 


































































































































































V. vermiformis CCAP 1534/13                 V. vermiformis CCAP 1534/7A  
 
Key: GW6471 (antagonist for PPARα), GSK3787 (antagonist for PPARβ/δ) and T007 













































Control GW6471 GSK3787 T007









































Appendix 6: Response of Vermamoeba vermiformis strains to CBD in the 
presence and absence of three PPAR antagonists at different concentrations 
(Section 5.2.1.4)  







































































































































































































































































































































V. vermiformis 173 






























































































































































































































































































































































































































































































































Appendix 7: Response of sensitive amoeba strains to CBD and AEA in the 
presence and absence of Haloperidol (Section 6.2.1.)  
Acanthamoeba castellanii CCAP1501/1A .(CBD only).                 Flamella arnhemensis CCAP1525/2 (CBD only). 
  
 














































































































































CONT HAL. CBD AEA CBD+HAL. AEA+HAL
174 
 
























































































































































CONT HAL. CBD AEA CBD+HAL. AEA+HAL
175 
 
Vahlkamphia avara CCAP 1588/1A + CBD/AEA   Vermamoeba vermiformis CCAP 1534/7A + CBD/AEA 
 
    




















































































































































CONT HAL. CBD AEA CBD+HAL. AEA+HAL
